Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia

ABSTRACT

The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics.

RELATED APPLICATIONS

The present application claims the benefit of U.S. Provisional PatentApplication Ser. No. 61/147,524, filed Jan. 27, 2009, which is hereinincorporated by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under grant numberNS26636 awarded by the National Institute of Neurological Disorders andStroke. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates generally to the THAP1 gene and mutationsin this gene, as well as the THAP1 protein and mutations in thisprotein, that are associated with dystonia. The invention relates to theidentification, isolation, cloning and characterization of the DNAsequence corresponding to the wild type and mutant THAP1 genes, as wellas isolation and characterization of their transcripts and geneproducts. The invention further relates to methods and kits useful fordetecting mutations in THAP1 that are associated with dystonia, as wellas to methods and kits useful for diagnosing dystonia. The presentinvention also relates to therapies for treating dystonia, includinggene therapeutics and protein/antibody based therapeutics.

BACKGROUND OF THE INVENTION

The citation and/or discussion of cited references in this section andthroughout the specification is provided merely to clarify thedescription of the present invention and is not an admission that anysuch reference is “prior art” to the present invention.

Dystonia is characterized by twisting movements and abnormal postures(Fahn, S. Adv. Neurol. (1988) 50: 1-8). At least 15 different types ofdystonia can be distinguished genetically, most of which are inheritedin an autosomal dominant (AD) manner with reduced penetrance.

DYT1, 2, 4, 6, 7 and 13, comprise primary forms, where dystonia is theonly neurologic feature (de Carvalho Aguiar, P. M. and Ozelius, L. J.,Lancet Neurol. (2002) 1: 316-25). The genetic basis for only one ofthese, DYT1, responsible for most cases of early onset generalizeddystonia, has been identified (Ozelius, L. J. et al., Nat. Genet. (1997)17: 40-8).

DYT6 is dominantly inherited with penetrance of about 60% independent ofgender. It is characterized by an average onset age of 16.1 years,cranial or cervical presentation in about half of the cases and frequentprogression to involve multiple body regions. First mapped to a 40 cM(peri-contromeric) region on chromosome 8 in two Amish-Mennonitefamilies (M and C) (Almasy, L. et al., Ann. Neurol. (1997) 42: 670-3),an additional Amish-Mennonite family (R) was shown to share the DYT6disease haplotype and all three families were descended from several“Old Order Amish” ancestral pairs (Sanders-Pullman, R. et al., Am. J.Med. Genet. A (2007) 143A: 2098-105). The linked region was narrowed to23 cM between markers D8S2317 and D8S2323; this region contains ˜120genes (March 2006 UCSC human genome assembly, http://genome.ucsc.edu/)(Sanders-Pullman, R. et al., Am. J. Med. Genet. A (2007) 143A:2098-105).

SUMMARY OF THE INVENTION

In one embodiment, the invention is directed to an isolated THAP1nucleic acid. In some embodiments, the invention is directed to anisolated THAP1 nucleic acid that encodes a THAP1 peptide comprising theamino acid sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQID NO: 16, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72,SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO:77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ IDNO: 82, SEQ ID NO: 83, SEQ ID NO: 84, or SEQ ID NO: 85. In someembodiments, the isolated THAP1 nucleic acid comprises the sequence ofSEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 50,SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO:55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ IDNO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68. In someembodiments, the isolated THAP1 nucleic acid encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 12. In someembodiments, the isolated THAP1 nucleic acid that encodes a THAP1peptide comprising the amino acid sequence of SEQ ID NO: 12 includes thesequence of SEQ ID NO: 2. In some embodiments, the isolated THAP1nucleic acid that encodes a THAP1 peptide comprising the amino acidsequence of SEQ ID NO: 12 includes the sequence of SEQ ID NO: 5.

In one embodiment, the invention is directed to an isolated THAP1nucleic acid, wherein the nucleic acid encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 13. In someembodiments, the isolated THAP1 nucleic acid that encodes a THAP1peptide comprising the amino acid sequence of SEQ ID NO: 13 includes thesequence of SEQ ID NO: 3. In some embodiments, the isolated THAP1nucleic acid that encodes a THAP1 peptide comprising the amino acidsequence of SEQ ID NO: 13 includes the sequence of SEQ ID NO: 6.

In one embodiment, the invention is directed to an isolated THAP1nucleic acid, wherein the nucleic acid encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 15. In someembodiments, an isolated THAP1 nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 15 includes thesequence of SEQ ID NO: 2. In some embodiments, an isolated THAP1 nucleicacid that encodes a THAP1 peptide comprising the amino acid sequence ofSEQ ID NO: 15 includes the sequence of SEQ ID NO: 5.

In one embodiment, the invention is directed to an isolated THAP1nucleic acid, wherein the nucleic acid encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 16. In someembodiments, an isolated THAP1 nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 16 includes thesequence of SEQ ID NO: 3. In some embodiments, an isolated THAP1 nucleicacid that encodes a THAP1 peptide comprising the amino acid sequence ofSEQ ID NO: 16 includes the sequence of SEQ ID NO: 6.

In one embodiment, the invention is directed to an isolated nucleic acidthat includes one or more of the following THAP1 mutations: a c.85C>Tmutation, a c.86G>C mutation, a c.241T>C mutation, a c.266A>G mutation,c.115G>A mutation, c.460delC mutation, a c.134_135insGGGTT;137_139delAACmutation, a c.161G>A mutation, a c.1A>G mutation, a c.61T>A mutation, ac.67C>T mutation, a c.36C>A mutation, a c.2delT mutation, a c.65T>Cmutation, a c.140C>T mutation, a c.392-394delTTT mutation, a c.11C>Tmutation, a c.580T>C mutation, a c.424A>G mutation, a c.250-251 delACmutation, and a c.505C>T mutation as compared to wild type THAP1 DNA(e.g., SEQ ID NO: 4).

In one embodiment, the invention is directed to an isolated THAP1peptide. In some embodiments, an isolated THAP1 peptide includes thesequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16,SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO:73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ 1DNO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQID NO: 83, SEQ ID NO: 84, or SEQ ID NO: 85.

In some embodiments, the invention is directed to an isolated THAP1peptide that comprises the sequence of SEQ ID NO: 12. In someembodiments, the invention is directed to an isolated THAP1 peptide,wherein the THAP1 peptide comprises the sequence of SEQ ID NO: 13. Insome embodiments, the invention is directed to an isolated THAP1peptide, wherein the THAP1 peptide comprises the sequence of SEQ ID NO:15. In some embodiments, the invention is directed to an isolated THAP1peptide, wherein the THAP1 peptide comprises the sequence of SEQ ID NO:16.

In one embodiment, the invention is directed to an isolated THAP1peptide, wherein the THAP1 peptide comprises one or more of thefollowing THAP1 mutations: a p.R29X mutation, a p.R29P mutation, ap.F81L mutation, a p.K89R mutation, a p.A39T mutation, a p.Q154fs18mutation, a p.F45fs73 mutation, a p.C54Y mutation, a p.S21T mutation, ap.H23Y mutation, a p.N12K mutation, a p.F22S mutation, a p.P47Lmutation, a p.ΔF132 mutation, a p.S4F mutation, a p.S194P mutation, ap.T142A mutation, a p.T84X mutation (where X denotes a stop codon), anda p.R169X mutation (where X denotes a stop codon) as compared to a wildtype THAP1 protein (e.g., SEQ ID NO: 11).

In one embodiment, the invention is directed to an expression construct.In some embodiments, the invention is directed to an expressionconstruct that includes a promoter operably linked to one or moreisolated THAP1 nucleic acids that encode a THAP1 peptide comprising theamino acid sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQID NO: 16, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72,SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO:77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ IDNO: 82, SEQ ID NO: 83, SEQ ID NO: 84, or SEQ ID NO: 85.

In some embodiments, the expression construct includes an isolatednucleic acid that encodes a THAP1 peptide comprising the amino acidsequence of SEQ ID NO: 12, wherein the nucleic acid is operably linkedto a promoter. In some embodiments, the expression construct includes anisolated nucleic acid that encodes a THAP1 peptide comprising the aminoacid sequence of SEQ ID NO: 13, wherein the nucleic acid is operablylinked to a promoter. In some embodiments, the expression constructincludes an isolated nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 15, wherein the nucleicacid is operably linked to a promoter. In some embodiments, theexpression construct includes an isolated nucleic acid that encodes aTHAP1 peptide comprising the amino acid sequence of SEQ ID NO: 16,wherein the nucleic acid is operably linked to a promoter.

In one embodiment, the invention is directed to an expression constructthat includes an isolated nucleic acid that includes one or more of thefollowing THAP1 mutations: a c.85C>T mutation, a c.86G>C mutation, ac.241T>C mutation, a c.266A>G mutation, c.115G>A mutation, c.460delCmutation, a c.134_135insGGGTT;137_139delAAC mutation, a c.161G>Amutation, a c.1A>G mutation, a c.61T>A mutation, a c.67C>T mutation, ac.36C>A mutation, a c.2delT mutation, a c.65T>C mutation, a c.140C>Tmutation, a c.392-394delTTT mutation, a c.11C>T mutation, a c.580T>Cmutation, a c.424A>G mutation, a c.250-251delAC mutation, and a c.505C>Tmutation as compared to a wild type THAP1 DNA (e.g., SEQ ID NO: 4).

In one embodiment, the invention is directed to an isolated celltransfected with an isolated THAP1 nucleic acid. In some embodiments,the invention is directed to an isolated cell transfected with one ormore isolated THAP1 nucleic acid that encodes a THAP1 peptide comprisingthe amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15,SEQ ID NO: 16, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO:72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ IDNO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, or SEQ ID NO: 85.

In some embodiments, the invention is directed to an isolated celltransfected with an isolated THAP1 nucleic acid that encodes a THAP1peptide comprising the amino acid sequence of SEQ ID NO: 12. In someembodiments, the invention is directed to an isolated cell transfectedwith an isolated THAP1 nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 13. In someembodiments, the invention is directed to an isolated cell transfectedwith an isolated THAP1 nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 15. In someembodiments, the invention is directed to an isolated cell transfectedwith an isolated THAP1 nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 16. In someembodiments, the invention is directed to an isolated cell transfectedwith an isolated THAP1 nucleic acid that includes one or more of thefollowing THAP1 mutations: a c.85C>T mutation, a c.86G>C mutation, ac.241T>C mutation, a c.266A>G mutation, a c.115G>A mutation, a c.460delCmutation, a c.134_135insGGGTT;137_139delAAC mutation, a c.161G>Amutation, a c.1A>G mutation, a c.61T>A mutation, a c.67C>T mutation, ac.36C>A mutation, a c.2delT mutation, a c.65T>C mutation, a c.140C>Tmutation, a c.392-394delTTT mutation, a c.11C>T mutation, a c.580T>Cmutation, a c.424A>G mutation, a c.250-251delAC mutation, and a c.505C>Tmutation.

In one embodiment, the invention is directed to a method of detectingthe presence of a THAP1 mutation in a biological sample from a subject,comprising: obtaining a biological sample comprising DNA or RNA from asubject; if the sample comprises RNA, producing cDNA from the RNAcontained in the biological sample; contacting the biological samplewith primer pairs that allow for specific amplification of all or partof the THAP1 DNA or cDNA, under conditions permitting hybridization ofthe primers to the DNA; amplifying the THAP1 DNA or cDNA; and comparingthe amplified products obtained from the subject to the amplifiedproducts obtained with a normal control biological sample, whereby adifference between the product from the subject and the product from thenormal sample indicates the presence of a THAP1 mutation in the subject.In some embodiments, the primer pairs use in this method are selectedfrom SEQ ID NO: 20 and SEQ ID NO: 21; SEQ ID NO: 22 and SEQ ID NO: 23;SEQ ID NO: 24 and SEQ ID NO: 25; SEQ ID NO: 26 and SEQ ID NO: 27; SEQ IDNO: 28 and SEQ ID NO: 29; and SEQ ID NO: 30 and SEQ ID NO: 31. In someembodiments, the THAP1 DNA is amplified by PCR or real-time PCR. In someembodiments, the THAP1 mutation includes one or more of the followingTHAP1 mutations: a c.134_135insGGGTT;137_139delAAC mutation, a c.241T>Cmutation, a c.85>T mutation, a c.86G>C mutation, a c.266A>G mutation, ac.115G>A mutation, a c.460delC mutation, a c.161G>A mutation, a c.1A>Gmutation, a c.61T>A mutation, a c.67C>T mutation, a c.36C>A mutation, ac.2delT mutation, a c.65T>C mutation, a c.140C>T mutation, ac.392-394delTTT mutation, a c.11C>T mutation, a c.580T>C mutation, ac.424A>G mutation, a c.250-251delAC mutation, and a c.505C>T mutation.In some embodiments, the method further includes digesting the DNA orcDNA with at least one restriction enzyme and comparing the restrictionfragments of the amplified product with the restriction fragmentsobtained from the amplification of a normal control biological sample,whereby a difference between the restriction fragments from the subjectand the restriction fragments from the normal sample indicates thepresence of a THAP1 mutation in the subject.

In one embodiment, the invention is directed to a method of detectingthe presence of a THAP1 mutation in a biological sample from a subject,comprising: obtaining a biological sample comprising RNA from a subject;producing cDNA from RNA contained in the biological sample; contactingthe cDNA with specific oligonucleotides permitting the amplification ofall or part of the transcript of the THAP1 gene, under conditionspermitting hybridization of the primers with the cDNA; amplifying thecDNA; and comparing the amplified products obtained to the amplifiedproducts obtained with a normal control biological sample, whereby adifference between the product from the subject and the product from thenormal sample indicates the presence of a THAP1 mutation in the subject.In some embodiments, the cDNA is amplified by PCR or real-time PCR. Insome embodiments, the PCR or real-time PCR is performed with a primerpair selected from SEQ ID NO: 20 and SEQ ID NO: 21; SEQ ID NO: 22 andSEQ ID NO: 23; SEQ ID NO: 24 and SEQ ID NO: 25; SEQ ID NO: 26 and SEQ IDNO: 27; SEQ ID NO: 28 and SEQ ID NO: 29; and SEQ ID NO: 30 and SEQ IDNO: 31. In some embodiments, the THAP1 mutation includes one or more ofthe following THAP1 mutations: a c.134_135insGGGTT;137_139delAACmutation, a c.241T→C mutation, a c.85>T mutation, a c.86G>C mutation, ac.266A>G mutation, a c.115G>A mutation, a c.460delC mutation, a c.161G>Amutation, a c.1A>G mutation, a c.61T>A mutation, a c.67C>T mutation, ac.36C>A mutation, a c.2delT mutation, and a c.65T>C mutation, a c.140C>Tmutation, a c.392-394delTTT mutation, a c.11C>T mutation, a c.580T>Cmutation, a c.424A>G mutation, a c.250-251delAC mutation, and a c.505C>Tmutation.

In one embodiment, the invention is directed to a method for detectingthe presence of a THAP1 mutation in a biological sample, comprising:obtaining a biological sample from a subject that comprises DNA or RNA;if the sample comprises RNA, producing cDNA from the RNA contained inthe biological sample; digesting the DNA or cDNA with at least onerestriction enzyme; and comparing the restriction fragments of theamplified product with the restriction fragments obtained from theamplification of a normal control biological sample, whereby adifference between the restriction fragments from the subject and therestriction fragments from the normal sample indicates the presence of aTHAP1 mutation in the subject. In some embodiments, the method alsoincludes contacting the DNA or cDNA with specific oligonucleotidespermitting the amplification of all or part of the THAP1 gene ortranscript of the THAP1 gene prior to digesting the DNA or cDNA with atleast one restriction enzyme. In some embodiments, the restrictionenzyme is DraI or SspI.

In one embodiment, the invention is directed to a method for detectingthe presence of a mutation in THAP1 in a nucleic acid sample, the methodcomprising: obtaining a biological sample from a subject that comprisesDNA or RNA; if the sample comprises RNA, producing cDNA from the RNAcontained in the biological sample; contacting the DNA or cDNA with anoligonucleotide, wherein the oligonucleotide comprises the sequence ofSEQ ID NO: 7 or comprises a sequence that is complementary to thesequence of SEQ ID NO: 7; and determining whether the oligonucleotidebinds to the DNA or cDNA, wherein the absence of binding indicates thepresence of a mutation in a THAP1 gene or transcript of the subject.

In one embodiment, the invention is directed to a method for detectingthe presence of a mutation in THAP1 in a nucleic acid sample, the methodcomprising: obtaining a biological sample from a subject that comprisesDNA or RNA; if the sample comprises RNA, producing cDNA from the RNAcontained in the biological sample; contacting the DNA or cDNA with anoligonucleotide, wherein the oligonucleotide comprises the sequence ofSEQ ID NO: 8 or comprises a sequence that is complementary to thesequence of SEQ ID NO: 8; and determining whether the oligonucleotidebinds to the DNA or cDNA, wherein the absence of binding indicates thepresence of a mutation in a THAP1 gene or transcript of the subject.

In one embodiment, the invention is directed to a method for detectingthe presence of a mutation in THAP1 in a nucleic acid sample, the methodcomprising: obtaining a biological sample from a subject that comprisesDNA or RNA; if the sample comprises RNA, producing cDNA from the RNAcontained in the biological sample; contacting the DNA or cDNA with anoligonucleotide, wherein the oligonucleotide comprises the sequence ofSEQ ID NO: 9 or comprises a sequence that is complementary to thesequence of SEQ ID NO: 9; and determining whether the oligonucleotidebinds to the DNA or cDNA, wherein the absence of binding indicates thepresence of a mutation in a THAP1 gene or transcript of the subject.

In one embodiment, the invention is directed to a method for detectingthe presence of a mutation in THAP1 in a nucleic acid sample, the methodcomprising: obtaining a biological sample from a subject that comprisesDNA or RNA; if the sample comprises RNA, producing cDNA from the RNAcontained in the biological sample; contacting the DNA or cDNA with anoligonucleotide, wherein the oligonucleotide comprises the sequence ofSEQ ID NO: 10 or comprises a sequence that is complementary to thesequence of SEQ ID NO: 10; and determining whether the oligonucleotidebinds to the DNA or cDNA, wherein the absence of binding indicates thepresence of a mutation in a THAP1 gene or transcript of the subject.

In one embodiment, the invention is directed to a kit for detecting thepresence of a THAP1 mutations in a biological sample. In someembodiments, a kit for detecting the presence of a THAP1 mutation in abiological sample includes an isolated THAP1 nucleic acid that encodes aTHAP1 peptide comprising the amino acid sequence of SEQ ID NO: 12, SEQID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 69, SEQ ID NO: 70,SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO:75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ IDNO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, orSEQ ID NO: 85. In some embodiments, the kit further comprises a primerpair selected from the group consisting of: SEQ ID NO: 20 and SEQ ID NO:21; SEQ ID NO: 22 and SEQ ID NO: 23; SEQ ID NO: 24 and SEQ ID NO: 25;SEQ ID NO: 26 and SEQ ID NO: 27; SEQ ID NO: 28 and SEQ ID NO: 29; andSEQ ID NO: 30 and SEQ ID NO: 31.

In some embodiments, a kit for detecting the presence of a THAP1mutation in a biological sample includes a nucleic acid that includesthe sequence of SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 9. In someembodiments, a kit for detecting the presence of a THAP1 mutation in abiological sample includes a nucleic acid that includes the sequence ofSEQ ID NO: 3, SEQ ID NO: 6 or SEQ 1D NO: 10. In some embodiments, a kitfor detecting the presence of a THAP1 mutation in a biological sampleincludes amplification primers selected from the group consisting of:SEQ ID NO: 20 and SEQ ID NO: 21; SEQ ID NO: 22 and SEQ ID NO: 23; SEQ IDNO: 24 and SEQ ID NO: 25; SEQ ID NO: 26 and SEQ ID NO: 27; SEQ ID NO: 28and SEQ ID NO: 29; and SEQ ID NO: 30 and SEQ ID NO: 31. In someembodiments, a kit for detecting the presence of a THAP1 mutation in abiological sample includes sequence determination primers selected fromthe group consisting of: SEQ ID NO: 20 and SEQ ID NO: 21; SEQ ID NO: 22and SEQ ID NO: 23; SEQ ID NO: 24 and SEQ ID NO: 25; SEQ ID NO: 26 andSEQ ID NO: 27; SEQ ID NO: 28 and SEQ ID NO: 29; and SEQ ID NO: 30 andSEQ ID NO: 31. In some embodiments, a kit for detecting the presence ofa THAP1 mutation in a biological sample includes an antibody that bindsto a wild-type THAP1 protein comprising the amino acid sequence of SEQID NO: 11, but not to a mutant THAP1 protein comprising the amino acidsequence of SEQ ID NO: 12 or SEQ ID NO: 13. In some embodiments, a kitfor detecting the presence of a THAP1 mutation in a biological sampleincludes an antibody that binds to a mutant THAP1 protein comprising theamino acid sequence of SEQ ID NO: 12, but not to a wild-type THAP1protein comprising the amino acid sequence of SEQ ID NO: 11. In someembodiments, a kit for detecting the presence of a THAP1 mutation in abiological sample includes an antibody that binds to a mutant THAP1protein comprising the amino acid sequence of SEQ ID NO: 13, but not toa wild-type THAP1 protein comprising the amino acid sequence of SEQ IDNO: 11.

In some embodiments, a method for treating dystonia includesadministering to a subject a nucleic acid that encodes a THAP1 peptidecomprising the amino acid sequence of SEQ ID NO: 11. In someembodiments, a method for treating dystonia includes administering to asubject a THAP1 peptide that comprises the amino acid sequence of SEQ IDNO: 11.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the F45fs73X and F81L mutations identified in THAP1 inindividuals with DYT6 dystonia. FIG. 1A shows a DNA sequence alignmentof wild type (WT) (bottom) and Mutant (Mut) (top) alleles at the site ofinsertion/deletion in exon 2. Sequence analysis of the THAP1 generevealed that the inserted pentanucleotide sequence GGGTT occurs inreverse complement orientation (AACCC) 2 bps downstream from theinsertion site suggesting that this could serve as a source of theinsertion (underlined). Moreover, the 3 bp deletion is contained withinthis reverse complementary sequence, suggesting that the insertion eventpreceded the deletion or occurred simultaneously. FIG. 1B shows aschematic representation of the THAP1 protein that depicts the THAPdomain (solid black), low-complexity proline rich region (zig zaglines), coiled-coil domain (black diamonds), and nuclear localizationsignal (white). The exon positions are indicated by brackets and numbersrefer to the amino acid sequence. The cross-hatched region on the mutantprotein represents the out of frame amino acid sequence of the mutant.FIG. 1C shows a protein sequence from the THAP domain compared acrossspecies using ClustalW. Zinc binding residues are indicated by thebracket labeled “Zn”. Four invariant residues necessary for DNA bindingare also indicated in bold. The AVPTIF motif, also essential for DNAbinding, is shown with a bracket, the F residue of this motif is mutatedto an L in family S. The mutation is indicated by an arrow from “F81L”.

FIG. 2 shows shared haplotype in families of Mennonite origin. Thepedigree of family W and fragments of family M are shown withcorresponding haplotypes drawn below. All individuals are represented bydiamonds for patient confidentiality. Symptomatic mutation carriers areblackened; asymptomatic mutation carriers are denoted by an asterisk.Individuals were genotyped for six SNP's and haplotypes were constructedby hand. The disease bearing haplotype, representative of the foundermutation, is highlighted in grey.

FIG. 3 shows transmission of the F81L mutation in family S. The pedigreeof family S is illustrated. Filled symbols represent symptomaticmutation carriers. An arrow points to the proband.

FIG. 4 shows DNA binding activity of wild type THAP1 versus the F81Lmutant proteins. In FIG. 4A, a Western blot with monoclonal anti-V5antibody shows the in vitro translated products for in vitrotranscribed/translated full-length wild type THAP1 (IVT WT THAP1) andF81L mutant (IVT F81L mutant) proteins. Whole cell lysate of HEK 293Tcells transfected with the plasmid expressing the V5 epitope-tagged wildtype THAP1 (293T WT THAP1) was used as the positive control, andtranscription/translation mix primed with empty expression vector wasused as the negative control (IVT Empty Vector). FIG. 4B shows anautoradiogram of electrophoretic mobility shift assay (EMSA) performedwith identical amounts of in vitro transcribed/translated products(lanes 2-5, control sample using empty expression vector; lanes 6-9,wild type THAP1; lanes 10-13, F81L mutant) using a radiolabeled THABSprobe, in the absence or presence of excess unlabeled THABSoligonucleotides as indicated on the bottom. Anti-THAP1 antibody wasused to detect the presence of THAP1 in the complexes. The blackarrowhead indicates the THAP1/THABS complex; the white arrowheadindicates the antibody/THAP1/THABS complex. RRL is rabbit reticulocytelysate primed with empty expression vector.

DETAILED DESCRIPTION

The invention relates to mutations in the THAP1 gene, which theinventors of the instant application discovered are associated withdystonia. In particular, the inventors of the instant applicationdiscovered that mutations in the THAP1 gene are associated with DYT6dystonia. As described in more detail in the Examples, a heterozygous 5bp (GGGTT) insertion followed by a 3 bp deletion (AAC)(c.134_135insGGGTT;137_139delAAC) in exon 2 of the THAP(Thanatos-associated protein) domain containing, apoptosis associatedprotein 1 (THAP1) gene was found to co-segregate with the disease ofdystonia in all affected individuals and obligate carriers in fourAmish-Mennonite families (families M, C, W and R), but was notidentified in Amish-Mennonite control chromosomes. The mutation causes aframe shift at amino acid position number 44 of the human THAP1wild-type protein, which corresponds to amino acid position number 44 ofSEQ ID NO: 11 (NP_060575), resulting in a premature stop codon atposition 73 (F45fs73X; see FIG. 1A, 1B). Analysis of six singlenucleotide polymorphisms (SNPs) in the region of the THAP1 gene in the Wand M families confirmed that the F45fs73X mutation is a foundermutation in the Amish-Mennonite population.

A second mutation in exon 2 of the THAP1 gene, a c.241T→C mutation, wasfound to co-segregate with dystonia in affected individuals in a fifthfamily (family S) of partial German ancestry, but was not observed in514 control chromosomes (154 Centre d'Etude du Polymorphisme Humain(CEPH; Center for the Study of Human Polymorphisms), 180 Amish-Mennoniteand 190 United Kingdom Caucasian controls). The c.241T→C mutation is athymine to cytosine mutation at nucleotide position 241 of SEQ ID NO: 4.The c.241T→C mutation replaces a phenylalanine with a leucine at aminoacid position number 81, which corresponds to amino acid position 81 ofSEQ ID NO: 11 (NP_060575), the human THAP1 wild-type protein. Thephenylalanine at amino acid position 81 is located in a highly conservedAVPTIF motif of the THAP1 protein (FIG. 1C).

The invention is also directed, in part, to mutations in THAP1 as listedin Table 1:

TABLE 1 Mutations in THAP1 Exon Mutations Protein Subject Ethnicity(SEQ ID NO) (SEQ ID NO) AE187 German Exon 2 c.85C > T p.R29XSEQ ID NO: 50 SEQ ID NO: 69 AUS-SP Australian Exon 2 c.85C > T p.R29XSEQ ID NO: 50 SEQ ID NO: 69 Min5545 Irish Exon 2 c.86G > C p.R29PSEQ ID NO: 51 SEQ ID NO: 70 S German/Irish Exon 2 c.241T > C p.F81LSEQ ID NO: 6 SEQ ID NO: 13 AE1573 Russia Exon 2 c.266A > G p.K89RSEQ ID NO: 52 SEQ ID NO: 71 GUS11075 Italian Exon 2 c.115G > A p.A39TSEQ ID NO: 53 SEQ ID NO: 72 AE232 German Exon 3 c.460delC p.Q154fs18SEQ ID NO: 54 SEQ ID NO: 73 AE189 German/Irish Exon 2 c.134 135insGGGTT;p.F45fs73 137_139delAAC SEQ ID NO: 12 SEQ ID NO: 5 GUS17859 ItalianExon 2 c.161G > A p.C54Y SEQ ID NO: 55 SEQ ID NO: 74 AE714 Brazil Exon 1c.1A > G P.? SEQ ID NO: 56 GUS25472 Italian Exon 1 c.61T > A p.521TSEQ ID NO: 57 SEQ ID NO: 75 AE1613 Amish- Exon 1 c.67C > T p.H23YMennonite SEQ ID NO: 58 SEQ ID NO: 76 GU25191 Irish Exon 1 c.36C > Ap.N12K SEQ ID NO: 59 SEQ ID NO: 77 AE2719 Irish Exon 1 c.2delT P.?SEQ ID NO: 60 GUS27111 Amish- Exon 1 c.65T > C p.F225 MennoniteSEQ ID NO: 61 SEQ ID NO: 78 M Amish- c.134_135insGGGTT; p.F45fs73Mennonite 137_139delAAC SEQ ID NO: 12 SEQ ID NO: 5 C Amish-c.134_135insGGGTT; p.F45fs73 Mennonite 137_139delAAC SEQ ID NO: 12SEQ ID NO: 5 R Amish- c.134_135insGGGTT; p.F45fs73 Mennonite137_139delAAC SEQ ID NO: 12 SEQ ID NO: 5 W Amish- c.134_135insGGGTT;p.F45fs73 Mennonite 137_139delAAC SEQ ID NO: 12 SEQ ID NO: 5 AE2558Amish- c.134_135insGGGTT; p.F45fs73 Mennonite 137_139de1AACSEQ ID NO: 12 SEQ ID NO: 5 AE3048 Amish- Exon 2 C.134_135insGGGTT;p.F45fs73 Mennonite 137_139delAAC SEQ ID NO: 12 SEQ ID NO: 5 15855Exon 2 c.140C > T p.P47L SEQ ID NO: 62 SEQ ID NO: 79 19820 Exon 3c.392-394de1TTT p.ΔF132 (deletes SEQ ID NO: 63 F132 but proteinstays in frame) SEQ ID NO: 80 20149 Exon 1 c.11C > T p.S4F SEQ ID NO: 64SEQ ID NO: 81 MIN Italian, Exon 3 c.580T > C p.S194P 18749 Portuguese,SEQ ID NO: 65 SEQ ID NO: 82 Irish GUS13411 Italian Exon 3 C.424A > Gp.T142A SEQ ID NO: 66 SEQ ID NO: 83 MIN5175 Dutch Exon 2 C.250-251delACp.T84X SEQ ID NO: 67 SEQ ID NO: 84 JANK Exon 3 c.505C > T p.R169X 4132SEQ ID NO: 68 SEQ ID NO: 85

In Table 1, the number in the description of the mutation is in relationto SEQ ID NO: 4. For example, c.134_135insGGGTT;137_139delAAC refers toa mutation in which there is an insertion of GGGTT between nucleotides134 and 135 of SEQ ID NO: 4 and a deletion of AAC corresponding tonucleotides 137-139 of SEQ ID NO: 4. Likewise, c.241T>C refers to amutation in which there is a thymine to cytosine mutation at nucleotideposition 241 of SEQ ID NO: 4. In Table 1, the number in the descriptionof the protein is in relation to SEQ ID NO: 11. For example, F81L refersto a phenylalanine to leucine mutation at amino acid position 81 of SEQID NO: 11. In Table 1, “p.?” indicates that the mutation affects thestart codon so the nature of the protein produced, if any, is unclear.

THAP1 is a member of a family of cellular factors sharing a highlyconserved THAP domain, which is an atypical zinc finger(CysX₂₋₄CysX₃₅₋₅₃CysX₂His) (Clouaire, T. et al., Proc. Natl. Acad. Sci.U.S.A. (2005) 102: 6907-12; Roussigne, M. et al., Oncogene (2003) 22:2432-42; Roussigne, M. et al., Trends Biochem. Sci. (2003) 28: 66-9).Associated with its DNA binding domain, THAP1 regulates endothelial cellproliferation via modulation of pRb/E2F cell cycle target genes (Cayrol,C. et al., Blood (2007) 109: 584-94). In addition to the THAP domain atthe N-terminus, THAP1 possesses a low complexity, proline rich region, acoiled-coil domain and nuclear localization signal (NLS) at itsC-terminus (FIG. 1). In vitro, the C-terminal region of THAP1 interactswith prostate apoptosis response-4 protein (Par-4) (Roussigne, M. etal., Oncogene (2003) 22: 2432-42), an effector of cell death linked toprostate cancer and neurodegenerative diseases, including Parkinson'sdisease (Duan, W. et al., Ann. Neurol. (1999) 46: 587-97). THAP1 mayrecruit Par-4 to specific promoters to modulate transcriptionalactivation of genes involved in apoptosis (Roussigne, M. et al.,Oncogene (2003) 22: 2432-42).

Recently, the three-dimensional structure of the THAP domain from humanTHAP1 was resolved and structure-function relationships were determined(Bessiere, D. et al., J. Biol. Chem. (2008) 283: 4352-63). It revealedfour Zn-binding residues participating in Zinc finger formation, as wellas a number of critical residues for DNA binding (FIG. 1C). Further, adeletion mutant, containing amino acids 1-63, resulted in unfoldedprotein with no DNA-binding activity. This suggests that the frameshiftmutation, F45fs73X, in the Amish-Mennonite families, should be similarlynonfunctional. Moreover, F45fs73X lacks the Cys54 and His57 residuesneeded for Zn binding and several of the other conserved residuescritical for DNA binding: Phe58, Pro78 and the AVPTIF motif (FIG. 1C).Alanine mutagenesis of each of these residues alone as well as deletionof the AVPTIF motif is sufficient to abolish the DNA binding activity ofTHAP1 (Bessiere, D. et al., J. Biol. Chem. (2008) 283: 4352-63).

Nucleic Acids and Proteins

In one embodiment, the invention relates to an isolated nucleic acidencoding a THAP1 peptide. As used herein, a “THAP1 peptide” is THAP(Thanatos-associated protein) domain containing, apoptosis associatedprotein 1. The term “THAP1 peptide” includes a peptide having an aminoacid sequence of SEQ ID NO: 11, as well as peptides having an amino acidsequence that has at least 80% sequence identity to SEQ ID NO: 11 over aregion of at least 40 amino acids. Preferably, the THAP1 peptide has atleast 90%, at least 95%, or at least 99% sequence identity to SEQ ID NO:11 over a region of at least 40 amino acids.

As used herein, the term “nucleic acid” or “oligonucleotide” refers tothe phosphate ester polymeric form of ribonucleosides (adenosine,guanosine, uridine or cytidine; “RNA molecules”) or deoxyribonucleosides(deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; “DNAmolecules”), or any phosphoester analogs thereof, such asphosphorothioates and thioesters, in either single stranded form, or adouble-stranded helix. The term “nucleic acid” or “oligonucleotide”includes, for example, genomic DNA, cDNA, DNA, RNA, and mRNA. Doublestranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The termnucleic acid molecule, and in particular DNA or RNA molecule, refersonly to the primary and secondary structure of the molecule, and doesnot limit it to any particular tertiary forms. Thus, this term includesdouble-stranded DNA found, inter alia, in linear (e.g., restrictionfragments) or circular DNA molecules, plasmids, and chromosomes. Indiscussing the structure of particular double-stranded DNA molecules,sequences may be described herein according to the normal convention ofgiving only the sequence in the 5′ to 3′ direction along thenon-transcribed strand of DNA (i.e., the strand having a sequencehomologous to the mRNA). A “recombinant DNA molecule” is a DNA moleculethat has undergone a molecular biological manipulation.

The sequence of nucleic acids disclosed herein are written according toThe International Union of Pure and Applied Chemistry (IUPAC) DNA codes.Specifically, “A” is Adenine; “C” is Cytosine; “G” is Guanine; “T” isThymine; “U” is Uracil; “R” is any Purine (A or G); “Y” is anyPyrimidine (C, T, or U); “M” is C or A; “K” is T, U, or G; “W” is T, U,or A; “S” is C or G; “B” is C, T, U, or G (not A); “D” is A, T, U, or G(not C); “H” is A, T, U, or C (not G); “V” is A, C, or G (not T, not U);and “N” is any base (A, C, G, T, or U).

As used herein, the term “isolated” means that the referenced materialis removed from the environment in which it is normally found. Thus, anisolated biological material can be free of cellular components, i.e.,components of the cells in which the material is found or produced.Isolated nucleic acid molecules include, for example, a PCR product, anisolated mRNA, a cDNA, or a restriction fragment. Isolated nucleic acidmolecules also include, for example, sequences inserted into plasmids,cosmids, artificial chromosomes, and the like. An isolated nucleic acidmolecule is preferably excised from the genome in which it may be found,and more preferably is no longer joined to non-regulatory sequences,non-coding sequences, or to other genes located upstream or downstreamof the nucleic acid molecule when found within the genome. An isolatedprotein may be associated with other proteins or nucleic acids, or both,with which it associates in the cell, or with cellular membranes if itis a membrane-associated protein.

The wild-type nucleic acid encoding for human wild-type THAP1 peptidecorresponds to the sequence set forth in SEQ ID NO: 4. GenBank accessionnumber NM_018105.2, which corresponds to SEQ ID NO: 1, is also a nucleicacid that encodes a human wild-type THAP1 peptide; this sequenceincludes 5′ UTR and 3′UTR regions. One of skill in the art willunderstand that a nucleic acid that is a ribonucleic acid (RNA) willhave uracil in place of thymine.

The amino acid sequence for human wild-type THAP1 peptide corresponds tothe sequence with GenBank accession number NP_060575, which is SEQ IDNO: 11.

In one embodiment, the invention relates to an isolated nucleic acidthat encodes a THAP1 peptide wherein the nucleic acid sequence comprisesa c.134_135insGGGTT;137_139delAAC mutation (e.g., SEQ ID NO: 5). As usedherein, “c.134_135insGGGTT;137_139delAAC” refers to a 5 bp (GGGTT)insertion followed by a 3 bp deletion (AAC) in a THAP1 peptide asfollows: With reference to SEQ ID NO: 4, the location of the 5 bp(GGGTT) insertion is after nucleotide 134 of SEQ ID NO: 4 (see FIG. 1).With reference to SEQ ID NO: 4, the location of the 3 bp deletion (AAC)corresponds to nucleotides 137-139 of SEQ ID NO: 4. That is, the nucleicacid sequence TTTAAACC (SEQ ID NO: 7), which corresponds to nucleotides133-140 of SEQ ID NO: 4, is mutated to TTGGGTTTAC (SEQ ID NO: 9) in thec.134_135insGGGTT;137_139delAAC mutant.

The c.134_135insGGGTT;137_139delAAC mutation (e.g., SEQ ID NO: 5) causesa frame shift at amino acid position number 44 of the human THAP1wild-type protein, which corresponds to amino acid position number 44 ofSEQ ID NO: 11 (NP_060575), resulting in a premature stop codon at anamino acid that corresponds to position 74 of SEQ ID NO: 11 (NP_060575)(see FIG. 1A, 1B). This protein mutation is referred to herein as“F45fs73X.” SEQ ID NO: 2 is a nucleic acid that comprises thec.134_135insGGGTT;137_139delAAC mutation (e.g., SEQ ID NO: 5) andencodes a peptide that comprises the F45fs73X mutation. In particular,SEQ ID NO: 2 encodes the peptide of SEQ ID NO: 12. Likewise, SEQ ID NO:5 is a nucleic acid that comprises the c.134_135insGGGTT;137_139delAACmutation and encodes a peptide that comprises the F45fs73X mutation. Inparticular, SEQ ID NO: 5 encodes SEQ ID NO: 12.

The present invention relates to nucleic acids of at least 10nucleotides that comprise TTGGGTTTAC (SEQ ID NO: 9).

In another embodiment, the invention relates to an isolated nucleic acidthat encodes a THAP1 peptide wherein the nucleic acid sequence comprisesa c.241T→C mutation. As used herein, “c.241T→C” refers to a thymine tocytosine mutation at a nucleotide position that corresponds tonucleotide position 241 of SEQ ID NO: 4. That is, the nucleic acidsequence ATATTTCTT (SEQ ID NO: 8), which corresponds to nucleotides238-246 of SEQ ID NO: 4, is mutated to ATACTTCTT (SEQ ID NO: 10) in thec.241T→C mutant.

With respect to the human THAP1 wild-type peptide (NP_060575; SEQ ID NO:11), the c.241T→C mutation replaces a phenylalanine with a leucine atamino acid position 81 of SEQ ID NO: 11. As used herein, “F81L” refersto a phenylalanine to leucine mutation in a protein at an amino acidposition that corresponds to amino acid position 81 of SEQ ID NO: 11(NP_060575).

SEQ ID NO: 3 is a nucleic acid that comprises the c.241T→C mutation andencodes a peptide that comprises the F81L mutation. In particular, SEQID NO: 3 encodes the peptide of SEQ ID NO: 13. Likewise, SEQ ID NO: 6 isa nucleic acid that comprises the c.241T→C mutation and encodes apeptide that comprises the F81L mutation. In particular, SEQ ID NO: 6encodes SEQ ID NO: 13.

The invention further comprises a nucleic acid with a sequence that iscomplementary to a nucleic acid encoding a THAP1 peptide. For example, anucleic acid can be an anti-sense sequence that may be used to inhibitthe expression of a THAP1 gene or mRNA in a cell. The complementarynucleic acid may be used as a probe to identify the presence of anucleic acid encoding a THAP1 peptide.

In one embodiment, the invention relates to THAP1 peptides. Morespecifically, the invention relates to peptides comprising an amino acidsequence that comprises the F45fs73X mutation including, for example,SEQ ID NO: 12 and SEQ ID NO: 15. The invention further relates topeptides comprising an amino acid sequence that comprises the F81Lmutation including, for example, SEQ ID NO: 13 and SEQ ID NO: 16.

In a further embodiment, the invention relates to peptides comprising anamino acid sequence of at least six amino acids that comprises the aminoacid corresponding to position 145 of SEQ ID NO: 11 and amino acidsimmediately downstream and/or upstream of this amino acid. The inventionrelates to peptides that comprise an amino acid sequence of at least sixamino acids that comprise the amino acid sequence of SEQ ID NO: 15. Theinvention further relates to peptides having an amino acid sequence ofat least six amino acids comprising the amino acid corresponding toposition 81 of SEQ ID NO: 11 and amino acids immediately downstreamand/or upstream of this amino acid, wherein the peptide includes theF81L mutation. For example, the amino acid sequence PTILLCTE (SEQ ID NO:16) comprises the amino acid corresponding to position 81 of SEQ ID NO:11 and includes the F81L mutation.

Methods of obtaining isolated nucleic acids and oligonucleotides of thepresent invention are well known to those of skill in the art. Forexample, nucleic acid molecules encoding THAP1 and mutant THAP1 peptidesmay be obtained by restriction enzyme digestion of THAP1 genes or genefragments, by automated synthesis of nucleic acid molecules, or by usingthe polymerase chain reaction (PCR) with oligonucleotide primers havingnucleotide sequences that are based upon known nucleotide sequences of,for example, THAP1 genomic DNA and mRNA. Nucleotide sequences encodingpeptides with amino acid substitutions or other mutations can beobtained, for example, by oligonucleotide-directed mutagenesis,linker-scanning mutagenesis, mutagenesis using the polymerase chainreaction, and the like (see Ausubel (1995): 8-10 through 8-22; andMcPherson (ed.), Directed Mutagenesis: A Practical Approach, IRL Press(1991)).

In one embodiment, nucleic acids and oligonucleotides of the presentinvention are obtained by PCR amplification. For example, DNA can beextracted from white blood cells using the Purgene procedure (GentraSystems Inc, Minneapolis, Minn.) or by other methods known in the art.Intron based, exon-specific primers can be designed from the UCSC humangenome assembly sequence (March 2006 assembly, http://genome.ucsc.edu/)using Integrated DNA Technologies Primer Quest online server which isderived from Primer3 software (release 0.9)(https://www.idtdna.com/Scitools/Applications/Primerquest/Default.aspx).For example, the following primers can be used to amplify THAP1 exons asfollows:

TABLE 2 Primers to Amplify THAP1 Exons Gene- Annealing ExonForward Primer Sequence Reverse Primer Sequence Temp. THAP1-TGTTCCAGGAGCGCGAGAAA AAACACCTGGCCTCAGCCAATA 60 exon1 (SEQ ID NO: 20)(SEQ ID NO: 21) THAP1- TCCTAAGCTGGAAAGTTTGGGTGCCACTGTTAACTACAAGGTTCCAGGCA 57 exon2 (SEQ ID NO: 22) (SEQ ID NO: 23)THAP1- GCCTGGTCAGTCCACAGATTCTT ACTCCTTTACAGGCTAGAGGAGGATA 57 exon3(SEQ ID NO: 24) (SEQ ID NO: 25) THAP1- AGGCAAGAACGGCAGCTTGAAAAACTGGATGTCCTTCAGCTAGGGT 57 exon3A (SEQ ID NO: 26) (SEQ ID NO: 27)THAP1- AGTATGGGTCAGATCATGGGACA AGCCTTGTCCCAACTCAGTCAA 57 exon3B(SEQ ID NO: 28) (SEQ ID NO: 29) THAP1- ACTGGGACCTGATCTATGATACGCTTGAATCACAGTGCTATCCACTGGC 57 exon3C (SEQ ID NO: 30) (SEQ ID NO: 31)The following PCR conditions can be used with the primers identified inTable 2: 35 cycles of 1 min at 95° C., 1 min at annealing temperatureidentified in Table 2 (57° for exons 2 and 3 and 60° for exon1) and 1min at 72° C. The first step of denaturation and the last step ofextension are each 10 minutes at 95 C.° and 72 C.°, respectively. THAP1Exon1 sequence is GC rich and therefore the PCR reaction can beperformed with AccuPrime™ GC-rich DNA polymerase (Invitrogen). The PCRamplification of the other THAP1 exons can be performed with, forexample, Taq DNA polymerase from Applied Biosystems (ABI). The amplifiedfragments can be subjected to an enzymatic cleanup process withexonuclease I and shrimp alkaline phosphatase (USB, Corporation,Cleveland, Ohio) for 15 min at 37° C. and 15 min at 85° C., followed bystandard dideoxy cycle sequencing. Sequence analysis can be performed,for example, by using Sequencher™ version 4.8 (Gene Codes, Ann Arbor,Mich.).

The primers in Table 2 can be used to amplify nucleic acids thatcomprise the mutations in Table 1. For example, the primers for exon 2(SEQ ID NO: 22 and SEQ ID NO: 23) can be used to amplying nucleic acidscomprising the mutations in Table 1 that are located in Exon 2 (asindicated by the third column of Table 1. Likewise, the primers for exon1 (SEQ ID NO: 20 and SEQ ID NO: 21) can be used to amplifying nucleicacids comprising the mutations in Table 1 that are located in Exon 1.

In another embodiment, the nucleic acids and oligonucleotides of theinvention can be obtained by cloning. For example, PCR fragments bearingthe c.134_135insGGGTT;137_139delAAC mutant allele, the c.241T→C mutantallele, or other mutant alleles described in Table 1 can be subclonedusing the TOPO TA Cloning® Kit (Invitrogen) as described by themanufacturer and confirmed by forward and reverse sequencing. PCR can beperformed according to techniques known to those of skill in the art. Inone embodiment, PCR is performed using the THAP1 exon 2 primersdescribed in Table 2 using the following PCR conditions: 35 cycles of 1min at 95° C., 1 min at annealing temperature identified in Table 2 (57° for exons 2 and 3 and 60° for exon1) and 1 min at 72° C. The firststep of denaturation and the last step of extension can each be 10minutes at 95 C.° and 72 C.°, respectively. Methods for optimizing PCRconditions are known to those of skill in the art. PCR products can becloned into, for example, the TOPO® vector. The products of the cloningreaction can then be transformed into competent cells such as, forexample, One Shot® chemically competent E. coli cells by heat shock. Thebacterial culture can be plated on a media plate containing a drug toselect for those cells that express the selectable marker. For example,a bacterial culture can be plated on a pre-warmed LB agar platecontaining, for example, 100 μg/ml spectinomycin, and incubatedovernight at 37° C. Cells that grow on the media containing drug canthen be screen for the constructs of interest. For example, PCR can beperformed using the PCR conditions described above for exon 2 of THAP1and the products can be sequenced using procedures known to those ofskill in the art to determine if the construct is wild-type THAP1 ormutant THAP1.

In yet another embodiment, the nucleic acids and oligonucleotides can beobtained by mutagenesis of the wild type THAP1 nucleic acid. Forexample, the full-length cDNA for the gene encoding human THAP1(Ultimate ORF clone ID: IOH10776) can be purchased from Invitrogen.Human THAP1 can be transferred from the entry vector to thepcDNA3.1/nV5-Dest expression vector by Gateway recombinational cloningtechnique according to the manufacturer's instructions to introduce a V5epitope tag at the N-terminus of THAP1, yielding pcDNA3.1/nV5-hTHAP1.The pcDNA3.1/nV5-hTHAP1-F81L mutant construct can be generated byQuikChange mutagenesis (Stratagene, La Jolla, Calif.), with the forwardprimer 5′-AGAATGCTGTGCCCACAATAcTTCTTTGTACTGAGCC-3′ (SEQ ID NO: 18) andthe reverse primer 5′-GGCTCAGTACAAAGAAgTATTGTGGGCACAGCATTCT-3′ (SEQ IDNO: 19) (the point mutation is indicated in lower case), using thepcDNA3.1/nV5-hTHAP1 construct as template. Preferably, all constructsare verified by sequencing. Primers that can be used to obtain otherTHAP1 mutant nucleic acids are listed in Table 3:

-   AGCTGTCAGAAGAAAAAACTTGGGTTTACCACCAAGTATAGCAG

TABLE 3 Primers for Making THAP1 Mutant Nucleic Acids Mutation PrimersC54Y Forward Primer: CCACCAAGTATAGCAGTATTTaTTCAGAGCACTTTACTCC(SEQ ID NO: 32) Reverse Primer: GGAGTAAAGTGCTCTGAAtAAATACTGCTATACTTGGTGG(SEQ ID NO: 33) F8IL Forward Primer:AGAATGCTGTGCCCACAATAcTTCTTTGTACTGAGCC (SEQ ID NO: 18) Reverse Primer:GGCTCAGTACAAAGAAgTATTGTGGGCACAGCATTCT (SEQ ID NO: 19) H23YForward Primer: GACAAGCCCGTTICTTTCtACAAGTTTCCTCTTACTC (SEQ ID NO: 34)Reverse Primer: GAGTAAGAGGAAACTTGTaGAAAGAAACGGGCTTGTC (SEQ ID NO: 35)K89R Forward Primer: GTACTGAGCCACATGACAgGAAAGAAGATCTTCTGGA(SEQ ID NO: 36) Reverse Primer: TCCAGAAGATCTTCTTTCcTGTCATGTGGCTCAGTAC(SEQ ID NO: 37) N12K Forward Primer: GCCTACGGCTGCAAGAAaCGCTACGACAAGG(SEQ ID NO: 38) Reverse Primer: CCTTGTCGTAGCGtTTCTTGCAGCCGTAGGC(SEQ ID NO: 39) F45fs73 Forward Primer:AGCTGTCAGAAGAAAAAACTTGGGTTTACCACCAAGTATAGCAG (SEQ ID NO: 40)Reverse Primer: AAGTTTTTTCTTCTGACAGCTGCCTCCCATTCTTTACAAAGAC(SEQ ID NO: 41) R29P Forward Primer:CACAAGTTTCCTCTTACTCcACCCAGTCTTTGTAAAGAA (SEQ ID NO: 42) Reverse Primer:TTCTTTACAAAGACTGGGTgGAGTAAGAGGAAACTTGTG (SEQ ID NO: 43) S21TForward Primer: CAAGGACAAGCCCGTTaCTTTCCACAAGTTTCCT (SEQ ID NO: 44)Reverse Primer: AGGAAACTTGTGGAAAGtAACGGGCTTGTCCTTG (SEQ ID NO: 45)154fsX180 Forward Primer: GGAAAAGGATTCATCAGCTAGAAAGCAAGTTGAAAAACTCAG(SEQ ID NO: 46) Reverse Primer:CTGAGTTTTTCAACTTGCTTTCTAGCTGATGAATCCTTTTCC (SEQ ID NO: 47)

The presence of a particular codon may have an adverse effect onexpression in a particular host; therefore, a nucleic acid sequence maybe optimized for a particular host system, such as prokaryotic oreukaryotic cells. Methods for altering nucleotide sequences to alleviatethe codon usage problem are well known to those of skill in the art(see, e.g., Kane, Curr. Opin. Biotechnol. (1995) 6: 494; Makrides,Microbiol. Rev. (1996) 60: 512; and Brown (Ed.), Molecular BiologyLabFax, BIOS Scientific Publishers, Ltd. (1991), which provides a CodonUsage Table at page 245 through page 253).

Peptides may be synthesized by recombinant techniques (see e.g., U.S.Pat. No. 5,593,866) and a variety of host systems are suitable forproduction of wild-type and mutant (e.g., F45fs73X, F81L and the otherTHAP1 mutations described in Table 1) THAP1, including bacteria (e.g.,E. coli), yeast (e.g., Saccharomyces cerevisiae), insect (e.g., Sf9),and mammalian cells (e.g., CHO, COS-7). Many expression vectors havebeen developed and are available for each of these hosts. Vectors andprocedures for cloning and expression in E. coli are discussed hereinand, for example, in Sambrook et al. (Sambrook et al., MolecularCloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y. (1987)) and in Ausubel et al., 1995.

In one embodiment, the invention is directed to expression constructsthat may be used to express, for example, wild-type or mutant (e.g.,c.134_135insGGGTT;137_139delAAC, c.241T→C, or any of the other THAP1mutations described in Table 1) THAP1 mRNA and protein. By “expressionconstruct” is meant a nucleic acid sequence comprising a target nucleicacid sequence or sequences whose expression is desired, operativelyassociated with expression control sequence elements which provide forthe proper transcription and translation of the target nucleic acidsequence(s) within the chosen host cells. Such sequence elements mayinclude a promoter and a polyadenylation signal. The “expressionconstruct” may further comprise “vector sequences”. By “vectorsequences” is meant any of several nucleic acid sequences established inthe art which have utility in the recombinant DNA technologies of theinvention to facilitate the cloning and propagation of the expressionconstructs including (but not limited to) plasmids, cosmids, phagevectors, viral vectors, and yeast artificial chromosomes.

Expression constructs of the present invention may comprise vectorsequences that facilitate the cloning and propagation of the expressionconstructs. A large number of vectors, including plasmid and fungalvectors, have been described for replication and/or expression in avariety of eukaryotic and prokaryotic host cells. Standard vectorsuseful in the current invention are well known in the art and include(but are not limited to) plasmids, cosmids, phage vectors, viralvectors, and yeast artificial chromosomes. The vector sequences maycontain a replication origin for propagation in Escherichia coli (E.coli); the SV40 origin of replication; an ampicillin, neomycin, orpuromycin resistance gene for selection in host cells; and/or genes(e.g., dihydrofolate reductase gene) that amplify the dominantselectable marker plus the gene of interest.

A DNA sequence encoding wild type or mutant (e.g.,c.134_135insGGGTT;137_139delAAC, c.241T→C, or any of the other THAP1mutations described in Table 1) THAP1 can be introduced into anexpression vector appropriate for the host. Potential host-vectorsystems include but are not limited to mammalian cell systemstransfected with expression plasmids or infected with virus (e.g.,vaccinia virus, adenovirus, adeno-associated virus, herpes virus, etc.);insect cell systems infected with virus (e.g., baculovirus);microorganisms such as yeast containing yeast vectors; or bacteriatransformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.

The DNA sequence can be derived from an existing cDNA or genomic cloneor it can be synthesized. A convenient method is amplification of thegene from a single-stranded template. The template can be the product ofan automated oligonucleotide synthesis or can be denatureddouble-stranded template. Amplification primers are derived from the 5′and 3′ ends of the template and typically incorporate restriction siteschosen with regard to the cloning site of the vector. If necessary,translational initiation and termination codons can be engineered intothe primer sequences. The sequence encoding the protein may becodon-optimized for expression in the particular host. Codonoptimization is accomplished by automated synthesis of the entire geneor gene region, ligation of multiple oligonucleotides, mutagenesis ofthe native sequence, or other techniques known to those in the art.

In some embodiments, the DNA sequence is cloned into a vector to createa fusion protein. The fusion partner of the invention may function totransport the fusion protein to certain cellular locations such asinclusion bodies, the periplasm, the outer membrane, or theextracellular environment. The fusion partner may function to allow thefusion protein to be visualized or detected. For example, the fusionpartner may contain an epitope that is recognized by an antibody, adomain that binds to a peptide or nucleic acid, or a peptide that ismore readily detectable (e.g., HA, myc, 6×His, Green FluorescentProtein). Fusion partner include, but are not limited to, HA, myc,6×His, Green Fluorescent Protein, glutathione-S-transferase (GST),protein A from Staphylococcus aureus, two synthetic IgG-binding domains(ZZ) of protein A, outer membrane protein F, β-galactosidase (lacZ), andvarious products of bacteriophage λ and bacteriophage T7. From theteachings provided herein, it is apparent that other proteins may beused as fusion partners. To facilitate isolation of the THAP1 sequencefrom the fusion protein, amino acids susceptible to chemical cleavage(e.g., CNBr) or enzymatic cleavage (e.g., V8 protease, trypsin) may beused to bridge the THAP1 wild-type or mutant peptide and the fusionpartner.

A wide variety of host cell/expression vector combinations may beemployed in expressing the DNA sequences of this invention. Usefulexpression vectors, for example, may consist of segments of chromosomal,non chromosomal and synthetic DNA sequences. Suitable vectors includederivatives of SV40 and known bacterial plasmids, e.g., E. coli plasmidscol El, pCR1, pBR322, pMal-C2, pET, pGEX (Smith et al., Gene (1988) 67:31-40), pCR2.1 and pcDNA 3.1+ (Invitrogen, Carlsbad, Calif.), pMB9 andtheir derivatives, plasmids such as RP4; phage DNAs, e.g., the numerousderivatives of phage 1, e.g., NM989, and other phage DNA, e.g., M13 andfilamentous single stranded phage DNA; yeast plasmids such as the 2 mplasmid or derivatives thereof; vectors useful in eukaryotic cells, suchas vectors useful in insect or mammalian cells; vectors derived fromcombinations of plasmids and phage DNAs, such as plasmids that have beenmodified to employ phage DNA or other expression control sequences; andthe like.

Other suitable vectors include viral vectors, such as lentiviruses,retroviruses, herpes viruses, adenoviruses, adeno-associated viruses,vaccinia virus, baculovirus, and other recombinant viruses withdesirable cellular tropism. Thus, a gene encoding a functional or mutantPTPN 11 protein or polypeptide domain fragment thereof can be introducedin vivo, ex vivo, or in vitro using a viral vector or through directintroduction of DNA. Expression in targeted tissues can be effected bytargeting the transgenic vector to specific cells, such as with a viralvector or a receptor ligand, or by using a tissue-specific promoter, orboth. Targeted gene delivery is described in International PatentPublication WO 95/28494, published October 1995.

Viral vectors commonly used for in vivo or ex vivo targeting and therapyprocedures (see below), as well as in vitro expression, are DNA-basedvectors and retroviral vectors. Methods for constructing and using viralvectors are known in the art (see, e.g., Miller and Rosman,BioTechniques (1992) 7: 980-990). Preferably, the viral vectors arereplication defective; that is, they are unable to replicateautonomously in the target cell. In general, the genome of thereplication defective viral vectors which are used within the scope ofthe present invention lack at least one region which is necessary forthe replication of the virus in the infected cell. These regions caneither be eliminated (in whole or in part), or can be renderednon-functional by any technique known to a person skilled in the art.These techniques include the total removal, substitution (by othersequences, in particular by the inserted nucleic acid), partial deletionor addition of one or more bases to an essential (for replication)region. Such techniques may be performed in vitro (on the isolated DNA)or in situ, using the techniques of genetic manipulation or by treatmentwith mutagenic agents. Preferably, the replication defective virusretains the sequences of its genome which are necessary forencapsidating the viral particles.

DNA viral vectors include an attenuated or defective DNA virus, such asbut not limited to herpes simplex virus (HSV), papillomavirus, EpsteinBarr virus (EBV), adenovirus, adeno-associated virus (AAV), baculovirus,and the like. RNA viral vectors include, for example, retroviruses,lentiviruses, and alphaviruses (e.g., Sindbis virus and VenezuelanEquine Encephalitis virus), and the like. Defective viruses, whichentirely or almost entirely lack viral genes, are preferred. Defectivevirus is not infective after introduction into a cell. Use of defectiveviral vectors allows for administration to cells in a specific,localized area, without concern that the vector can infect other cells.Thus, a specific tissue can be specifically targeted. Examples ofparticular vectors include, but are not limited to, a defective herpesvirus 1 (HSV1) vector (Kaplitt et al., Molec. Cell. Neurosci. (1991) 2:320-330), defective herpes virus vector lacking a glyco-protein L gene(Patent Publication RD 371005 A), or other defective herpes virusvectors (International Patent Publication No. WO 94/21807, publishedSep. 29, 1994; International Patent Publication No. WO 92/05263,published Apr. 2, 1994); an attenuated adenovirus vector, such as thevector described by Stratford-Perricaudet et al. (J. Clin. Invest.(1992) 90: 626-630; see also La Salle et al., Science (1993) 259:988-990); and a defective adeno-associated virus vector (Samulski etal., J. Virol. (1987) 61: 3096-3101; Samulski et al., J. Virol. (1989)63: 3822-3828; Lebkowski et al., Mol. Cell. Biol. (1988) 8: 3988-3996).

Various companies produce viral vectors commercially, including but byno means limited to Avigen, Inc. (Alameda, Calif.; AAV vectors), CellGenesys (Foster City, Calif.; retroviral, adenoviral, AAV vectors, andlentiviral vectors), Clontech (retroviral and baculoviral vectors),Genovo, Inc. (Sharon Hill, Pa.; adenoviral and AAV vectors), Genvec(adenoviral vectors), IntroGene (Leiden, Netherlands; adenoviralvectors), Molecular Medicine (retroviral, adenoviral, AAV, and herpesviral vectors), Norgen (adenoviral vectors), Oxford BioMedica (Oxford,United Kingdom; lentiviral vectors), Transgene (Strasbourg, France;adenoviral, vaccinia, retroviral, and lentiviral vectors) and Invitrogen(Carlbad, Calif.).

Within a preferred embodiment, the vector is capable of replication inbacterial cells. Thus, the vector may contain a bacterial origin ofreplication. Preferred bacterial origins of replication include f1-oriand col E1 ori, especially the ori derived from pUC plasmids. Low copynumber vectors (e.g., pPD 100) may also be used, especially when theproduct is deleterious to the host. The plasmids also preferably includeat least one selectable marker that is functional in the host. Aselectable marker gene confers a phenotype on the host that allowstransformed cells to be identified and/or selectively grown. Suitableselectable marker genes for bacterial hosts include the chloroamphenicolresistance gene (Cm r), ampicillin resistance gene (Ampr), tetracyclineresistance gene (Tcr), kanamycin resistance gene (Kanr), and othersknown in the art. To function in selection, some markers may require acomplementary deficiency in the host. The vector may also contain a genecoding for a repressor protein, which is capable of repressing thetranscription of a promoter that contains a repressor binding site.Altering the physiological conditions of the cell can depress thepromoter. For example, a molecule may be added that competitively bindsthe repressor, or the temperature of the growth media may be altered.Repressor proteins include, but are not limited to the E. coli lacIrepressor (responsive to induction by IPTG), the temperature sensitiveXcI857 repressor, and the like.

Preferably, the expression vector contains a promoter sequence. Suitablepromoters, including both constitutive and inducible promoters, arewidely available and are well known in the art. Commonly used promotersfor expression in bacteria include promoters from T7, T3, T5, and SP6phages, and the trp, lpp, and lac operons. Hybrid promoters (see, U.S.Pat. No. 4,551,433), such as tac and trc, may also be used. Examples ofplasmids for expression in bacteria include the pET expression vectorspET3a, pET 11a, pET 12a-c, and pET 15b (see U.S. Pat. No. 4,952,496;available from Novagen, Madison, Wis.). Low copy number vectors (e.g.,pPD 100) can be used for efficient overproduction of peptidesdeleterious to the E. coli host (Dersch et al., FEMS Microbiol. Lett.123: 19, 1994). Bacterial hosts for the T7 expression vectors maycontain chromosomal copies of DNA encoding T7 RNA polymerase operablylinked to an inducible promoter (e.g., lacUV promoter; see, U.S. Pat.No. 4,952,496), such as found in the E. coli strains HMS 174(DE3)pLysS,BL21(DE3)pLysS, HMS174(DE3) and BL21(DE3). T7 RNA polymerase can also bepresent on plasmids compatible with the T7 expression vector. Thepolymerase may be under control of a lambda promoter and repressor(e.g., pGP1-2; Tabor and Richardson, Proc. Natl. Acad. Sci. USA (1985)82: 1074, 1985).

Other promoters that may be used to control THAP1 expression include,but are not limited to, cytomegalovirus (CMV) promoter (U.S. Pat. Nos.5,385,839 and 5,168,062), the SV40 early promoter region (Benoist andChambon, Nature 1981, 290:304-310), the promoter contained in the 3′long terminal repeat of Rous sarcoma virus (Yamamoto, et al., Cell 1980,22:787-797), the herpes thymidine kinase promoter (Wagner et al., Proc.Natl. Acad. Sci. U.S.A. (1981) 78: 1441-1445), the regulatory sequencesof the metallothionein gene (Brinster et al., Nature 1982; 296:39 42);prokaryotic expression vectors such as the β-lactamase promoter(Villa-Komaroff et al., Proc. Natl. Acad. Sci. U.S.A. (1978) 75:3727-3731), or the tac promoter (DeBoer et al., Proc. Natl. Acad. Sci.U.S.A. 1983; 80:21-25); see also “Useful proteins from recombinantbacteria” in Scientific American 1980; 242:74-94. Still other usefulpromoters that may be used include promoter elements from yeast or otherfungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase)promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatasepromoter; and transcriptional control regions that exhibit hematopoietictissue specificity, in particular: beta-globin gene control region whichis active in myeloid cells (Mogram et al., Nature 1985; 315:338-340;Kollias et al., Cell 1986; 46:89-94), hematopoietic stem celldifferentiation factor promoters, erythropoietin receptor promoter(Maouche et al., Blood 1991; 15:2557), etc.

Other regulatory sequences may also be included. Such sequences includean enhancer, ribosome binding site, transcription termination signalsequence, secretion signal sequence, origin of replication, selectablemarker, and the like. The regulatory sequences are operably linked withone another to allow transcription and subsequent translation.

The invention further provides for an isolated cell comprising anexpression construct. The expression construct comprises a nucleic acidthat encodes a THAP1 peptide, including a THAP1 peptide that comprisesthe F45fs73X mutation, the F81L mutation or any of the other THAP1mutations described in Table 1. For example, the THAP1 nucleic acid maycomprise any of SEQ ID NOS: 2, 3, 5, 6, 9 or 10. The nucleic acid mayencode a peptide that comprises any of SEQ ID NOS: 12, 13, 15, or 16. Inone embodiment, the cell is a eukaryotic cell. In another embodiment,the isolated cell is a prokaryotic cell.

Expression constructs of the invention can be introduced into host cellsby methods well known to those of skill in the art including, forexample, electroporation, microinjection, cell fusion, DEAE dextran,Ca²⁺-mediated techniques, use of a gene gun, or use of a DNA vectortransporter (see, e.g., Wu et al., J. Biol. Chem. (1992) 267: 963-967;Wu and Wu, J. Biol. Chem. (1988) 263: 14621-14624; Hartmut et al.,Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990; Williamset al., Proc. Natl. Acad. Sci. U.S.A. 1991; 88:2726-2730).Receptor-mediated DNA delivery approaches can also be used (Curiel etal., Hum. Gene Ther. 1992; 3:147-154; Wu and Wu, J. Biol. Chem. 1987;262:4429-4432). U.S. Pat. Nos. 5,580,859 and 5,589,466 disclose deliveryof exogenous DNA sequences, free of transfection facilitating agents, ina mammal. Recently, a relatively low voltage, high efficiency in vivoDNA transfer technique, termed electrotransfer, has been described (Miret al., C.P. Acad. Sci. 1998; 321:893; WO 99/01157; WO 99/01158; WO99/01175).

In one embodiment, the expression construct can be introduced in vivo bylipofection, as naked DNA, or with other transfection facilitatingagents (peptides, polymers, etc.). Synthetic cationic lipids can be usedto prepare liposomes for in vivo transfection of a gene encoding amarker (Felgner et al., Proc. Natl. Acad. Sci. U.S.A. (1987) 84:7413-7417; Felgner and Ringold, Science (1989) 337: 387-388; Mackey etal., Proc. Natl. Acad. Sci. U.S.A. (1988) 85: 8027-8031; Ulmer et al.,Science (1993) 259: 1745-1748). Useful lipid compounds and compositionsfor transfer of nucleic acids are described in International PatentPublications WO 95/18863 and WO 96/17823, and in U.S. Pat. No.5,459,127. Lipids may be chemically coupled to other molecules for thepurpose of targeting (see, Mackey et al., Proc. Natl. Acad. Sci. U.S.A.(1988) 85: 8027-8031). Targeted peptides, and proteins such asantibodies, or non-peptide molecules could be coupled to liposomeschemically. Other molecules are also useful for facilitatingtransfection of a nucleic acid in vivo, such as a cationic oligopeptide(e.g., International Patent Publication WO 95/21931), peptides derivedfrom DNA binding proteins (e.g., International Patent Publication WO96/25508), or a cationic polymer (e.g., International Patent PublicationWO 95/21931).

Preferably, for in vivo administration, an appropriate immunosuppressivetreatment is employed in conjunction with a viral vector, e.g.,adenovirus vector, to avoid immuno-deactivation of the viral vector andtransfected cells. For example, immunosuppressive cytokines, such asinterleukin-12 (IL-12), interferon-γ (IFN-γ), or anti-CD4 antibody, canbe administered to block humoral or cellular immune responses to theviral vectors (see, e.g., Wilson, Nat. Med. 1995; 1:887-889). In thatregard, it is advantageous to employ a viral vector that is engineeredto express a minimal number of antigens.

Soluble forms of the protein can be obtained by collecting culturefluid, or solubilizing-inclusion bodies, e.g., by treatment withdetergent, and if desired sonication or other mechanical processes, asdescribed above. The solubilized or soluble protein can be isolatedusing various techniques, such as polyacrylamide gel electrophoresis(PAGE), isoelectric focusing, 2 dimensional gel electrophoresis,chromatography (e.g., ion exchange, affinity, immunoaffinity, and sizingcolumn chromatography), centrifugation, differential solubility,immunoprecipitation, or by any other standard technique for thepurification of proteins.

Methods of Detecting a THAP1 Mutation

According to the invention, mutated forms of THAP1 nucleic acids andproteins, as well as deregulated expression of THAP1 (e.g.over-expression of THAP1), can be detected by a variety of suitablemethods known to those of skill in the art.

In a preferred embodiment, the determination of mutations in the THAP1gene encompasses the use of nucleic acid sequences, such as specificoligonucleotides, to detect mutations in, for example, THAP1 genomic DNAor mRNA in a biological sample. Such oligonucleotides may specificallyhybridize to a site of mutation, or to a region adjacent to this site ofmutation present in a THAP1 nucleic acid. One may also employ primersthat permit amplification of all or part of THAP1. Alternatively, or incombination with such techniques, oligonucleotide sequencing describedherein or known to the skilled artisan can be applied to detect THAP1mutations.

In one embodiment, one skilled in the art may use oligonucleotideprimers in an amplification technique, such as the polymerase chainreaction (PCR), to specifically amplify the target DNA in a biologicalsample. Thus, the present invention is directed to a method of detectingthe presence of a THAP1 mutation in a biological sample from a subject,comprising:

a) obtaining a biological sample comprising DNA from a subject;

b) contacting the biological sample with primer pairs that allow forspecific amplification of all or part of the THAP1 DNA, under conditionspermitting hybridization of the primers to the DNA;

c) amplifying the THAP1 DNA; and

d) comparing the amplified products obtained from the subject to theamplified products obtained with a normal control biological sample,whereby a difference between the product from the subject and theproduct from the normal sample indicates the presence of a THAP1mutation in the subject.

PCR is a method that allows exponential amplification of a DNA sequence(including sequences up to several kilobases) from a double strandedDNA. PCR entails the use of a pair of primers that are complementary toa defined sequence on each of the two strands of the DNA. These primersare extended by a DNA polymerase so that a copy is made of thedesignated sequence. After making this copy, the same primers can beused again, not only to make another copy of the input DNA strand butalso of the copy made in the first round of synthesis. This leads tologarithmic amplification. Since it is necessary to raise thetemperature to separate the two strands of the double strand DNA in eachround of the amplification process, a major step forward was thediscovery of a thermo-stable DNA polymerase (Taq polymerase) that wasisolated from Thermus aquaticus, a bacterium that grows in hot pools; asa result it is not necessary to add new polymerase in every round ofamplification. After several (often about 40) rounds of amplification,the PCR product is usually abundant enough to be detected with anethidium bromide stain so that it can be analyzed on an agarose gel.

In other embodiments, real-time PCR, also called quantitative real timePCR, quantitative PCR (Q-PCR/qPCR), or kinetic polymerase chainreaction, is a laboratory technique based on PCR, which is used toamplify and simultaneously quantify a targeted DNA molecule. qPCRenables both detection and quantification (as absolute number of copiesor relative amount when normalized to DNA input or additionalnormalizing genes) of a specific sequence in a DNA sample. For example,in the embodiments disclosed herein, qPCR may be used to quantify theamount of fungal DNA in a patient sample. The procedure follows thegeneral principle of PCR; its key feature is that the amplified DNA isquantified as it accumulates in the reaction in real time after eachamplification cycle. Two common methods of quantification are the use offluorescent dyes that intercalate with double-stranded DNA, and modifiedDNA oligonucleotide probes that fluoresce when hybridized with acomplementary DNA. The qPCR results may be quantitated using the ΔΔCtmethod. This method involves calculating a ΔCt between the averagetarget gene Ct and average housekeeping gene Ct for a given target ineach treatment group. The ΔΔCt is used to calculate the “n-fold” changein gene expression between groups.

As used herein, a “polymerase” refers to an enzyme that catalyzes thepolymerization of nucleotides. Generally, the enzyme will initiatesynthesis at the 3′-end of the primer annealed to a nucleic acidtemplate sequence. “DNA polymerase” catalyzes the polymerization ofdeoxyribonucleotides. Known DNA polymerases include, for example,Pyrococcus furiosus (Pfu) DNA polymerase (Lundberg et al., 1991, Gene,108:1), E. coli DNA polymerase I (Lecomte and Doubleday, 1983, NucleicAcids Res. 11:7505), T7 DNA polymerase (Nordstrom et al., 1981, J. Biol.Chem. 256:3112), Thermus thermophilus (Tth) DNA polymerase (Myers andGelfand 1991, Biochemistry 30:7661), Bacillus stearothermophilus DNApolymerase (Stenesh and McGowan, 1977, Biochim Biophys Acta 475:32),Thermococcus litoralis (Tli) DNA polymerase (also referred to as VentDNA polymerase, Cariello et al., 1991, Nucleic Acids Res, 19: 4193),Thermotoga maritima (Tma) DNA polymerase (Diaz and Sabino, 1998 Braz J.Med. Res, 31:1239), Thermus aquaticus (Taq) DNA polymerase (Chien etal., 1976, J. Bacteoriol, 127: 1550), Pyrococcus kodakaraensis KOD DNApolymerase (Takagi et al., 1997, Appl. Environ. Microbiol. 63:4504),JDF-3 DNA polymerase (Patent application WO 0132887), AccuPrime™ GC-richDNA polymerase (Invitrogen, Carlsbad, Calif.), and Pyrococcus GB-D(PGB-D) DNA polymerase (Juncosa-Ginesta et al., 1994, Biotechniques,16:820). The polymerase activity of any of the above enzymes can bedetermined by means well known in the art.

The term “primer,” as used herein, refers to an oligonucleotide capableof acting as a point of initiation of DNA synthesis under conditions inwhich synthesis of a primer extension product complementary to a nucleicacid strand is induced, i.e., either in the presence of four differentnucleoside triphosphates and an agent for extension (e.g., a DNApolymerase or reverse transcriptase) in an appropriate buffer and at asuitable temperature. A primer is preferably a single-stranded DNA. Theappropriate length of a primer depends on the intended use of the primerbut typically ranges from 6 to 50 nucleotides, preferably from 15-35nucleotides. Short primer molecules generally require coolertemperatures to form sufficiently stable hybrid complexes with thetemplate. A primer need not reflect the exact sequence of the templatenucleic acid, but must be sufficiently complementary to hybridize withthe template. The design of suitable primers for the amplification of agiven target sequence is well known in the art and described in theliterature cited herein. As used herein, a “forward primer” isunderstood to mean a primer that is capable of hybridizing to a regionof DNA along the 5′ (coding) strand of DNA. A “reverse” primer isunderstood to mean a primer that is capable of hybridizing to a regionof DNA along the 3′ (non-coding) strand of DNA.

As used herein, a primer is “specific,” for a target sequence if, whenused in an amplification reaction under sufficiently stringentconditions, the primer hybridizes primarily only to the target nucleicacid. Typically, a primer is specific for a target sequence if theprimer-target duplex stability is greater than the stability of a duplexformed between the primer and any other sequence found in the sample.One of skill in the art will recognize that various factors, such assalt conditions as well as base composition of the primer and thelocation of the mismatches, will affect the specificity of the primer,and that routine experimental confirmation of the primer specificitywill be needed in most cases. Hybridization conditions can be chosenunder which the primer can form stable duplexes only with a targetsequence. Thus, the use of target-specific primers under suitablystringent amplification conditions enables the specific amplification ofthose target sequences which contain the target primer binding sites.The use of sequence-specific amplification conditions enables thespecific amplification of those target sequences which contain theexactly complementary primer binding sites.

A “primer set” or “primer pair” refers to a specific combination of aforward primer and a reverse primer. The “primer set” or “primer pair”may be used in a PCR reaction to generate a specific PCR product oramplicon.

In certain embodiments, the term “primer” is also intended to encompassthe oligonucleotides used in ligation-mediated amplification processes,in which one oligonucleotide is “extended” by ligation to a secondoligonucleotide which hybridizes at an adjacent position. Thus, the term“primer extension”, as used herein, refers to both the polymerization ofindividual nucleoside triphosphates using the primer as a point ofinitiation of DNA synthesis and to the ligation of two oligonucleotidesto form an extended product.

Methods of obtaining a biological sample comprising nucleic acid, suchas DNA, from a subject are well known in the art. In a preferredembodiment, DNA is extracted from white blood cells using the Purgeneprocedure (Gentra Systems Inc, Minneapolis, Minn.). DNA can also beobtained from buccal cells either from a cheek swab or from a mouthwashsample and extracted using the Puregene procedure.

Useful primer pairs that permit specific amplification of all or part ofTHAP1 genomic DNA or cDNA can be designed from the UCSC human genomeassembly sequence (March 2006 assembly, http://genome:ucsc.edu/) usingIntegrated DNA Technologies Primer Quest online server which is derivedfrom Primer3 software (release 0.9)(https://www.idtdna.com/Scitools/Applications/Primerquest/Default.aspx).Examples of primers that can be used include the primers set forth inTable 2. For example, the c.241T>C mutation (e.g., SEQ ID NO: 6) can beamplified using exon 2 forward (SEQ ID NO: 22) and reverse (SEQ ID NO:23) primers and the following amplification conditions: 95° C. 10 min;95° C. 1 min-57° C. 1 min-72° C. 1 min (35 cycles); 72° C. 10 min.

The amplified nucleic acid from the subject is then compared to theamplified products obtained with a normal control biological sample orto the sequence of wild-type THAP1 nucleic acid, including a THAP1genomic DNA or mRNA, such as SEQ ID NO: 1 and SEQ ID NO: 4. Differencesbetween the sequence of the THAP1 nucleic acid from the subject and thesequence of the wild-type THAP1 nucleic acid (or amplification productsobtained from a normal control biological sample) are identified asTHAP1 mutations. In particular, a c.134_135insGGGTT;137_139delAACmutation (e.g., SEQ ID NO: 5), a c.241T→C mutation, or any of themutations identified in Table 1 would be identified as a THAP1 mutation.

The method of the invention can also be applied to the detection of anabnormality in the transcript of the THAP1 gene, e.g. by amplifying themRNAs contained in a biological sample, for example by RT-PCR. Thusanother aspect of the present invention is a method of detecting thepresence of a THAP1 mutation in a biological sample from a subject,comprising the steps of:

a) obtaining a biological sample comprising RNA from a subject;

b) producing cDNA from RNA contained in the biological sample;

c) contacting the cDNA with specific primers permitting theamplification of all or part of the transcript of the THAP1 gene, underconditions permitting hybridization of the primers with the cDNA;

d) amplifying the cDNA; and

e) comparing the amplified products obtained from the subject to theamplified products obtained with a normal control biological sample,whereby a difference between the product from the subject and theproduct from the normal sample indicates the presence of a THAP1mutation in the subject.

A biological sample comprising RNA from a subject may be obtained fromany cell source from which RNA can be isolated using standard methodswell known to those of ordinary skill in the art such as guanidiumthiocyanate-phenol-chloroform extraction (Chomocyznski et al., Anal.Biochem. 1987; 162-156) Other methods of obtaining a biological samplecomprising RNA include homogenizing tissue samples prior to RNAextraction and extracting total RNA from tissue homogenates, cell orblood samples using Trizol reagent (Invitrogen, Carlsbad, Calif.) inconjugation with PureLink™ Micro-to-Midi Total RNA purification system(Invitrogen, Carlsbad, Calif.) according to the manufacturer'sinstructions. In particular, lysates can be prepared using 1 ml ofTrizol reagent and incubating for 5 minutes at room temperature. Afterhomogenization, ethanol is added to the sample and then the sample isprocessed through a spin cartridge. RNA binds to the silica basedmembrane in the spin cartridge and impurities are effectively removed bywashing. The purified total RNA is eluted, for example in 30 μl of RNasefree water. Complementary DNA (cDNA) can then be produced from the RNAby procedures known to those of skill in the art. For example, reversetranscription (RT) can be used to reverse transcribe RNA, includingtotal cellular RNA or poly(A) RNA, using a reverse transcriptase enzyme,a primer, dNTPs and an RNase inhibitor. As one of skill in the art willappreciate, several different types of primers can be used, includingoligo (dT) primers, random (hexamer) primers and gene specific primers.

For a RT reaction, 1-2 micrograms of RNA is typically used. Generally,the RNA is first incubated with a primer at 70° C. to denature the RNAsecondary structure and then quickly chilled on ice to let the primeranneal to the RNA. Generally, other components of the RT reaction areadded including dNTPs, RNase inhibitor, reverse transcriptase and RTbuffer. The RT reaction can be extended at 42° C. for, for example, 1hr. The reaction can then be heated at 70° C. degree to inactivate theenzyme. Sometimes removal of the template RNA by treating the RTreaction with RNase H is performed before using the reaction in RT-PCR.The isolated RNA can alternatively be subjected to coupled reversetranscription and amplification by polymerase chain reaction (RT-PCR),using specific oligonucleotide primers that are specific for a selectedsite. In one embodiment, RT-PCR can be performed using the Platinum™quantitative RT-PCR ThermoScrip™ one-step system (GIBCO BRL). In oneembodiment, first strand cDNA is prepared using SuperScript™ FirstStrand Synthesis System for RT-PCR (Invitrogen, Carlsbad, Calif.)according to the manufacturer's instructions. In one embodiment, forreverse transcription 500 ng to 1 μg of RNA is used. The RNA isincubated with random hexamer primers and dNTPs at 65° C. to denatureRNA secondary structure and then quickly chilled on ice to let theprimer anneal to the RNA. The cDNA Synthesis Mix containing 10×RTbuffer, 25 mM MgCl₂, 0.1M DTT, RNase OUT Recombinant RNase Inhibitor andSuperScript™ III Reverse Transcriptase enzyme is added. The reaction isperformed in two steps: 50 minutes at 50° C. followed by 5 minutes at85° C. Then the reaction is treated by RNaseH to remove the RNAtemplate.

Amplification of the cDNA and comparison of the amplified products witha normal control biological sample or to the sequence of wild-type THAP1nucleic acid such as a THAP1 genomic DNA or mRNA can be performed asdescribed above. In particular, a c.134_135insGGGTT;137_139delAAC, ac.241T→C mutation, or any other mutation identified in Table 1 would beidentified as a THAP1 mutation.

The primers and conditions for primer annealing can be chosen to ensurespecific reverse transcription and amplification only of a particular(e.g., mutant) THAP1 sequence; thus, the appearance of an amplificationproduct can be diagnostic of the presence of a particular geneticvariation. In another embodiment, the primers and conditions for primerannealing can be chosen so that an amplification product is obtainedwith wild-type or mutant THAP1, but not both. The mRNA isreverse-transcribed and amplified, after which the amplified sequencesare identified by, e.g., direct sequencing.

In a preferred embodiment, the amplified fragments are subjected to anenzymatic cleanup process with exonuclease I and shrimp alkalinephosphatase (USB, Corporation, Cleveland, Ohio) for 15 min at 37° C. and15 min at 85° C., followed by standard dideoxy cycle sequencing.

Sequence analysis can be performed by a variety of suitable methodsknown to those of skilled in the art. In a preferred embodiment,sequence analysis is performed using Sequencher™ (Gene Codes, Ann Arbor,Mich.).

In still another embodiment, the DNA or cDNA obtained from RNA can befirst cloned and then sequenced to identify a mutation. Methods ofcloning DNA and cDNA are well known to those of skill in the art. In apreferred embodiment, the DNA or cDNA is subcloned using the TOPO TACloning® Kit (Invitrogen) as described by the manufacturer and confirmedby forward and reverse sequencing.

In a further embodiment, a method of detecting the presence of a THAP1mutation in a biological sample from a subject comprises obtaining abiological sample from a subject that comprises DNA or RNA; optionallyproducing cDNA from the RNA contained in the biological sample (e.g., ifthe biological sample comprises mRNA and not DNA); contacting the DNA orcDNA with specific oligonucleotides permitting the amplification of allor part of the THAP1 gene or transcript of the THAP1 gene; digesting theamplified product with at least one restriction enzyme; and comparingthe restriction fragments of the amplified product from the subject withthe restriction fragments obtained from the amplification of a normalcontrol biological sample, whereby a difference between the restrictionfragments from the subject and the restriction fragments from the normalsample indicates the presence of a THAP1 mutation in the subject. Ifsufficient cDNA or DNA is present, the cDNA or DNA may be treated withat least one restriction enzyme without an intervening amplificationstep. For example, DNA or cDNA (obtained from RNA) PCR products can bedigested with the restriction enzymes DraI to test for ac.134_135insGGGTT;137_139delAAC mutation (e.g., SEQ ID NO: 5) or SspI totest for a c.241T>C mutation (e.g., SEQ ID NO: 6). For SspI, digestionof a 400 bp PCR product from wild-type THAP1, obtained using the exon 2primers in Table 2, will result in restriction fragments of 245, 108,and 47 base pairs in length. Digestion of a 400 bp PCR product from ac.241T>C THAP1 mutant will result in restriction fragments of 292 and108 base pairs. The c.241T>C mutation (e.g., SEQ ID NO: 6) lacks a SspIrestriction site in the 292 base pair fragment that is present in wildtype. Therefore, in a heterozygous individual (one wild type and onec.241T>C allele), a SspI digestion of the PCR products would result inrestriction fragments of 292, 245, 108, and 47 base pairs. DraIdigestion of a 400 bp PCR product from wild type THAP1 results inrestriction fragments of 36, 105, 113 and 146 base pairs. Digestion of a400 bp PCR product from a c.134_135insGGGTT;137_139delAAC mutant resultsin restriction fragments of 36 bp, 113 bp and 251 base pairs. Thec.134_135insGGGTT;137_139delAAC mutant is missing a DraI restrictionsite in the 251 base pair fragment. Therefore, in a heterozygousindividual (one wild type and one c.134_135insGGGTT;137_139delAACallele), a DraI digestion of the PCR products would result inrestriction fragments of 36, 105, 113, 146, and 251 base pairs. Thedisease is dominantly inherited so we would not expect any homozygousmutation carriers. The restriction enzyme Taq1 may be used to test for aR29X mutation and the restriction enzyme MwoI may be used to test for aQ154fs180X mutation.

One skilled in the art may use hybridization probes in solution and inembodiments employing solid-phase procedures. In embodiments involvingsolid-phase procedures, the test nucleic acid is adsorbed or otherwiseaffixed to a selected matrix or surface. The fixed, single-strandednucleic acid is then subjected to specific hybridization with selectedprobes.

The THAP1 nucleic acids of the invention can also be used as probes,e.g., in therapeutic and diagnostic assays. For instance, the presentinvention provides a probe comprising an oligonucleotide that comprisesa sequence that is capable of hybridizing specifically to a region of awild-type THAP1 gene. In one embodiment, a method for detecting thepresence of a THAP1 mutation comprises:

obtaining a biological sample from a subject that comprises DNA or RNA;

if the sample comprises RNA, producing cDNA from the RNA contained inthe biological sample;

contacting the DNA or cDNA with an oligonucleotide, wherein theoligonucleotide comprises the sequence of SEQ ID NO: 7 or comprises asequence that is complementary to the sequence of SEQ ID NO: 7; and

determining whether the oligonucleotide bound to the DNA or cDNA.

Lack of binding of an oligonucleotide that comprises the sequence of SEQID NO: 7 or that comprises a sequence that is complementary to thesequence of SEQ ID NO: 7 to the DNA or cDNA from a subject indicates thepresence of a mutation in a THAP1 gene or transcript of the subject.

In another embodiment, a method for detecting the presence of a THAP1mutation comprises:

obtaining a biological sample from a subject that comprises DNA or RNA;

if the sample comprises RNA, producing cDNA from the RNA contained inthe biological sample;

contacting the DNA or cDNA with an oligonucleotide, wherein theoligonucleotide comprises the sequence of SEQ ID NO: 8 or comprises asequence that is complementary to the sequence of SEQ ID NO: 8; and

determining whether the oligonucleotide bound to the DNA or cDNA.

Lack of binding of an oligonucleotide that comprises the sequence of SEQID NO: 8 or that comprises a sequence that is complementary to thesequence of SEQ ID NO: 8 to the DNA or cDNA from a subject indicates thepresence of a mutation in a THAP1 gene or transcript of the subject.

The present invention also provides a probe comprising a substantiallypurified oligonucleotide, which oligonucleotide comprises a sequencethat is capable of hybridizing specifically to a region of a THAP1 genewhich differs from that of the wild-type THAP1 gene or mRNA (e.g., SEQID NO: 1, SEQ ID NO: 4), e.g., a mutant or polymorphic region. Suchprobes can then be used to specifically detect which mutation of theTHAP1 gene is present in a sample taken from a subject. The mutant orpolymorphic region can be located in the promoter, exon, or intronsequences of the THAP1 gene.

In one embodiment, a method for detecting the presence of a THAP1mutation comprises

obtaining a biological sample from a subject that comprises DNA or RNA;

if the sample comprises RNA, producing cDNA from the RNA contained inthe biological sample;

contacting the DNA or cDNA with an oligonucleotide, wherein theoligonucleotide comprises the sequence of SEQ ID NO: 9 or comprises asequence that is complementary to the sequence of SEQ ID NO: 9; and

determining whether the oligonucleotide bound to the DNA or cDNA.

Binding of an oligonucleotide that comprises the sequence of SEQ ID NO:9 or that comprises a sequence that is complementary to the sequence ofSEQ ID NO: 9 to the DNA or cDNA from a subject indicates the presence ofa c.134_135insGGGTT;137_139delAAC mutation (e.g., SEQ ID NO: 5) in aTHAP1 gene or transcript of the subject.

In one embodiment, a method for detecting the presence of a THAP1mutation comprises

obtaining a biological sample from a subject that comprises DNA or RNA;

if the sample comprises RNA, producing cDNA from the RNA contained inthe biological sample;

contacting the DNA or cDNA with an oligonucleotide, wherein theoligonucleotide comprises the sequence of SEQ ID NO: 10 or comprises asequence that is complementary to the sequence of SEQ ID NO: 10; and

determining whether the oligonucleotide bound to the DNA or cDNA.

Binding of an oligonucleotide that comprises the sequence of SEQ ID NO:10 or that comprises a sequence that is complementary to the sequence ofSEQ ID NO: 10 to the DNA or cDNA from a subject indicates the presenceof a c.241T>C mutation (e.g., SEQ ID NO: 6) in a THAP1 gene ortranscript of the subject.

Probes of the invention include one or more of the nucleotidesubstitutions listed in Table 1, as well as the wild-type flankingregions (see, e.g., SEQ ID NOS: 2, 3, 5, 6, 9 or 10). For each suchprobe, the complement of that probe is also a preferred probe of theinvention. Particularly preferred probes of the invention have a numberof nucleotides sufficient to allow specific hybridization to the targetnucleotide sequence. Thus, probes of suitable lengths that include oneor more of the nucleotide substitutions listed in Table 1, includingsequences that include SEQ ID NOS: 2, 3, 5, 6, 9, 10 or 50-68), or thatare complementary to the mutant sequences provided herein, can beconstructed and tested by the skilled artisan for the appropriate levelof specificity depending on the application intended. Where the targetnucleotide sequence is present in a large fragment of DNA, such as agenomic DNA fragment of several tens or hundreds of kilobases, the sizeof the probe may have to be longer to provide sufficiently specifichybridization, as compared to a probe which is used to detect a targetsequence which is present in a shorter fragment of DNA. For example, insome diagnostic methods, a portion of the THAP1 gene may first beamplified and thus isolated from the rest of the chromosomal DNA andthen hybridized to a probe. In such a situation, a shorter probe willlikely provide sufficient specificity of hybridization. For example, aprobe having a nucleotide sequence of about 10 nucleotides may besufficient, although probes of about 15 nucleotides, even morepreferably 20 nucleotides, are preferred.

In a preferred embodiment, the probe or primer further comprises a labelattached thereto, which preferably is capable of being detected. Thelabel can, for example, be selected from radioisotopes, fluorescentcompounds, enzymes, and enzyme co-factors.

In another preferred embodiment of the invention, the isolated nucleicacid, which is used, e.g., as a probe or a primer, is modified, such asto become more stable. Exemplary nucleic acid molecules which aremodified include phosphoramidate, phosphothioate and methylphosphonateanalogs of DNA (see also U.S. Pat. Nos. 5,176,996; 5,264,564; and5,256,775).

In yet another embodiment, one may use HPLC or denaturing HPLC (DHPLC)techniques to analyze the THAP1 nucleic acids. DHPLC was developed whenobserving that, when HPLC analyses are carried out at a partiallydenaturing temperature, i.e., a temperature sufficient to denature aheteroduplex at the site of base pair mismatch, homoduplexes can beseparated from heteroduplexes having the same base pair length(Hayward-Lester et al., Genome Research (1995) 5:494; Underhill et al.,Proc. Natl. Acad. Sci. USA (1996) 93:193; Doris et al., DHPLC Workshop(1997) Stanford University). Thus, the use of DHPLC was applied tomutation detection (Underhill et al., Genome Research (1997) 7:996; Liuet al., Nucleic Acid Res. (1998) 26:1396). DHPLC can separateheteroduplexes that differ by as little as one base pair. “Matched IonPolynucleotide Chromatography” (MIPC), or Denaturing “Matched IonPolynucleotide Chromatography” (DMIPC) as described in U.S. Pat. No.6,287,822 or 6,024,878, are separation methods that can also be usefulin connection with the present invention.

Alternatively, one can use the DGGE method (Denaturing Gradient GelElectrophoresis), or the SSCP method (Single Strand ConformationPolymorphism) for detecting an abnormality in the THAP1 gene. DGGE is amethod for resolving two DNA fragments of identical length on the basisof sequence differences as small as a single base pair change, usingelectrophoresis through a gel containing varying concentrations ofdenaturant (Guldberg et al., Nuc. Acids Res. (1994) 22:880). SSCP is amethod for detecting sequence differences between two DNAs, comprisinghybridization of the two species with subsequent mismatch detection bygel electrophoresis (Ravnik-Glavac et al., Hum. Mol. Genet. (1994)3:801). “HOT cleavage”, a method for detecting sequence differencesbetween two DNAs, comprising hybridization of the two species withsubsequent mismatch detection by chemical cleavage (Cotton et al., Proc.Natl. Acad. Sci. USA (1988) 85:4397), can also be used. Such methods arepreferably followed by direct sequencing. Advantageously, the RT-PCRmethod may be used for detecting abnormalities in the THAP1 transcript,as it allows one to visualize the consequences of a splicing mutationsuch as exon skipping or aberrant splicing due to the activation of acryptic site. Preferably this method is followed by direct sequencing aswell.

More recently developed techniques using microarrays, preferablymicroarray techniques allowing for high-throughput screening, can alsobe advantageously implemented for detecting an abnormality in the THAP1gene or for assaying expression of the THAP1 gene. Microarrays may bedesigned so that the same set of identical oligonucleotides is attachedto at least two selected discrete regions of the array, so that one caneasily compare a normal sample, contacted with one of the selectedregions of the array, against a test sample, contacted with another ofthe selected regions. These arrays avoid the mixture of normal sampleand test sample, using microfluidic conduits. Useful microarraytechniques include those developed by Nanogen, Inc (San Diego, Calif.)and those developed by Affymetrix. However, all types of microarrays,also called “gene chips” or “DNA chips”, may be adapted for theidentification of mutations. Such microarrays are well known in the art(see for example the following: U.S. Pat. Nos. 6,045,996; 6,040,138;6,027,880; 6,020,135; 5,968,740; 5,959,098; 5,945,334; 5,885,837;5,874,219; 5,861,242; 5,843,655; 5,837,832; 5,677,195 and 5,593,839).

The solid support on which oligonucleotides are attached may be madefrom glass, silicon, plastic (e.g., polypropylene, nylon),polyacrylamide, nitrocellulose, or other materials. One method forattaching the nucleic acids to a surface is by printing on glass plates,as is described generally by Schena et al., Science (1995) 270:467-470.This method is especially useful for preparing microarrays of cDNA. Seealso DeRisi et al., Nature Genetics (1996) 14:457-460, Shalon et al.,Genome Res. (1996) 6:639-645; and Schena et al., Proc. Natl. Acad. Sci.USA (1995) 93:10539-11286. Another method of making microarrays is byuse of an inkjet printing process to bind genes or oligonucleotidesdirectly on a solid phase, as described, e.g., in U.S. Pat. No.5,965,352.

Other methods for making microarrays, e.g., by masking (Maskos andSouthern, Nuc. Acids Res. (1992) 20:1679-1684), may also be used. Inprincipal, any type of array, for example, dot blots on a nylonhybridization membrane (see Sambrook et al., Molecular Cloning ALaboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory,Cold Spring Harbor, N.Y., 1989) could be used, although, as will berecognized by those of skill in the art, very small arrays will bepreferred because hybridization volumes will be smaller. For theseassays nucleic acid hybridization and wash conditions are chosen so thatthe attached oligonucleotides “specifically bind” or “specificallyhybridize” to at least a portion of the THAP1 nucleic acid present inthe tested sample, i.e., the probe hybridizes, duplexes or binds to theTHAP1 locus with a complementary nucleic acid sequence but does nothybridize to a site with a non-complementary nucleic acid sequence. Asused herein, one polynucleotide sequence is considered complementary toanother when, if the shorter of the polynucleotides is less than orequal to 25 bases, there are no mismatches using standard base-pairingrules or, if the shorter of the polynucleotides is longer than 25 bases,there is no more than a 5% mismatch. Preferably, the polynucleotides areperfectly complementary (no mismatches). It can easily be demonstratedthat specific hybridization conditions result in specific hybridizationby carrying out a hybridization assay including negative controls (see,e.g., Shalon et al., supra, and Chee et al., Science (1996)274:610-614).

A variety of methods are available for detection and analysis of thehybridization events. Depending on the reporter group (fluorophore,enzyme, radioisotope, etc.) used to label the DNA probe, detection andanalysis are carried out fluorimetrically, colorimetrically or byautoradiography. By observing and measuring emitted radiation, such asfluorescent radiation or a particle emission, information may beobtained about the hybridization events. When fluorescently labeledprobes are used, the fluorescence emissions at each site of transcriptarray can, preferably be detected by scanning confocal laser microscopy.In one embodiment, a separate scan, using the appropriate excitationline, is carried out for each of the two fluorophores used.Alternatively, a laser can be used that allows simultaneous specimenillumination at wavelengths specific to the two fluorophores andemissions from the two fluorophores can be analyzed simultaneously (seeShalon et al. Genome Res. (1996) 6:639-695).

As an alternative to analyzing THAP1 nucleic acids, the THAP1 proteincan be evaluated (e.g. overproduction or underproduction of the protein,dysregulated expression of the protein, functional characteristics ofthe protein). In addition, the ability of the THAP1 protein to bind toDNA (see Example 2) can be evaluated to determine THAP1 activity.

In preferred embodiments, THAP1 protein is detected by immunoassay. Forexample, Western blotting permits detection of a specific variant, orthe presence of THAP1 peptides. In particular, an immunoassay can detecta specific (wild-type or mutant) amino acid sequence in a THAP1 protein.Other immunoassay formats can also be used in place of Western blotting,as described below for the production of antibodies. These includeenzyme-linked immunosorbent assays (ELISA).

An ELISA is a biochemical technique used to detect the presence of anantibody or an antigen in a sample. In ELISA, an unknown amount ofantigen is affixed to a surface, and then a specific antibody is washedover the surface so that it can bind to the antigen. This antibody islinked to an enzyme, and in the final step a substance is added so thatthe enzyme can convert to some detectable signal. Thus in the case offluorescence ELISA, when light of the appropriate wavelength is shoneupon the sample, any antigen/antibody complexes will fluoresce so thatthe amount of antigen in the sample can be inferred through themagnitude of the fluorescence. Performing an ELISA involves at least oneantibody with specificity for a particular antigen. The sample with anunknown amount of antigen is immobilized on a solid support (usually apolystyrene microtiter plate) either non-specifically (via adsorption tothe surface) or specifically (via capture by another antibody specificto the same antigen, in a “sandwich” ELISA). After the antigen isimmobilized the detection antibody is added, forming a complex with theantigen. The detection antibody can be covalently linked to an enzyme,or can itself be detected by a secondary antibody which is linked to anenzyme through bioconjugation. Between each step the plate is typicallywashed with a mild detergent solution to remove any proteins orantibodies that are not specifically bound. After the final wash stepthe plate is developed by adding an enzymatic substrate to produce avisible signal, which indicates the quantity of antigen in the sample.Older ELISAs utilize chromogenic substrates, though newer assays employfluorogenic substrates enabling much higher sensitivity.

In one embodiment, an antibody against THAP1, or an epitopic fragment ofTHAP1 is immobilized onto a selected surface, for example, a surfacecapable of binding proteins such as the wells of a polystyrenemicrotiter plate. After washing to remove incompletely adsorbedpolypeptides, a nonspecific protein such as a solution of bovine serumalbumin (BSA) may be bound to the selected surface. This allows forblocking of nonspecific adsorption sites on the immobilizing surface andthus reduces the background caused by nonspecific bindings of antiseraonto the surface. The immobilizing surface is then contacted with asample, to be tested in a manner conducive to immune complex(antigen/antibody) formation. This may include diluting the sample withdiluents, such as solutions of BSA, bovine gamma globulin (BGG) and/orphosphate buffered saline (PBS)/Tween. The sample is then allowed toincubate for from 2 to 4 hours, at temperatures between about 25° to 37°C. Following incubation, the sample-contacted surface is washed toremove non-immunocomplexed material. The washing procedure may includewashing with a solution, such as PBS/Tween or borate buffer. Followingformation of specific immunocomplexes between the test sample and thebound antibody, and subsequent washing, the occurrence, and an evenamount of immunocomplex formation may be determined by subjecting theimmunocomplex to a second antibody against THAP1 that recognizes adifferent epitope on the protein. To provide detecting means, the secondantibody may have an associated activity such as an enzymatic activitythat will generate, for example, a color development upon incubatingwith an appropriate chromogenic substrate. Quantification may then beachieved by measuring the degree of color generation using, for example,a visible spectra spectrophotometer.

Typically the detection antibody is conjugated to an enzyme such asperoxidase and the protein is detected by the addition of a solublechromophore peroxidase substrate such as tetramethylbenzidine followedby 1 M sulfuric acid. The test protein concentration is determined bycomparison with standard curves.

These protocols are detailed in Current Protocols in Molecular Biology,V. 2 Ch. 11 and Antibodies, a Laboratory Manual, Ed Harlow, David Lane,Cold Spring Harbor Laboratory (1988) pp 579-593.

Alternatively, a biochemical assay can be used to detect expression, oraccumulation of THAP1 protein, e.g., by detecting the presence orabsence of a band in samples analyzed by polyacrylamide gelelectrophoresis; by the presence or absence of a chromatographic peak insamples analyzed by any of the various methods of high performanceliquid chromatography, including reverse phase, ion exchange, and gelpermeation; by the presence or absence of THAP1 in analytical capillaryelectrophoresis chromatography, or any other quantitative or qualitativebiochemical technique known in the art.

The immunoassays discussed above involve using antibodies directedagainst the THAP1 protein or fragments thereof. The production of suchantibodies is described below.

Anti-THAP1 Antibodies

Anti-THAP1 antibodies include but are not limited to polyclonalantibodies, monoclonal antibodies, anti-idiotypic antibodies, humanizedantibodies, chimeric antibodies, single chain antibodies, antibodyfragments (e.g., Fab, and F(ab′)₂, F_(v) variable regions, orcomplementarity determining regions), and a Fab expression library (see,in general, Antibodies: A Laboratory Manual, Harlow and Lane (eds.),Cold Spring Harbor Laboratory Press, 1988).

Various procedures known in the art may be used for the production ofpolyclonal antibodies to THAP1 polypeptides or derivatives or analogsthereof. For the production of antibody, various host animals can beimmunized by injection with the antigenic polypeptide, including but notlimited to rabbits, mice, rats, sheep, goats, etc. Generally, thepeptide or a conjugated peptide (e.g., conjugated to bovine serumalbumin (BSA), ovalbumin, etc.) is injected subcutaneously into rabbits,mice, other rodents or another suitable host animal. After twelve weeks,blood samples are taken and serum is separated for testing in an ELISAassay against the original peptide, with a positive result indicatingthe presence of antibodies specific to the target peptide. This serumcan then be stored and used in ELISA assays to specifically measure theamount of the specific antimicrobial cationic peptide and/or analog orderivative thereof.

Monoclonal antibodies directed toward THAP1 may be readily generatedfrom hybridoma cell lines using conventional techniques (see U.S. Pat.Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993; see alsoAntibodies: A Laboratory Manual, 1988). These include but are notlimited to the hybridoma technique originally developed by Kohler andMilstein (Nature 1975; 256:495-497), as well as the trioma technique,the human B-cell hybridoma technique (Kozbor et al., Immunology Today1983; 4:72; Cote et al., Proc. Natl. Acad. Sci. U.S.A. 1983;80:2026-2030), and the EBV-hybridoma technique to produce humanmonoclonal antibodies (Cole et al., in Monoclonal Antibodies and CancerTherapy, Alan R. Liss, Inc., pp. 77-96, 1985). In an additionalembodiment of the invention, monoclonal antibodies can be produced ingerm-free animals (International Patent Publication No. WO 89/12690,published 28 December, 1989). Briefly, within one embodiment, a subjectanimal, such as a rat or mouse, is injected with a peptide of choice.The peptide is generally administered in an emulsion with an adjuvant,such as Freund's complete or incomplete adjuvant, which is intended toincrease the immune response. The animal is generally boosted at leastonce prior to harvest of the spleen and/or lymph nodes andimmortalization of those cells. Various immortalization techniques, suchas mediated by Epstein-Barr virus or fusion to produce a hybridoma, maybe used. In a preferred embodiment, immortalization occurs by fusionwith a suitable myeloma cell line to create a hybridoma that secretesmonoclonal antibody. Suitable myeloma lines include, for example, NS-1(ATCC No. TIB 18), and P3X63-Ag 8.653 (ATCC No. CRL 1580). The preferredfusion partners do not express endogenous antibody genes. After aboutseven days, the hybridomas may be screened for the presence ofantibodies that are reactive against an antimicrobial cationic peptideand analog or derivative thereof. A wide variety of assays may beutilized (see Antibodies: A Laboratory Manual, 1988).

Other techniques known in the art may be utilized to constructmonoclonal antibodies (see Huse et al., Science 246:1275-1281, 1989;Sastry et al., Proc. Natl. Acad. Sci. USA 86:5728-5732, 1989;Alting-Mees et al., Strategies in Molecular Biology 3:1-9, 1990;describing recombinant techniques). These techniques include cloningheavy and light chain immunoglobulin cDNA in suitable vectors, such asλImmunoZap(H) and λImmunoZap(L). These recombinants may be screenedindividually or co-expressed to form Fab fragments or antibodies (seeHuse et al., supra; Sastry et al., supra). Positive plaques maysubsequently be converted into non-lytic plasmids to allow high-levelexpression of monoclonal antibody fragments in a host, such as E. coli.

According to the invention, techniques described for the production ofsingle chain antibodies (U.S. Pat. Nos. 5,476,786 and 5,132,405 toHuston; U.S. Pat. No. 4,946,778) can be adapted to produce THAP1polypeptide-specific single chain antibodies. Indeed, these genes can bedelivered for expression in vivo. An additional embodiment of theinvention utilizes the techniques described for the construction of Fabexpression libraries (Huse et al., Science 1989; 246:1275-1281) to allowrapid and easy identification of monoclonal Fab fragments with thedesired specificity for a THAP1 polypeptide, or its derivatives, oranalogs.

Similarly, portions or fragments of antibodies, such as Fab and Fvfragments, may also be constructed utilizing conventional enzymaticdigestion or recombinant DNA techniques to yield isolated variableregions of an antibody. Within one embodiment, the genes that encode thevariable region from a hybridoma producing a monoclonal antibody ofinterest are amplified using nucleotide primers for the variable region.In addition, techniques may be utilized to change a “murine” antibody toa “human” antibody, without altering the binding specificity of theantibody to the antimicrobial cationic peptide and analog or derivativethereof.

Antibody fragments which contain the idiotype of the antibody moleculecan be generated by known techniques. For example, such fragmentsinclude but are not limited to: the F(ab′)₂ fragment which can beproduced by pepsin digestion of the antibody molecule; the Fab′fragments which can be generated by reducing the disulfide bridges ofthe F(ab′)₂ fragment, and the Fab fragments which can be generated bytreating the antibody molecule with papain and a reducing agent.

Antibodies are generally accepted as specific if they bind with a K_(d)of greater than or equal to 10⁻⁷ M, preferably greater than of equal to10⁻⁸ M, and more preferably greater than of equal to 10⁻⁹ M. Theaffinity of a monoclonal antibody or binding partner may be readilydetermined by one of ordinary skill in the art (see, e.g., Scatchard,Ann. N.Y. Acad. Sci. (1949) 51:660-672).

Once suitable antibodies have been identified, they may be isolated orpurified by many techniques well known to those of ordinary skill in theart. In the production of antibodies, screening for the desired antibodycan be accomplished by techniques known in the art, e.g.,radioimmunoassay, ELISA, “sandwich” immunoassays, immunoradiometricassays, gel diffusion precipitin reactions, immunodiffusion assays, insitu immunoassays (using colloidal gold, enzyme or radioisotope labels,for example), western blots, precipitation reactions, agglutinationassays (e.g., gel agglutination assays, hemagglutination assays),complement fixation assays, immunofluorescence assays, protein A assays,and immunoelectrophoresis assays, etc. In one embodiment, antibodybinding is detected by detecting a label on the primary antibody. Inanother embodiment, the primary antibody is detected by detectingbinding of a secondary antibody or reagent to the primary antibody. In afurther embodiment, the secondary antibody is labeled. Many means areknown in the art for detecting binding in an immunoassay and are withinthe scope of the present invention.

Kits

The invention further relates to kits for determining the presence ofone or more THAP1 mutations in a biological sample from a subject. Inone embodiment, the invention relates to nucleic acid-based diagnostickits. The nucleic acid-based diagnostic kits of the invention includereagents for determining the sequence of the THAP1 gene or mRNA atparticular positions in a biological sample. The sequence of the THAP1gene or mRNA can be determined using any suitable procedure known in theart, including hybridization with specific probes for PCR amplification,restriction fragmentation, direct sequencing, SSCP, and other techniquesknown in the art.

A kit for determining the presence of a THAP1 mutation may compriseprobe DNA. The probe DNA may be pre-labeled, for example with afluorescent compound, a radioisotope, an enzyme or any other moleculethat allows the probe to be detected; alternatively, the probe DNA maybe unlabeled and the ingredients for labeling may be included in thekit. Ingredients for labeling the probe may include, for example,fluorescent compounds, radioisotopes, enzymes, and enzyme co-factors.

In one embodiment, the probe DNA comprises a nucleic acid sequence thatcomprises SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 8. Inanother embodiment, the probe DNA comprises a nucleic acid sequence thatcomprises SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 9. In yet anotherembodiment, the probe DNA comprises a nucleic acid sequence thatcomprises SEQ ID NO: 3, SEQ ID NO: 6 or SEQ ID NO: 10. In someembodiments, the probe DNA comprises a nucleic acid sequence thatcomprises the nucleic acid mutations identified in Table 1.

The probe DNA should be competent to discriminate between the wild-typeTHAP1 gene or transcript and a mutant THAP1 gene or transcript. One ofskill in the art will understand how to modify the length and sequenceof the DNA probe, as well as the hybridization conditions such astemperature, salt concentration, and detergent concentration so that theDNA probe is competent to discriminate between wild-type and mutantTHAP1.

The kit may also include hybridization reagents, including solid-phasematrices, hybridization buffers or components for making hybridizationbuffers.

The kits of the invention may also include reagents for producing cDNAfrom RNA. This includes reverse transcriptase, buffer for the reversetranscriptase reaction, RNase inhibitors, deoxyribonucleotides (dATP,dCTP, dGTP, and dTTP), and primers such as oligo (dT) primers, random(hexamer) primers or gene specific primers. The kit may include reagentsfor isolating DNA or RNA from a subject.

In some embodiments, a kit for determining the presence of a THAP1mutation comprises primers that may be used to amplify a region of theTHAP1 gene by PCR. Such amplification primers include, for example, theprimers set forth in Table 2.

The kit may include sequence determination primers. Sequencedetermination primers are primers that may be used to sequence a regionof the THAP1 gene or transcript. Sequence determination primers may bepre-labeled or may contain an affinity purification or attachmentmoiety. Exemplary sequence determination primer include the primers setforth in Table 2. The kit may further include materials needed forsequencing the THAP1 gene or transcript such as DNA polymerase,deoxyribonucleotides (e.g., dATP, dCTP, dGTP, dTTP), anddeoxyribonucleotide analogs that terminate DNA elongation whenincorporated. The deoxyribonucleotide analogs may be labeled to allowfor detection of their incorporation.

The invention also provides antibody-based methods for detecting mutant(or wild type) THAP1 proteins in a biological sample. The methodscomprise the steps of: (i) contacting a sample with one or more antibodypreparations, wherein each of the antibody preparations is specific formutant (or wild type) THAP1 under conditions in which a stableantigen-antibody complex can form between the antibody and THAP1 in thesample; and (ii) detecting any antigen-antibody complex formed in step(i) using any suitable means known in the art, wherein the detection ofa complex indicates the presence of mutant (or wild type) THAP1.

Typically, immunoassays use either a labeled antibody or a labeledantigenic component (e.g., that competes with the antigen in the samplefor binding to the antibody). Suitable labels include without limitationenzyme-based, fluorescent, chemiluminescent, radioactive, or dyemolecules. Assays that amplify the signals from the probe are alsoknown, such as, for example, those that utilize biotin and avidin, andenzyme-labeled immunoassays, such as ELISA assays.

Kits for detecting the presence of a THAP1 mutation may includeantibodies that are capable of binding specifically to, for example,wild-type THAP1 or to mutant THAP1 such as the F81L THAP1 protein, theF45fs73 THAP1 protein, or any of the other THAP1 mutant proteins inTable 1. In one embodiment, a kit may include a purified rabbitanti-human THAP1 polyclonal antibody such as, for example, the purifiedrabbit anti-human THAP1 polyclonal antibody from ProteinTech Group(Chicago, Ill.). The antibodies may be pre-labeled; alternatively, theantibody may be unlabeled and the ingredients for labeling may beincluded in the kit. A secondary, labeled antibody that is capable ofbinding to the first antibody that binds wild-type or mutant THAP1protein may also be included in the kit. In one embodiment, a kit fordetecting the presence of a THAP1 mutation in a biological samplecomprises an antibody that binds to a wild-type THAP1 protein comprisingthe amino acid sequence of SEQ ID NO: 11, but not to a mutant THAP1protein comprising the amino acid sequence of, for example, SEQ ID NO:12 or SEQ ID NO: 13. In another embodiment of the invention, a kit fordetecting the presence of a THAP1 mutation in a biological samplecomprises an antibody that binds to a mutant THAP1 protein comprisingthe amino acid sequence of SEQ ID NO: 12, but not to a wild-type THAP1protein comprising the amino acid sequence of SEQ ID NO: 11. In yetanother embodiment of the present invention, a kit for detecting thepresence of a THAP1 mutation in a biological sample comprises anantibody that binds to a mutant THAP1 protein comprising the amino acidsequence of SEQ ID NO: 13, but not to a wild-type THAP1 proteincomprising the amino acid sequence of SEQ ID NO: 11.

One of skill in the art will understand how to adjust protein/antibodybinding conditions for various procedures. For example, one of skill inthe art will appreciate that increasing the temperature, detergent(e.g., SDS) or salt concentration will result in more stringentconditions. In one embodiment, the following conditions can be used inthe instant invention for procedures, such as Western blotting: Proteinscan be resolved by SDS-PAGE (e.g., 8 μL of in vitro translatedproduct/lane) and then can be transferred electrophoretically onto aHybond-C nitrocellulose membrane (GE Healthcare). The membrane can beblocked with 5% nonfat dry milk diluted in Tris-buffered saline-0.2%Tween 20 and incubated successively with the primary antibody (e.g.,anti-V5, 1:5000 in blocking buffer) overnight at 4° C. and with asecondary antibody (e.g, an anti-mouse horseradish peroxidase-conjugatedsecondary antibody; 1:3000; GE Healthcare) for 1 h at room temperature.Immunoreactivity can be detected with an enhanced chemiluminescencemethod (ECL detection reagent; GE Healthcare).

The kit may contain reaction components for immunoassays using theantibodies described above, including solid-phase matrices, standards,or reagents that allow for detection of the antibody or second labeledantibody.

The kits referred to above may include instructions for conducting thetest. Furthermore, in preferred embodiments, the diagnostic kits areadaptable to high-throughput and/or automated operation.

Definitions

The following definitions are provided for clarity and illustrativepurposes only, and are not intended to limit the scope of the invention.

Conservative Amino Acid Substitution

Among the common amino acids, a “conservative amino acid substitution”is illustrated, for example, by a substitution among amino acids withineach of the following groups: (1) glycine, alanine, valine, leucine, andisoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine andthreonine, (4) aspartate and glutamate, (5) glutamine and asparagine,and (6) lysine, arginine and histidine, or a combination thereof.

The amino acid designations are herein set forth as either the standardone- or three-letter code. Unless otherwise indicated, a named aminoacid refers to the L-enantiomer. Polar amino acids include asparagine(Asp or N) and glutamine (Gln or Q); as well as basic amino acids suchas arginine (Arg or R), lysine (Lys or K), histidine (His or H), andderivatives thereof; and acidic amino acids such as aspartic acid (Aspor D) and glutamic acid (Glu or E), and derivatives thereof. Hydrophobicamino acids include tryptophan (Trp or W), phenylalanine (Phe or F),isoleucine (Ile or I), leucine (Leu or L), methionine (Met or M), valine(Val or V), and derivatives thereof; as well as other non-polar aminoacids such as glycine (Gly or G), alanine (Ala or A), proline (Pro orP), and derivatives thereof. Amino acids of intermediate polarityinclude serine (Ser or S), threonine (Thr or T), tyrosine (Tyr or Y),cysteine (Cys or C), and derivatives thereof. A capital letter indicatesan L-enantiomer amino acid; a small letter indicates a D-enantiomeramino acid. Variants may also include modified amino acids, including2,3-diamino butyric acid, 3- or 4-mercaptoproline derivatives,N⁵-acetyl-N⁵-hydroxy-L-ornitine, and α-N-hydroxyamino acids. Othermodified amino acids will be known to those of skill in the art.

Dystonia

As used herein, “dystonia” refers to a disease characterized by twistingmovements and abnormal postures. DYT6 dystonia refers to a form ofdystonia that is inherited in an autosomal dominant (AD) manner and thatis a primary form of dystonia, where dystonia is the only neurologicfeature (de Carvalho Aguiar, P. M. and Ozelius, L. J., Lancet Neurol.(2002) 1: 316-25). DYT6 dystonia is inherited with penetrance of about60% independent of gender. It is characterized by an average onset ageof 16.1 years, cranial or cervical presentation in about half of thecases and frequent progression to involve multiple body regions.

Proband

“Proband” as used herein means the individual or member of a familybeing studied in a genetic investigation and is often the the firstaffected family member who seeks medical attention for a geneticdisorder.

Founder Mutation

As used herein, a “founder mutation” refers to a mutation that appearsin the DNA of one or more individuals who are founders of a distinctpopulation.

Single Nucleotide Polymorphism (SNP)

As used herein, a “single nucleotide polymorphism”, or SNP, refers to aDNA sequence variation that occurs when a single nucleotide—adenine,guanine, thymine, or cytosine—in the genome or other shared sequencediffers, for example, between the members of a species, between membersof a population, or between paired chromosomes in an individual.

Express and Expression

The terms “express” and “expression” mean allowing or causing theinformation in a gene or DNA sequence to become manifest, for exampleproducing a protein by activating the cellular functions involved intranscription and translation of a corresponding gene or DNA sequence. ADNA sequence is expressed in or by a cell to form an “expressionproduct” such as a protein. The expression product itself, e.g., theresulting protein, may also be said to be “expressed” by the cell. Anexpression product can be characterized as intracellular, extracellularor secreted. The term “intracellular” means something that is inside acell. The term “extracellular” means something that is outside a cell. Asubstance is “secreted” by a cell if it appears in significant measureoutside the cell, from somewhere on or inside the cell.

Transfection

The term “transfection” means the introduction of a foreign nucleic acidinto a cell. The term “transformation” means the introduction of a“foreign” (i.e. extrinsic or extracellular) gene, DNA or RNA sequence toa cell, so that the host cell will express the introduced gene orsequence to produce a desired substance, typically a protein or enzymecoded by the introduced gene or sequence. The introduced gene orsequence may also be called a “cloned” or “foreign” gene or sequence,may include regulatory or control sequences, such as start, stop,promoter, signal, secretion, or other sequences used by a cells geneticmachinery. The gene or sequence may include nonfunctional sequences orsequences with no known function. A host cell that receives andexpresses introduced DNA or RNA has been “transformed” and is a“transformant” or a “clone”. The DNA or RNA introduced to a host cellcan come from any source, including cells of the same genus or speciesas the host cell, or cells of a different genus or species. In certainembodiments of the present invention, for example, MFB-F11 mousefibroblast cells are stably transfected with a reporter plasmidconsisting of TGF-β-responsive Smad-binding elements coupled to asecreted alkaline phosphatase reporter gene (SBE-SEAP).

Electroporation

“Electroporation”, as used herein, is a significant increase in theelectrical conductivity and permeability of the cell plasma membranecaused by an externally applied electrical field. It is usually used inmolecular biology as a way of introducing some substance into a cell,such as loading it with a molecular probe, a drug that can change thecell's function, or a piece of coding DNA.

Expression System

The term “expression system” means a host cell and compatible vectorunder suitable conditions, e.g. for the expression of a protein codedfor by foreign DNA carried by the vector and introduced to the hostcell.

Gene or Structural Gene

The term “gene”, also called a “structural gene” means a DNA sequencethat codes for or corresponds to a particular sequence of amino acidswhich comprise all or part of one or more proteins or enzymes, and mayor may not include regulatory DNA sequences, such as promoter sequences,which determine for example the conditions under which the gene isexpressed. Some genes, which are not structural genes, may betranscribed from DNA to RNA, but are not translated into an amino acidsequence. Other genes may function as regulators of structural genes oras regulators of DNA transcription.

A coding sequence is “under the control of” or “operatively associatedwith” expression control sequences in a cell when RNA polymerasetranscribes the coding sequence into RNA, particularly mRNA, which isthen trans-RNA spliced (if it contains introns) and translated into theprotein encoded by the coding sequence.

The term “expression control sequence” refers to a promoter and anyenhancer or suppression elements that combine to regulate thetranscription of a coding sequence. In a preferred embodiment, theelement is an origin of replication.

Protein, Peptide or Polypeptide

The definitions of protein, peptide and polypeptide are well-known inthe art. The term “protein”, as used herein, is synonymous with the term“peptide” or “polypeptide”, and is understood to mean a chain of aminoacids arranged linearly and joined together by peptide bonds between thecarboxyl and amino groups of adjacent amino acid residues.

Heterologous

The term “heterologous” refers to a combination of elements notnaturally occurring. For example, heterologous DNA refers to DNA notnaturally located in the cell, or in a chromosomal site of the cell.Preferably, the heterologous DNA includes a gene foreign to the cell.For example, the present invention includes chimeric DNA molecules thatcomprise a DNA sequence and a heterologous DNA sequence which is notpart of the DNA sequence. A heterologous expression regulatory elementis such an element that is operatively associated with a different genethan the one it is operatively associated with in nature. In the contextof the present invention, a gene encoding a protein of interest isheterologous to the vector DNA in which it is inserted for cloning orexpression, and it is heterologous to a host cell containing such avector, in which it is expressed.

Homologous

The term “homologous” as used in the art commonly refers to therelationship between nucleic acid molecules or proteins that possess a“common evolutionary origin,” including nucleic acid molecules orproteins within superfamilies (e.g., the immunoglobulin superfamily) andnucleic acid molecules or proteins from different species (Reeck et al.,Cell 1987; 50: 667). Such nucleic acid molecules or proteins havesequence homology, as reflected by their sequence similarity, whether interms of substantial percent similarity or the presence of specificresidues or motifs at conserved positions.

Host Cell

The term “host cell” means any cell of any organism that is selected,modified, transformed, grown or used or manipulated in any way for theproduction of a substance by the cell. For example, a host cell may beone that is manipulated to express a particular gene, a DNA or RNAsequence, a protein or an enzyme. Host cells can further be used forscreening or other assays that are described infra. Host cells may becultured in vitro or one or more cells in a non-human animal (e.g., atransgenic animal or a transiently transfected animal). Suitable hostcells include but are not limited to Streptornyces species and E. coli.

Treating or Treatment

“Treating” or “treatment” of a state, disorder or condition includes:

(1) Preventing or delaying the appearance of clinical or sub-clinicalsymptoms of the state, disorder or condition developing in a mammal thatmay be afflicted with or predisposed to the state, disorder or conditionbut does not yet experience or display clinical or subclinical symptomsof the state, disorder or condition; or

(2) Inhibiting the state, disorder or condition, i.e., arresting,reducing or delaying the development of the disease or a relapse thereof(in case of maintenance treatment) or at least one clinical orsub-clinical symptom thereof; or

(3) Relieving the disease, i.e., causing regression of the state,disorder or condition or at least one of its clinical or sub-clinicalsymptoms.

The benefit to a subject to be treated is either statisticallysignificant or at least perceptible to the patient or to the physician.

Patient or Subject

“Patient” or “subject” refers to mammals and includes human andveterinary subjects.

Therapeutically Effective Amount

A “therapeutically effective amount” means the amount of a compoundthat, when administered to a mammal for treating a state, disorder orcondition, is sufficient to effect such treatment. The “therapeuticallyeffective amount” will vary depending on the compound, the disease andits severity and the age, weight, physical condition and responsivenessof the mammal to be treated.

Prophylactically Effective Amount

A “prophylactically effective amount” refers to an amount effective, atdosages and for periods of time necessary, to achieve the desiredprophylactic result. Typically, since a prophylactic dose is used insubjects prior to or at an earlier stage of disease, theprophylactically effective amount will be less than the therapeuticallyeffective amount.

About or Approximately

The term “about” or “approximately” means within an acceptable range forthe particular value as determined by one of ordinary skill in the art,which will depend in part on how the value is measured or determined,e.g., the limitations of the measurement system. For example, “about”can mean a range of up to 20%, preferably up to 10%, more preferably upto 5%, and more preferably still up to 1% of a given value.Alternatively, particularly with respect to biological systems orprocesses, the term can mean within an order of magnitude, preferablywithin 5-fold, and more preferably within 2-fold, of a value. Unlessotherwise stated, the term ‘about’ means within an acceptable errorrange for the particular value.

Include or Comprise

As used herein, the terms “include” and “comprise” are usedsynonymously. It should be understood that the terms “a” and “an” asused herein refer to “one or more” of the enumerated components. The useof the alternative (e.g., “or”) should be understood to mean either one,both, or any combination thereof of the alternatives.

Purified

The term “purified” as used herein refers to material that has beenisolated under conditions that reduce or eliminate the presence ofunrelated materials, i.e. contaminants, including native materials fromwhich the material is obtained. The isolated material is preferablysubstantially free of cell or culture components, including tissueculture components, contaminants, and the like. As used herein, the term“substantially free” is used operationally, in the context of analyticaltesting of the material. Preferably, purified material substantiallyfree of contaminants is at least 50% pure; more preferably, at least 90%pure, and more preferably still at least 99% pure. Purity can beevaluated by chromatography, gel electrophoresis, immunoassay,composition analysis, biological assay, and other methods known in theart.

Mutant

As used herein, the terms “mutant” and “mutation” refer to anydetectable change in genetic material (e.g., DNA) or any process,mechanism, or result of such a change. This includes gene mutations, inwhich the structure (e.g., DNA sequence) of a gene is altered, any geneor DNA arising from any mutation process, and any expression product(e.g., protein or enzyme) expressed by a modified gene or DNA sequence.As used herein, the term “mutating” refers to a process of creating amutant or mutation.

Nucleic Acid Hybridization

The term “nucleic acid hybridization” refers to anti-parallel hydrogenbonding between two single-stranded nucleic acids, in which A pairs withT (or U if an RNA nucleic acid) and C pairs with G. Nucleic acidmolecules are “hybridizable” to each other when at least one strand ofone nucleic acid molecule can form hydrogen bonds with the complementarybases of another nucleic acid molecule under defined stringencyconditions. Stringency of hybridization is determined, e.g., by (i) thetemperature at which hybridization and/or washing is performed, and (ii)the ionic strength and (iii) concentration of denaturants such asformamide of the hybridization and washing solutions, as well as otherparameters. Hybridization requires that the two strands containsubstantially complementary sequences. Depending on the stringency ofhybridization, however, some degree of mismatches may be tolerated.Under “low stringency” conditions, a greater percentage of mismatchesare tolerable (i.e., will not prevent formation of an anti-parallelhybrid). See Molecular Biology of the Cell, Alberts et al., 3rd ed., NewYork and London: Garland Publ., 1994, Ch. 7.

Typically, hybridization of two strands at high stringency requires thatthe sequences exhibit a high degree of complementarity over an extendedportion of their length. Examples of high stringency conditions include:hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at65° C., followed by washing in 0.1×SSC/0.1% SDS at 68° C. (where 1×SSCis 0.15M NaCl, 0.15M Na citrate) or for oligonucleotide moleculeswashing in 6×SSC/0.5% sodium pyrophosphate at about 37° C. (for 14nucleotide-long oligos), at about 48° C. (for about 17 nucleotide-longoligos), at about 55° C. (for 20 nucleotide-long oligos), and at about60° C. (for 23 nucleotide-long oligos)). Accordingly, the term “highstringency hybridization” refers to a combination of solvent andtemperature where two strands will pair to form a “hybrid” helix only iftheir nucleotide sequences are almost perfectly complementary (seeMolecular Biology of the Cell, Alberts et al., 3rd ed., New York andLondon: Garland Publ., 1994, Ch. 7).

Conditions of intermediate or moderate stringency (such as, for example,an aqueous solution of 2×SSC at 65° C.; alternatively, for example,hybridization to filter-bound DNA in 0.5 M NaHPO4, 7% SDS, 1 mM EDTA at65° C., and washing in 0.2×SSC/0.1% SDS at 42° C.) and low stringency(such as, for example, an aqueous solution of 2×SSC at 55° C.), requirecorrespondingly less overall complementarity for hybridization to occurbetween two sequences. Specific temperature and salt conditions for anygiven stringency hybridization reaction depend on the concentration ofthe target DNA and length and base composition of the probe, and arenormally determined empirically in preliminary experiments, which areroutine (see Southern, J. Mol. Biol. 1975; 98: 503; Sambrook et al.,Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 2, ch. 9.50, CSHLaboratory Press, 1989; Ausubel et al. (eds.), 1989, Current Protocolsin Molecular Biology, Vol. I, Green Publishing Associates, Inc., andJohn Wiley & Sons, Inc., New York, at p. 2.10.3).

As used herein, the term “standard hybridization conditions” refers tohybridization conditions that allow hybridization of sequences having atleast 75% sequence identity. According to a specific embodiment,hybridization conditions of higher stringency may be used to allowhybridization of only sequences having at least 80% sequence identity,at least 90% sequence identity, at least 95% sequence identity, or atleast 99% sequence identity.

Nucleic acid molecules that “hybridize” to any desired nucleic acids ofthe present invention may be of any length. In one embodiment, suchnucleic acid molecules are at least 10, at least 15, at least 20, atleast 30, at least 40, at least 50, and at least 70 nucleotides inlength. In another embodiment, nucleic acid molecules that hybridize areof about the same length as the particular desired nucleic acid.

Techniques to isolate and modify specific nucleic acids and proteins arewell known to those of skill in the art. In accordance with the presentdisclosure there may be employed conventional molecular biology,microbiology, and recombinant DNA techniques within the skill of theart. Such techniques are explained fully in the literature. See, e.g.,Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual,Second Edition. Cold Spring Harbor, N.Y.: Cold Spring Harbor LaboratoryPress, 1989 (herein “Sambrook et al., 1989”); DNA Cloning: A PracticalApproach, Volumes I and II (D. N. Glover ed. 1985); OligonucleotideSynthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization [B. D. Hames& S. J. Higgins eds. (1985)]; Transcription And Translation [B. D. Hames& S. J. Higgins, eds. (1984)]; Animal Cell Culture [R. I. Freshney, ed.(1986)]; Immobilized Cells And Enzymes [IRL Press, (1986)]; B. Perbal, APractical Guide To Molecular Cloning (1984); Ausubel, F. M. et al.(eds.). Current Protocols in Molecular Biology. John Wiley & Sons, Inc.,1994. These techniques include site directed mutagenesis employingoligonucleotides with altered nucleotides for generating PCR productswith mutations (e.g., the “Quikchange” kit manufactured by Stratagene).

Oligonucleotide Preparation

Oligonucleotides can be prepared by any suitable method, includingdirect chemical synthesis by a method such as the phosphotriester methodof Narang et al., 1979, Meth. Enzymol. 68:90-99; the phosphodiestermethod of Brown et al., 1979, Meth. Enzymol. 68:109-151; thediethylphosphoramidite method of Beaucage et al., 1981, TetrahedronLett. 22:1859-1862; and the solid support method of U.S. Pat. No.4,458,066, each incorporated herein by reference. A review of synthesismethods of conjugates of oligonucleotides and modified nucleotides isprovided in Goodchild, 1990, Bioconjugate Chemistry 1(3): 165-187,incorporated herein by reference.

Complementary

As used herein, “complementary” refers to a nucleic acid molecule thatcan form hydrogen bond(s) with another nucleic acid molecule by eithertraditional Watson-Crick base pairing or other non-traditional types ofpairing (e.g., Hoogsteen or reversed Hoogsteen hydrogen bonding) betweencomplementary nucleosides or nucleotides.

Target Sequence, Region or Nucleic Acid

The terms “target, “target sequence”, “target region”, and “targetnucleic acid,” as used herein, are synonymous and refer to a region orsubsequence of a nucleic acid which is to be amplified or detected.

Amplification Reaction

The term “amplification reaction” refers to any chemical reaction;including an enzymatic reaction, which results in increased copies of atemplate nucleic acid sequence or results in transcription of a templatenucleic acid. Amplification reactions include reverse transcription andthe polymerase chain reaction (PCR), including Real Time PCR (see U.S.Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods andApplications (Innis et al., eds, 1990)). Exemplary “amplificationreactions conditions” or “amplification conditions” typically compriseeither two or three step cycles. Two step cycles have a denaturationstep followed by a hybridization/elongation step. Three step cyclescomprise a denaturation step followed by a hybridization step followedby a separate elongation step.

Reaction Mixture

The term “reaction mixture,” as used herein, refers to a solutioncontaining reagents necessary to carry out a given reaction. An“amplification reaction mixture”, which refers to a solution containingreagents necessary to carry out an amplification reaction, typicallycontains oligonucleotide primers and a DNA polymerase or ligase in asuitable buffer. A “PCR reaction mixture” typically containsoligonucleotide primers, a DNA polymerase (most typically a thermostableDNA polymerase), dNTPs, and a divalent metal cation in a suitablebuffer. A reaction mixture is referred to as complete if it contains allreagents necessary to enable the reaction, and incomplete if it containsonly a subset of the necessary reagents. It will be understood by one ofskill in the art that reaction components are routinely stored asseparate solutions, each containing a subset of the total components,for reasons of convenience, storage stability, or to allow forapplication-dependent adjustment of the component concentrations, andthat reaction components are combined prior to the reaction to create acomplete reaction mixture. Furthermore, it will be understood by one ofskill in the art that reaction components are packaged separately forcommercialization and that useful commercial kits may contain any subsetof the reaction components which includes the blocked primers of thedisclosure.

Ligation and Ligase

The term “ligation” as used herein refers to the covalent joining of twopolynucleotide ends. In various embodiments, ligation involves thecovalent joining of a 3′ end of a first polynucleotide (the acceptor) toa 5′ end of a second polynucleotide (the donor). Ligation results in aphosphodiester bond being formed between the polynucleotide ends. Invarious embodiments, ligation may be mediated by any enzyme, chemical,or process that results in a covalent joining of the polynucleotideends. In certain embodiments, ligation is mediated by a ligase enzyme.

As used herein, “ligase” refers to an enzyme that is capable ofcovalently linking the 3′ hydroxyl group of a nucleotide to the 5′phosphate group of a second nucleotide. Examples of ligases include E.coli DNA ligase, T4 DNA ligase, etc.

The ligation reaction can be employed in DNA amplification methods suchas the “ligase chain reaction” (LCR), also referred to as the “ligaseamplification reaction” (LAR), see Barany, Proc. Natl. Acad. Sci.,88:189 (1991); and Wu and Wallace, Genomics 4:560 (1989) incorporatedherein by reference. In LCR, four oligonucleotides, two adjacentoligonucleotides which uniquely hybridize to one strand of the targetDNA, and a complementary set of adjacent oligonucleotides, thathybridize to the opposite strand are mixed and DNA ligase is added tothe mixture. Provided that there is complete complementarity at thejunction, ligase will covalently link each set of hybridized molecules.Importantly, in LCR, two probes are ligated together only when theybase-pair with sequences in the target sample, without gaps ormismatches. Repeated cycles of denaturation, hybridization and ligationamplify a short segment of DNA. LCR has also been used in combinationwith PCR to achieve enhanced detection of single-base changes, seeSegev, PCT Public. No. WO9001069 A1 (1990).

Orthologs

As used herein, the term “orthologs” refers to genes in differentspecies that apparently evolved from a common ancestral gene byspeciation. Normally, orthologs retain the same function through thecourse of evolution. Identification of orthologs can provide reliableprediction of gene function in newly sequenced genomes. Sequencecomparison algorithms that can be used to identify orthologs includewithout limitation BLAST, FASTA, DNA Strider, and the GCG pileupprogram. Orthologs often have high sequence similarity. The presentinvention encompasses all orthologs of the desired protein.

Operatively Associated

By “operatively associated with” is meant that a target nucleic acidsequence and one or more expression control sequences (e.g., promoters)are physically linked so as to permit expression of the polypeptideencoded by the target nucleic acid sequence within a host cell.

Percent Sequence Similarity or Percent Sequence Identity

The terms “percent (%) sequence similarity”, “percent (%) sequenceidentity”, and the like, generally refer to the degree of identity orcorrespondence between different nucleotide sequences of nucleic acidmolecules or amino acid sequences of proteins that may or may not sharea common evolutionary origin (see Reeck et al., supra). Sequenceidentity can be determined using any of a number of publicly availablesequence comparison algorithms, such as BLAST, FASTA, DNA Strider, GCG(Genetics Computer Group, Program Manual for the GCG Package, Version 7,Madison, Wis.), etc.

To determine the percent identity between two amino acid sequences ortwo nucleic acid molecules, the sequences are aligned for optimalcomparison purposes. The percent identity between the two sequences is afunction of the number of identical positions shared by the sequences(i.e., percent identity=number of identical positions/total number ofpositions (e.g., overlapping positions)×100). In one embodiment, the twosequences are, or are about, of the same length. The percent identitybetween two sequences can be determined using techniques similar tothose described below, with or without allowing gaps. In calculatingpercent sequence identity, typically exact matches are counted.

The determination of percent identity between two sequences can beaccomplished using a mathematical algorithm. A non-limiting example of amathematical algorithm utilized for the comparison of two sequences isthe algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 1990,87:2264, modified as in Karlin and Altschul, Proc. Natl. Acad. Sci. USA1993, 90:5873-5877. Such an algorithm is incorporated into the NBLASTand XBLAST programs of Altschul et al., J. Mol. Biol. 1990; 215: 403.BLAST nucleotide searches can be performed with the NBLAST program,score=100, wordlength=12, to obtain nucleotide sequences homologous tosequences of the invention. BLAST protein searches can be performed withthe XBLAST program, score=50, wordlength=3, to obtain amino acidsequences homologous to protein sequences of the invention. To obtaingapped alignments for comparison purposes, Gapped BLAST can be utilizedas described in Altschul et al., Nucleic Acids Res. 1997, 25:3389.Alternatively, PSI-Blast can be used to perform an iterated search thatdetects distant relationship between molecules. See Altschul et al.(1997) supra. When utilizing BLAST, Gapped BLAST, and PSI-Blastprograms, the default parameters of the respective programs (e.g.,XBLAST and NBLAST) can be used. See ncbi.nlm.nih.gov/BLAST/ on theWorldWideWeb. Another non-limiting example of a mathematical algorithmutilized for the comparison of sequences is the algorithm of Myers andMiller, CABIOS 1988; 4:11-17. Such an algorithm is incorporated into theALIGN program (version 2.0), which is part of the GCG sequence alignmentsoftware package. When utilizing the ALIGN program for comparing aminoacid sequences, a PAM120 weight residue table, a gap length penalty of12, and a gap penalty of 4 can be used.

In a preferred embodiment, the percent identity between two amino acidsequences is determined using the algorithm of Needleman and Wunsch (J.Mol. Biol. 1970, 48:444-453), which has been incorporated into the GAPprogram in the GCG software package (Accelrys, Burlington, Mass.;available at accelrys.com on the WorldWideWeb), using either a Blossum62 matrix or a PAM250 matrix, a gap weight of 16, 14, 12, 10, 8, 6, or4, and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferredembodiment, the percent identity between two nucleotide sequences isdetermined using the GAP program in the GCG software package using aNWSgapdna.CMP matrix, a gap weight of 40, 50, 60, 70, or 80, and alength weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set ofparameters (and the one that can be used if the practitioner isuncertain about what parameters should be applied to determine if amolecule is a sequence identity or homology limitation of the invention)is using a Blossum 62 scoring matrix with a gap open penalty of 12, agap extend penalty of 4, and a frameshift gap penalty of 5.

In addition to the cDNA sequences encoding various desired proteins, thepresent invention further provides polynucleotide molecules comprisingnucleotide sequences having certain percentage sequence identities toany of the aforementioned sequences. Such sequences preferably hybridizeunder conditions of moderate or high stringency as described above, andmay include species orthologs.

Pharmaceutically Acceptable

When formulated in a pharmaceutical composition, a therapeutic compoundof the present invention can be admixed with a pharmaceuticallyacceptable carrier or excipient. As used herein, the phrase“pharmaceutically acceptable” refers to molecular entities andcompositions that are generally believed to be physiologically tolerableand do not typically produce an allergic or similar untoward reaction,such as gastric upset, dizziness and the like, when administered to ahuman.

Pharmaceutically Acceptable Derivative

The term “pharmaceutically acceptable derivative” as used herein meansany pharmaceutically acceptable salt, solvate or prodrug, e.g. ester, ofa compound of the invention, which upon administration to the recipientis capable of providing (directly or indirectly) a compound of theinvention, or an active metabolite or residue thereof. Such derivativesare recognizable to those skilled in the art, without undueexperimentation. Nevertheless, reference is made to the teaching ofBurger's Medicinal Chemistry and Drug Discovery, 5th Edition, Vol 1:Principles and Practice, which is incorporated herein by reference tothe extent of teaching such derivatives. Preferred pharmaceuticallyacceptable derivatives are salts, solvates, esters, carbamates, andphosphate esters. Particularly preferred pharmaceutically acceptablederivatives are salts, solvates, and esters. Most preferredpharmaceutically acceptable derivatives are salts and esters.

Pharmaceutical Compositions and Administration

While it is possible to use a composition provided by the presentinvention for therapy as is, it may be preferable to administer it in apharmaceutical formulation, e.g., in admixture with a suitablepharmaceutical excipient, diluent, or carrier selected with regard tothe intended route of administration and standard pharmaceuticalpractice. Accordingly, in one aspect, the present invention provides apharmaceutical composition or formulation comprising at least one activecomposition, or a pharmaceutically acceptable derivative thereof, inassociation with a pharmaceutically acceptable excipient, diluent,and/or carrier. The excipient, diluent and/or carrier must be“acceptable” in the sense of being compatible with the other ingredientsof the formulation and not deleterious to the recipient thereof.

The compositions of the invention can be formulated for administrationin any convenient way for use in human or veterinary medicine.

Pharmaceutical Carrier

The term “carrier” refers to a diluent, adjuvant, excipient, or vehiclewith which the compound is administered. Such pharmaceutical carrierscan be sterile liquids, such as water and oils, including those ofpetroleum, animal, vegetable or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like. Water or aqueoussolution saline solutions and aqueous dextrose and glycerol solutionsare preferably employed as carriers, particularly for injectablesolutions. Alternatively, the carrier can be a solid dosage formcarrier, including but not limited to one or more of a binder (forcompressed pills), a glidant, an encapsulating agent, a flavorant, and acolorant. Suitable pharmaceutical carriers are described in “Remington'sPharmaceutical Sciences” by E. W. Martin (1990, Mack Publishing Co.,Easton, Pa. 18042).

In one embodiment, the pharmaceutical composition is convenientlyadministered as a liquid oral formulation. Although there are nophysical limitations to delivery of the formulation, oral delivery ispreferred because of its ease and convenience, and because oralformulations readily accommodate additional mixtures, such as milk,yogurt, and infant formula. Other oral dosage forms are well known inthe art and include tablets, caplets, gelcaps, capsules, and medicalfoods. Tablets, for example, can be made by well-known compressiontechniques using wet, dry, or fluidized bed granulation methods.

Such oral formulations may be presented for use in a conventional mannerwith the aid of one or more suitable excipients, diluents, and carriers.Pharmaceutically acceptable excipients assist or make possible theformation of a dosage form for a bioactive material and includediluents, binding agents, lubricants, glidants, disintegrants, coloringagents, and other ingredients. Preservatives, stabilizers, dyes and evenflavoring agents may be provided in the pharmaceutical composition.Examples of preservatives include sodium benzoate, ascorbic acid andesters of p-hydroxybenzoic acid. Antioxidants and suspending agents maybe also used. An excipient is pharmaceutically acceptable if, inaddition to performing its desired function, it is non-toxic, welltolerated upon ingestion, and does not interfere with absorption ofbioactive materials.

Acceptable excipients, diluents, and carriers for therapeutic use arewell known in the pharmaceutical art, and are described, for example, inRemington: The Science and Practice of Pharmacy. Lippincott Williams &Wilkins (A. R. Gennaro edit. 2005). The choice of pharmaceuticalexcipient, diluent, and carrier can be selected with regard to theintended route of administration and standard pharmaceutical practice.

The invention also encompasses pharmaceutical compositions and vaccines.The pharmaceutical compositions and vaccine compositions of theinvention include at least one of the compositions of the invention, asuitable antigen (for vaccines), and a pharmaceutically acceptablecarrier or excipient. Methods of formulating pharmaceutical compositionsand vaccines are well-known to those of ordinary skill in the art, asdescribed in Remington's, supra.

Formulations

The compositions, vaccines and formulations of the present invention maycomprise pharmaceutically acceptable diluents, preservatives,solubilizers, emulsifiers, adjuvants and/or carriers. Such compositionsinclude diluents of various buffer content (e.g., Tris-HCl, acetate,phosphate), pH and ionic strength; additives such as detergents andsolubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants(e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g.,Thimersol, benzyl alcohol) and bulking substances (e.g., lactose,mannitol); incorporation of the material into particulate preparationsof polymeric compounds such as polylactic acid, polyglycolic acid, etc.or into liposomes. Hylauronic acid may also be used. See, e.g.,Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack PublishingCo., Easton, Pa. 18042) pages 1435 1712 which are herein incorporated byreference.

Contemplated for use herein are oral solid dosage forms, which aredescribed generally in Remington's Pharmaceutical Sciences, 18th Ed.1990 (Mack Publishing Co. Easton Pa. 18042) at Chapter 89, which isherein incorporated by reference. Solid dosage forms include tablets,capsules, pills, troches or lozenges, cachets, pellets, powders, orgranules. Also, liposomal or proteinoid encapsulation may be used toformulate the present compositions (as, for example, proteinoidmicrospheres reported in U.S. Pat. No. 4,925,673). Liposomalencapsulation may be used and the liposomes may be derivatized withvarious polymers (e.g., U.S. Pat. No. 5,013,556). A description ofpossible solid dosage forms for the therapeutic is given by Marshall, K.In: Modern Pharmaceutics Edited by G. S. Banker and C. T. Rhodes Chapter10, 1979, herein incorporated by reference. In general, the formulationwill include the therapeutic agent and inert ingredients which allow forprotection against the stomach environment, and release of thebiologically active material in the intestine.

Also contemplated for use herein are liquid dosage forms for oraladministration, including pharmaceutically acceptable emulsions,solutions, suspensions, and syrups, which may contain other componentsincluding inert diluents; adjuvants, wetting agents, emulsifying andsuspending agents; and sweetening, flavoring, coloring, and perfumingagents.

For oral formulations, the location of release may be the stomach, thesmall intestine (the duodenum, the jejunem, or the ileum), or the largeintestine. One skilled in the art has available formulations which willnot dissolve in the stomach, yet will release the material in theduodenum or elsewhere in the intestine, e.g., by the use of an entericcoating. Examples of the more common inert ingredients that are used asenteric coatings are cellulose acetate trimellitate (CAT),hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55,polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, celluloseacetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. Thesecoatings may be used as mixed films.

A coating or mixture of coatings can also be used on tablets, which arenot intended for protection against the stomach. This can include sugarcoatings, or coatings which make the tablet easier to swallow. Capsulesmay consist of a hard shell (such as gelatin) for delivery of drytherapeutic (i.e. powder), for liquid forms a soft gelatin shell may beused. The shell material of cachets could be thick starch or otheredible paper. For pills, lozenges, molded tablets or tablet triturates,moist massing techniques can be used. The formulation of the materialfor capsule administration could also be as a powder, lightly compressedplugs, or even as tablets. These therapeutics could be prepared bycompression.

One may dilute or increase the volume of the therapeutic agent with aninert material. These diluents could include carbohydrates, especiallymannitol, lactose, anhydrous lactose, cellulose, sucrose, modifieddextrans and starch. Certain inorganic salts may be also be used asfillers including calcium triphosphate, magnesium carbonate and sodiumchloride. Some commercially available diluents are Fast-Flo, Emdex,STA-Rx 1500, Emcompress and Avicell.

Disintegrants may be included in the formulation of the therapeuticagent into a solid dosage form. Materials used as disintegrates includebut are not limited to starch, including the commercial disintegrantbased on starch, Explotab, Sodium starch glycolate, Amberlite, sodiumcarboxymethylcellulose, ultramylopectin, sodium alginate, gelatin,orange peel, acid carboxymethyl cellulose, natural sponge and bentonitemay all be used. The disintegrants may also be insoluble cationicexchange resins. Powdered gums may be used as disintegrants and asbinders. and can include powdered gums such as agar, Karaya ortragacanth. Alginic acid and its sodium salt are also useful asdisintegrants. Binders may be used to hold the therapeutic agenttogether to form a hard tablet and include materials from naturalproducts such as acacia, tragacanth, starch and gelatin. Others includemethyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose(CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose(HPMC) could both be used in alcoholic solutions to granulate thepeptide (or derivative).

An antifrictional agent may be included in the formulation to preventsticking during the formulation process. Lubricants may be used as alayer between the peptide (or derivative) and the die wall, and thesecan include but are not limited to; stearic acid including its magnesiumand calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin,vegetable oils and waxes. Soluble lubricants may also be used such assodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol ofvarious molecular weights, Carbowax 4000 and 6000.

Glidants that might improve the flow properties drug during formulationand to aid rearrangement during compression might be added. The glidantsmay include starch, talc, pyrogenic silica and hydrated silicoaluminate.

To aid dissolution of the therapeutic agent into the aqueous environmenta surfactant might be added as a wetting agent. Surfactants may includeanionic detergents such as sodium lauryl sulfate, dioctyl sodiumsulfosuccinate and dioctyl sodium sulfonate. Cationic detergents mightbe used and could include benzalkonium chloride or benzethomiumchloride. The list of potential nonionic detergents that could beincluded in the formulation as surfactants are lauromacrogol 400,polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fattyacid ester, methyl cellulose and carboxymethyl cellulose. Thesesurfactants could be present in the formulation of the protein orderivative either alone or as a mixture in different ratios.

Controlled release oral formulations may used in practicing the presentinvention. The therapeutic agent could be incorporated into an inertmatrix which permits release by either diffusion or leaching mechanisms,e.g., gums. Slowly degenerating matrices may also be incorporated intothe formulation. Some enteric coatings also have a delayed releaseeffect. Another form of a controlled release is by a method based on theOros therapeutic system (Alza Corp.), i.e. the therapeutic agent isenclosed in a semipermeable membrane which allows water to enter andpush agent out through a single small opening due to osmotic effects.

Other coatings may be used for the formulation. These include a varietyof sugars which could be applied in a coating pan. The therapeutic agentcould also be given in a film coated tablet and the materials used inthis instance are divided into 2 groups. The first are the nonentericmaterials and include methyl cellulose, ethyl cellulose, hydroxyethylcellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose,hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose,providone and the polyethylene glycols. The second group consists of theenteric materials that are commonly esters of phthalic acid. A mix ofmaterials might be used to provide the optimum film coating. Filmcoating may be carried out in a pan coater or in a fluidized bed or bycompression coating.

Preparations according to this invention for parenteral administrationinclude sterile aqueous or non-aqueous solutions, suspensions, oremulsions. Examples of non-aqueous solvents or vehicles are propyleneglycol, polyethylene glycol, vegetable oils, such as olive oil and cornoil, gelatin, and injectable organic esters such as ethyl oleate. Suchdosage forms may also contain adjuvants, preserving, wetting,emulsifying, and dispersing agents. The pharmaceutical compositions maybe sterilized by, for example, filtration through a bacteria retainingfilter, by incorporating sterilizing agents into the compositions, byirradiating the compositions, or by heating the compositions. They canalso be manufactured using sterile water, or some other sterileinjectable medium, immediately before use.

Dosage

The dosage of the therapeutic formulation or vaccine of the presentinvention will vary widely, depending upon the nature of the disease,the patient's medical history, the frequency of administration, themanner of administration, the clearance of the agent from the host, andthe like. The initial dose may be larger, followed by smallermaintenance doses. The dose may be administered as infrequently asweekly or biweekly, or fractionated into smaller doses and administereddaily, semi-weekly, etc., to maintain an effective dosage level.

Following methodologies which are well-established in the art, effectivedoses and toxicity of the compounds, vaccines and compositions of theinstant invention, which performed well in in vitro tests, are thendetermined in preclinical studies using small animal models (e.g., miceor rats) in which the tumor-associated antigens, dendritic cells,polypeptides, apoptotic cells, TLR adjuvants or agonists, apoptoticcell-associated agents, pharmaceutical, or vaccine compositions havebeen found to be therapeutically effective and in which these drugs canbe administered by the same route proposed for the human clinicaltrials.

For any pharmaceutical composition or vaccine used in the methods of theinvention, the therapeutically effective dose can be estimated initiallyfrom animal models. Dose-response curves derived from animal systems arethen used to determine testing doses for the initial clinical studies inhumans. In safety determinations for each composition, the dose andfrequency of administration should meet or exceed those anticipated foruse in the clinical trial.

As disclosed herein, the dose of the components in the compositions,vaccines and formulations of the present invention is determined toensure that the dose administered continuously or intermittently willnot exceed an amount determined after consideration of the results intest animals and the individual conditions of a patient. A specific dosenaturally varies depending on the dosage procedure, the conditions of apatient or a subject animal such as age, body weight, sex, sensitivity,feed, dosage period, drugs used in combination, and seriousness of thedisease. The appropriate dose and dosage times under certain conditionscan be determined by the test based on the above-described indices butmay be refined and ultimately decided according to the judgment of thepractitioner and each patient's circumstances (age, general condition,severity of symptoms, sex, etc.) according to standard clinicaltechniques. DC are loaded with apoptotic cells or TLR-ligand carryingapoptotic cells or apoptotic cells carrying inactivated microbes at aratio of 1 DC to 2 apoptotic cells. DC vaccines will be administeredevery 28 to 30 days at 1-12×10⁶ DCs/vaccination. As a safety measure,vaccination may be initialized at 1×10⁶ DC/vaccination for the first 4vaccines. If no toxicity is observed, after completion of 4vaccinations, doses may be increased to 4×10⁶ DC, and finally to amaximum of 12×10⁶ DC/vaccine. These are suggested guidelines based on DCvaccinations of patients with metastatic melanoma in the study byPalucka et al. (2006) J Immunother; 29:545-57. Actual dosage andcomposition or pharmaceutical formulations of TLR ligands in combinationwith apoptotic cell-associated agents may be determined in pre-clinicaland clinical trials by standard practices known in the art.

Toxicity and therapeutic efficacy of the compositions, vaccines, andformulations of the invention can be determined by standardpharmaceutical procedures in experimental animals, e.g., by determiningthe LD50 (the dose lethal to 50% of the population) and the ED50 (thedose therapeutically effective in 50% of the population). The dose ratiobetween therapeutic and toxic effects is the therapeutic index and itcan be expressed as the ratio ED50/LD50. Compositions that exhibit largetherapeutic indices are preferred.

The data obtained from animal studies can be used in formulating a rangeof doses for use in humans. The therapeutically effective doses of inhumans lay preferably within a range of circulating concentrations thatinclude the ED50 with little or no toxicity. The dosage can vary withinthis range depending upon the dosage form employed and the route ofadministration utilized. Ideally, a single dose of each drug should beused daily.

The abbreviations in the specification correspond to units of measure,techniques, properties or compounds as follows: “min” means minutes, “h”means hour(s), “μl” means microliter(s), “ml” means milliliter(s), “mM”means millimolar, “M” means molar, “mmole” means millimole(s), “kb”means kilobase, “bp” means base pair(s), and “IU” means InternationalUnits. “Polymerase chain reaction” is abbreviated PCR; “Reversetranscriptase polymerase chain reaction” is abbreviated RT-PCR; “DNAbinding domain” is abbreviated DBD; “Untranslated region” is abbreviatedUTR; “Sodium dodecyl sulfate” is abbreviated SDS; and “High PressureLiquid Chromatography” is abbreviated HPLC.

EXAMPLES

The following examples are included to demonstrate certain embodimentsof the invention. These specific examples are described solely forpurposes of illustration, and are not intended to limit the scope ofthis disclosure. It should be appreciated by those of skill in the artthat the techniques disclosed in the examples which follow representtechniques discovered by the inventor to function well in the practiceof the invention, and thus can be considered to constitute preferredmodes for its practice. However, those of skill in the art should, inlight of the present disclosure, appreciate that many changes can bemade in the specific embodiments which are disclosed and still obtain alike or similar result without departing from the spirit and scope ofthe invention. Although specific targets, terms, and values have beenemployed herein, such targets, terms, and values will likewise beunderstood as exemplary and non-limiting to the scope of this invention.

Example 1 Materials and Methods

Materials

In all Examples, all chemicals were obtained from Sigma-Aldrich (St.Louis, Mo.), unless otherwise indicated. DNA restriction enzymes and DNAmodifying enzymes were obtained from New England BioLabs (Beverly,Mass.).

Patients

All study subjects (or parent/guardian if the study subject was lessthan 18 years of age) gave informed consent prior to participation, andthe study was approved by Beth Israel Medical Center and Mount SinaiSchool of Medicine institutional review boards. Videotaped examinationsand determination of affected status was undertaken as described inBressman, S. B. et al., Ann. Neurol. (1989) 26: 612-20, which is herebyincorporated by reference in its entirety. Clinical details of affectedindividuals in all families analyzed (families M, C, R, W and S) aregiven in Table 4.

Control samples included unrelated spouses from Amish-Mennonite dystoniafamilies (n=55), unrelated Amish-Mennonites from Dr. Jonathan Haines(n=85), CEPH controls (n=77) and Human Random DNA control samplesrepresenting UK healthy Caucasian blood donors (Sigma-Aldrich) (n=95).

TABLE 4 Clinical Characteristics of 29 THAP1 Patients from Five FamiliesSITES INVOLVED Age onset Age exam upper lower right Gender (yrs) (yrs)face face neck larynx pharynx tongue jaw arm 416 F 13 42 • • • • • • 413M 13 46 • • • • • • 411 M 9 47 • • 302 F 13 79 • • • • • • 303 M 21 66 •• • • • • 502 M 9 13 • FAMILY M 524 M 16 19 • 212* M 14 78 • • • • 309*F 34 54 • • • • • 314* F Unk. 63 • 319* M 7 64 • • • • 334* F 13 57 • •• 342* F 24 40 • • • 404* F 6 34 • • • 417* F 5 15 • 481* M 31 49 • 486*F 28 45 • 514* F 15 17 • • 516* F 8 18 • • • • 517* F 10 12 • 522* M 1023 • • • • • • • • FAMILY C 417* M 38 55 • • • 419* F 9 44 • • • • •470* F 20 43 • • • 498* F 21 47 • • • • • 512* F 6 17 • • 526* F 16 19 •• • FAMILY R 309* M 18 35 • • • • 401* M 6 10 • • • • SITES INVOLVEDleft right left Dystonia Site of Protein arm leg leg trunk distributiononset Allele variant variant 416 • • • • G Cranial c.241T > C 413 • • •G Leg 411 S Cranial 302 • • • • G Arm 303 • S Cranial c.134 135insGGGTT;137 502 • S Arm FAMILY M 524 F Cranial c.134 135insGGGTT; 137 212* • • •• G Cranial 309* • M Arm 314* F Arm 319* • • • • G Leg 334* • • • • GNeck 342* • • M Cranial 404* • • • G Arm 417* • M Arm 481* F Arm 486* •S Arm 514* S Neck 516* • • M Arm 517* • • • G Arm 522* S Cranial FAMILYC 417* • S Arm c.134 135insGGGTT; 137 419* • • G Neck 470* S Cranial498* S Cranial 512* S Arm 526* S Neck FAMILY R 309* • • • G Cranialc.134 135insGGGTT; 137 F45fs73x 401* • • • G Neck Gender: F—female,M—male; Dystonia distribution: G—generalized, F—focal, M—multifocal,S—segmental *reported previously in Almasy 1997 and Saunders-Pullman2007 and update here.PCR Amplification and Sequencing

DNA was extracted from white blood cells using the Purgene procedure(Gentra Systems Inc, Minneapolis, Minn.). Intron based, exon-specificprimers were designed from the UCSC human genome assembly sequence(March 2006 assembly, http://genome.ucsc.edu/) using Integrated DNATechnologies Primer Quest online server which is derived from Primer3software (release 0.9)(https://www.idtdna.com/Scitools/Applications/Primerquest/Default.aspx).Primers that may be used include, for example, the primers set forth inTable 2. Standard PCR amplification was performed using the primers setforth in Table 2 and the PCR conditions as follows: 35 cycles of 1 minat 95° C., 1 min at the annealing temperature identified in Table 2 (57°for exons 2 and 3 and 60° for exon1) and 1 min at 72° C. The first stepof denaturation and the last step of extension were each 10 minutes at95 C.° and 72 C.°, respectively. THAP1 Exon1 sequence is GC rich andtherefore the PCR reaction was performed with AccuPrime™ GC-rich DNApolymerase (Invitrogen). The PCR amplification of the other THAP1 exonswas performed with Taq DNA polymerase from Applied Biosystems (ABI). Theamplified fragments underwent an enzymatic cleanup process withexonuclease I and shrimp alkaline phosphatase (USB, Corporation,Cleveland, Ohio) for 15 min at 37° C. and 15 min at 85° C., followed bystandard dideoxy cycle sequencing. Sequence analysis was performed usingSequencher™ version 4.8 (Gene Codes, Ann Arbor, Mich.).

Mutant Allele Cloning

PCR fragments bearing the c.134_135insGGGTT;137_139delAAC mutant allelewere subcloned using the TOPO TA Cloning® Kit (Invitrogen) as describedby the manufacturer and confirmed by forward and reverse sequencing. PCRwas performed with THAP1 exon2 primers (Table 2) using the following PCRconditions: 35 cycles of 1 min at 95° C., 1 min at 57° C. and 1 min at72° C. PCR products were cloned into the TOPO® vector. The products ofcloning reaction were transformed into One Shot® chemically competent E.coli cells by heat-shock, bacterial culture was plated on a prewarmed LBagar plate containing 100 μg/ml spectinomycin, and incubated overnightat 37° C. Ten colonies were picked straight into PCR mixture and PCRreaction was performed following the protocol for THAP1 exon2 PCR. Theproducts were sequenced using routine procedure to reveal either themutant or wild type allele.

Restriction Analysis

PCR products were digested with the restriction enzymes DraI to test fora c.134_135insGGGTT;137_139delAAC mutation (e.g., SEQ ID NO: 5) or SspIto test for c.241T>C mutation (e.g., SEQ ID NO: 6). The exon 2 primersidentified in Table 2 were used to generate a PCR product that was thendigested with either DraI or SspI. DraI digestion of a 400 bp PCRproduct from wild type THAP1 results in restriction fragments of 36,105, 113 and 146 base pairs. Digestion of a 400 bp PCR product from ac.134_135insGGGTT;137_139delAAC mutant results in restriction fragmentsof 36 bp, 113 bp and 251 base pairs. The c.134_135insGGGTT;137_139delAACmutant is missing a DraI restriction site in the 251 base pair fragment.Therefore, in a heterozygous individual (one wild type and onec.134_135insGGGTT;137_139delAAC allele), a DraI digestion of the PCRproducts would result in restriction fragments of 36, 105, 113, 146, and251 base pairs.

Genotyping

Four reported SNPs: rs11996576, rs2304873, rs2070713, rs2974349 (dbSNP,build 28) and two novel SNPs (ss105110360 and ss105110361, dbSNP build30) were amplified using the THAP1 exon 2 primers disclosed in Table 2using the following PCR conditions: 35 cycles of 1 min at 95° C., 1 minat 57° C. and 1 min at 72° C. The PCR products were then sequenced.Haplotypes were constructed by hand (FIG. 2 and FIG. 3). A controlfrequency for the disease bearing chromosome was calculated bymultiplying the individual marker allele frequencies that make up thehaplotype.

Bioinformatic Analysis

Sequences of the tentative THAP1 orthologs and paralogs were withdrawnfrom the Gene database at NCBI. Multiple sequence alignment wasperformed with ClustalW^(14,15) using the default parameters. Domain andMotif analysis was performed by Simple Modular Architecture ResearchTool (SMART) (http://smart.embl-heidelberg.de/).

Plasmid Vectors and Antibodies

The full-length cDNA for the gene encoding human THAP1 (Ultimate ORFclone ID: IOH10776) was purchased from Invitrogen. Human THAP1 wastransferred from the entry vector to the pcDNA3.1/nV5-Dest expressionvector by Gateway recombinational cloning technique according to themanufacturer's instructions to introduce a V5 epitope tag at theN-terminus of THAP1, yielding pcDNA3.1/nV5-hTHAP1. ThepcDNA3.1/nV5-hTHAP1-F81L mutant construct was generated by QuikChangemutagenesis (Stratagene, La Jolla, Calif.), with the forward primer5′-AGAATGCTGTGCCCACAATAcTTCTTTGTACTGAGCC-3′ (SEQ ID NO: 18) and thereverse primer 5′-GGCTCAGTACAAAGAAgTATTGTGGGCACAGCATTCT-3′ (SEQ ID NO:19) (the point mutation is indicated in lower case), using thepcDNA3.1/nV5-hTHAP1 construct as template. All constructs were verifiedby sequencing.

The mouse monoclonal anti-V5 antibody was obtained from Invitrogen andthe purified rabbit anti-Human THAP1 polyclonal antibody fromProteinTech Group (Chicago, Ill.). Secondary antibodies were purchasedfrom GE Healthcare (Piscataway, N.J.).

In Vitro Transcription/Translation

In vitro transcription/translation was performed using the TnT-coupledreticulocyte lysate system (Promega, Madison, Wis.) according to themanufacturer's instructions, with the T7 RNA polymerase promoter of thepcDNA3.1/nV5 vectors. The reactions were carried out with 1 μg of thecorresponding pcDNA3.1/nV5 plasmid in 50 μL of lysate and incubated for1.5 h at 30° C. Products were subjected to SDS-PAGE prior to bindingassays as described below.

Cell Culture and Transfection

HEK 293T cells were grown in DMEM (GIBCO) supplemented with 10% dialyzedfetal calf serum (GIBCO) and antibiotics at 37° C. in a humidifiedatmosphere of 5% CO2. Cells were transfected with pcDNA3.1/nV5-hTHAP1 at60-70% confluence by using Lipofectamine 2000 (Invitrogen), according tothe manufacturer's instructions. Two days post-transfection, cells wereharvested and lysed in 1% SDS. This lysate was used as a positivecontrol in subsequent western blot analysis.

Immunoblotting

Proteins resolved by SDS-PAGE (8 μL of in vitro translated product/lane)were transferred electrophoretically onto a Hybond-C nitrocellulosemembrane (GE Healthcare). The membrane was blocked with 5% nonfat drymilk diluted in Tris-buffered saline-0.2% Tween 20 and incubatedsuccessively with the primary antibody (anti-V5, 1:5000 in blockingbuffer) overnight at 4° C. and with the anti-mouse horseradishperoxidase-conjugated secondary antibody (1:3000; GE Healthcare) for 1 hat room temperature. Immunoreactivity was detected with an enhancedchemiluminescence method (ECL detection reagent; GE Healthcare).

Example 2 Identification of the DYT6 Gene

The gene associated with DYT6 had previously been mapped to a 40 cM(peri-contromeric) region on chromosome 8 in two Amish-Mennonitefamilies (M and C) (Almasy, L. et al., Ann. Neurol. (1997) 42: 670-3),and an additional Amish-Mennonite family (R) was shown to share the DYT6disease haplotype. All three families were descended from several “OldOrder Amish” ancestral pairs (Sanders-Pullman, R. et al., Am. J. Med.Genet. A (2007) 143A: 2098-105). The linked region had previously beenfurther narrowed to a 23 cM region between markers D8S2317 and D8S2323;this region contains ˜120 genes (March 2006 UCSC human genome assembly,http://genome.ucsc.edu/) (Sanders-Pullman, R. et al., Am. J. Med. Genet.A (2007) 143A: 2098-105).

Eighteen genes in one affected individual from each of the M and CAmish-Mennonite families (see Almasy, L. et al., Ann. Neurol. (1997) 42:670-3) were sequenced, including all coding exons, the 5′ and 3′ UTRsand at least 50 bp of upstream and downstream intronic sequencesurrounding each exon. A heterozygous 5 bp (GGGTT) insertion followed bya 3 bp deletion (AAC) (c.134_135insGGGTT;137_139delAAC) in exon 2 of theTHAP (Thanatos-associated protein) domain containing, apoptosisassociated protein 1 (THAP1) gene, was identified in both individuals offamilies M and C described above. The mutation causes a frame shift atamino acid position number 44 of the protein resulting in a prematurestop codon at position 73 (F45fs73X, FIG. 1A,B).

The sequence of the F45fs73X mutation was confirmed by cloning andsequencing of the mutant allele. PCR fragments bearing thec.134_135insGGGTT;137_139delAAC mutant allele obtained using the exon 2primers set forth in Table 2 were subcloned using the TOPO TA Cloning®Kit (Invitrogen) as described by the manufacturer. The sequence of thePCR fragments was confirmed by forward and reverse sequencing.

To determine whether the mutation was associated with the DYT6 disease,we screened 23 affected individuals from the three Amish-Mennonitefamilies M, C and R [22 previously described (Saunders-Pullman, R. etal., Am. J. Med. Genet. A (2007) 143A: 2098-105) and another (M-524; seeTable 4) that was subsequently identified], as well as 157 familymembers who showed no symptoms associated with dystonia. The F45fs73Xmutation completely co-segregated with the disease in all affectedindividuals and obligate carriers and was not present in 280Amish-Mennonite control chromosomes.

Upon identification of the truncating mutation in THAP1, two clinicallysimilar families with known or suspected Amish-Mennonite ancestry werescreened. Family W comprised two affected individuals, the proband andhis grandfather. They reported Amish-Mennonite ancestors, but a directrelationship to families M, C, or R was not established. Family S was ofpartial German ancestry, residing in the same region as branches ofFamily M; previous marker analysis was consistent with linkage tochromosome 8 (data not shown). There were four affected members in the Sfamily with an average age onset of 12 years (range 9-13 years). Threeof the affected individuals were previously reported (Family 6; seeKramer, P. L. et al., Am. J. Hum. Genet. (1994) 55: 468-75). TheF45fs73X mutation was detected in family W and co-segregated with thedisease (see FIG. 2=Supplementary FIG. 1), but this mutation was notpresent in family S.

To examine whether the mutation arose independently in family W or was afounder mutation, six SNPs from the THAP1 region were genotyped, and thedisease bearing chromosomes from family M and W were compared. The M andW families share a haplotype A-G-G-G-T-T (SEQ ID NO: 49) (FIG. 2) thatwould be expected to occur in only 0.75% of control chromosomes based onthe individual marker allele frequencies (dbSNP at NCBI, build 128;http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp build 128). Thehaplotype results in family W confirm that the F45fs73X mutation is afounder mutation in the Amish-Mennonite population.

Since the insertion/deletion mutation was not found in family S (FIG.3), the remainder of the THAP1 gene was sequenced for the other affectedfamily S individuals (the remaining family S individuals were checkedfor the mutation by restriction enzyme digestion as described herein).Strikingly, we found a different mutation in exon 2, c.241T>C, thatco-segregated with the disease in this family (FIG. 1C) but was notobserved in 514 control chromosomes (154 CEPH, 170 Amish-Mennonite and190 UK controls). The T to C substitution replaces a phenylalanine witha leucine (F81L) in a highly conserved and functionally significantAVPTIF motif of the THAP1 protein (FIG. 1C). This finding of a differentmutation in family S, as well as subsequent genealogic analysis whichfailed to identify Amish-Mennonite ancestry, demonstrate THAP1 as acause of dystonia outside the Amish-Mennonite population.

Example 2 Role of F81 in DNA-Binding Activity of THAP1

The F81L missense mutation identified in Family S involves the F residueof the AVPTIF motif. Both this motif and the F81 amino acid areconserved in most orthologs of human THAP1 (FIG. 1C) and in severalparalogs suggesting strong selection pressures against amino acidvariations in this domain. To test the effect of the F81L mutation onthe DNA-binding activity of THAP1, we performed electrophoretic mobilityshift assays using the THAP-domain-binding sequence (THABS) probe5′-AGCAAGTAAGGGCAACTACTTCAT-3′ (SEQ ID NO: 17) (Clouaire. T. et al.,Proc. Natl Acad. Sci U.S.A. (2005) 102: 6907-12).

Double-stranded oligonucleotide was prepared by annealing syntheticcomplementary oligonucleotides (5′-AGCAAGTAAGGGCAACTACTTCAT-3′ (SEQ IDNO: 17) and the reverse complement of this oligo 5′ATGAAGTAGTTGCCCTTACTTGCT-3′ (SEQ ID NO: 48)) in 20 mM Tris/HCl (pH 7.5),10 mM MgCl2, 50 mM NaCl, 1 mM dithiothreitol (DTT) by heating for 5 minat 95° C., and cooling to room temperature overnight. Probes wereend-labeled with [gamma-³²P]ATP using T4 polynucleotide kinase.Unincorporated nucleotides were removed by column chromatography(illustra MicroSpin™ G-25 Columns, GE Healthcare), according to themanufacturer's protocol. Binding reactions were performed in 20 μl ofbinding buffer (20 mM Tris/HCl (pH 7.5), 150 mM KCl, 0.1% Igepal, 100μg/mL BSA, 2.5 mM DTT, 5% glycerol, 50 μg/mL of poly(dI-dC), 50 g/mLsalmon sperm DNA and a protease inhibitor cocktail, EDTA-free) (RocheDiagnostics, Indianapolis, Ind.) containing 50,000 cpm of the³²P-labeled probe and 5 μL of in vitro translated reaction. Forcompetition experiments, >200X excess unlabeled oligonucleotides werefirst added into the initial incubation reaction before adding thelabeled probe. Samples were incubated at room temperature for 5 minutes,followed by a further 20 minutes in the presence of radiolabeled probe.Supershift experiments were carried out by adding 1 g of the anti-THAP1antibody to the binding reaction mixtures. Samples were subjected toelectrophoresis on a native 4% polyacrylamide gel(acrylamide/bisacrylamide ratio 37.5:1). Following buffer at 150 V atroom temperature, gels were dried and exposed to storage Phosphorscreens that were scanned and analyzed using a Typhoon phosphorimager(GE Healthcare).

Wild-type human THAP1 cDNA was mutated to F81L by site-directedmutagenesis Human THAP1 was transferred from the entry vector to thepcDNA3.1/nV5-Dest expression vector by Gateway recombinational cloningtechnique according to the manufacturer's instructions to introduce a V5epitope tag at the N-terminus of THAP1, yielding pcDNA3.1/nV5-hTHAP1.The pcDNA3.1/nV5-hTHAP1-F81L mutant construct was generated byQuikChange mutagenesis (Stratagene, La Jolla, Calif.), with the forwardprimer 5′-AGAATGCTGTGCCCACAATAcTTCTTTGTACTGAGCC-3′ (SEQ ID NO: 18) andthe reverse primer 5′-GGCTCAGTACAAAGAAgTATTGTGGGCACAGCATTCT-3′ (SEQ IDNO: 19) (the point mutation is indicated in lower case), using thepcDNA3.1/nV5-hTHAP1 construct as template. All constructs were verifiedby sequencing.

The two constructs were expressed in an in vitrotranscription/translation (IVTT) system and assessed by western forequal levels of protein expression (FIG. 4A). When the radiolabeledTHABS probe was incubated with the IVTT wild-type THAP1, a major shiftedband was detected (FIG. 4B, lane 6, arrowhead). The presence of THAP1 inthe band was confirmed by its supershift with specific anti-THAP1antibody (FIG. 4B, lane 8). The bands were competed off by unlabeledTHABS oligonucleotide (FIG. 4B, lanes 7 and 9) indicating that these arespecific DNA-protein interactions. The F81L mutant revealed a similarbinding pattern (FIG. 4B, lanes 10 and 12), but bands were dramaticallyreduced in intensity compared with wild-type THAP1, indicating a reducedbinding affinity to the target DNA. It is likely that both mutationsidentified in the DYT6 families result in the loss of DNA binding whichwould cause transcriptional dysregulation of downstream targets.

SEQUENCE LISTING In names of sequences, ″h″indicates Homo sapiens species.hTHAP1 mRNA (NM_018105.2) (SEQ ID NO: 1)-WT mRNA    1gaggttgaag ctgcctccgc catcttggag atgggagacg ggcgatggct gtggtccttc   61tgctaatgca aacaacaaaa cgggcacact agtcaccccc gagggaggcc accatcactg  121taactgttgg ccaaagctac aaaagaagcg agggaatcca accgagcgca gcgacactga  181gaacagcttc ccctgccttc tgcggcggca gaagtgaagt gcctgaggac cggaaggatg  241gtgcagtcct gctccgccta cggctgcaag aaccgctacg acaaggacaa gcccgtttct  301ttccacaagt ttcctcttac tcgacccagt ctttgtaaag aatgggaggc agctgtcaga  361agaaaaaact ttaaacccac caagtatagc agtatttgtt cagagcactt tactccagac  421tgctttaaga gagagtgcaa caacaagtta ctgaaagaga atgctgtgcc cacaatattt  481ctttgtactg agccacatga caagaaagaa gatcttctgg agccacagga acagcttccc  541ccacctcctt taccgcctcc tgtttcccag gttgatgctg ctattggatt actaatgccg  601cctcttcaga cccctgttaa tctctcagtt ttctgtgacc acaactatac tgtggaggat  661acaatgcacc agcggaaaag gattcatcag ctagaacagc aagttgaaaa actcagaaag  721aagctcaaga ccgcacagca gcgatgcaga aggcaagaac ggcagcttga aaaattaaag  781gaggttgttc acttccagaa agagaaagac gacgtatcag aaagaggtta tgtgattcta  841ccaaatgact actttgaaat agttgaagta ccagcataaa aaaatgaaat gtgtattgat  901ttctaatggg gcaataccac atatcctcct ctagcctgta aaggagtttc atttaaaaaa  961ataacatttg attacttata taaaaacagt tcagaatatt tttttaaaaa aaattctata 1021tatactgtaa aattataaat ttttttgttt gtaatttcag gttttttaca ttttaacaaa 1081atattttaaa agttataaac taacctcaga cctctaatgt aagttggttt caagattggg 1141gattttgggg ttttttttta gtatttatag aaataatgta aaaataaaaa gtaaagagaa 1201tgagaacagt gtggtaaaag ggtgatttca gtttaaaact taaaattagt actgttttat 1261tgagagaatt tagttatatt ttaaatcaga agtatgggtc agatcatggg acataacttc 1321ttagaatata tatatacata tgtacatatt ctcatatgta aagtcacaag gttcatttat 1381ctttctgaat cagttatcaa agataaattg gcaagtcagt acttaagaaa aaagatttga 1441ttatcatcac agcagaaaaa agtcattgca tatctgatca ataacttcag attctaagag 1501tggatttttt ttttttacat gggctcctat tttttcccct actgtcttgc attataaaat 1561tagaagtgta ttttcagtgg aagaaacatt tttcaataaa taaagtaagg cattgtcatc 1621aatgaagtaa ttaaaactgg gacctgatct atgatacgct tttttctttc attacaccct 1681agctgaagga catccagttc cccagctgta gttatgtatc tgccttcaag tctctgacaa 1741atgtgctgtg ttagtagagt ttgatttgta tcatatgata atcttgcact tgactgagtt 1801gggacaaggc ttcacataaa aaattatttc ttcactttta acacaagtta gaaattatat 1861cccatttagt taaatgcgtg atttatattc agaacaacct actatgtagc gtttatttta 1921ctgaatgtgg agatttaaac actgaggttt ctgttcaaac tgtgagttct gttctttgtg 1981agaaatttta catatattgg aagtgaaaat atgttctgag taaacaaata ttgctatggg 2041agttatcttt ttagatttag aataactgtt ccaatgataa ttattacttt tatatttcaa 2101agtacactaa gatcgttgaa gagcaataga acctttaaga cagtattaaa ggtgtgaaac 2161aatggcaaaa aaaaaaaaaa aaaaaaaaa hTHAP1 mRNA-mutation 1 (SEQ ID NO: 2)   1 gaggttgaag ctgcctccgc catcttggag atgggagacg ggcgatggct gtggtccttc  61 tgctaatgca aacaacaaaa cgggcacact agtcaccccc gagggaggcc accatcactg 121 taactgttgg ccaaagctac aaaagaagcg agggaatcca accgagcgca gcgacactga 181 gaacagcttc ccctgccttc tgcggcggca gaagtgaagt gcctgaggac cggaaggatg 241 gtgcagtcct gctccgccta cggctgcaag aaccgctacg acaaggacaa gcccgtttct 301 ttccacaagt ttcctcttac tcgacccagt ctttgtaaag aatgggaggc agctgtcaga 361 agaaaaaact tgggtttacc accaagtata gcagtatttg ttcagagcac tttactccag 421 actgctttaa gagagagtgc aacaacaagt tactgaaaga gaatgctgtg cccacaatat 481 ttctttgtac tgagccacat gacaagaaag aagatcttct ggagccacag gaacagcttc 541 ccccacctcc tttaccgcct cctgtttccc aggttgatgc tgctattgga ttactaatgc 601 cgcctcttca gacccctgtt aatctctcag ttttctgtga ccacaactat actgtggagg 661 atacaatgca ccagcggaaa aggattcatc agctagaaca gcaagttgaa aaactcagaa 721 agaagctcaa gaccgcacag cagcgatgca gaaggcaaga acggcagctt gaaaaattaa 781 aggaggttgt tcacttccag aaagagaaag acgacgtatc agaaagaggt tatgtgattc 841 taccaaatga ctactttgaa atagttgaag taccagcata aaaaaatgaa atgtgtattg 901 atttctaatg gggcaatacc acatatcctc ctctagcctg taaaggagtt tcatttaaaa 961 aaataacatt tgattactta tataaaaaca gttcagaata tttttttaaa aaaaattcta1021 tatatactgt aaaattataa atttttttgt ttgtaatttc aggtttttta cattttaaca1081 aaatatttta aaagttataa actaacctca gacctctaat gtaagttggt ttcaagattg1141 gggattttgg ggtttttttt tagtatttat agaaataatg taaaaataaa aagtaaagag1201 aatgagaaca gtgtggtaaa agggtgattt cagtttaaaa cttaaaatta gtactgtttt1261 attgagagaa tttagttata ttttaaatca gaagtatggg tcagatcatg ggacataact1321 tcttagaata tatatataca tatgtacata ttctcatatg taaagtcaca aggttcattt1381 atctttctga atcagttatc aaagataaat tggcaagtca gtacttaaga aaaaagattt1441 gattatcatc acagcagaaa aaagtcattg catatctgat caataacttc agattctaag1501 agtggatttt ttttttttac atgggctcct attttttccc ctactgtctt gcattataaa1561 attagaagtg tattttcagt ggaagaaaca tttttcaata aataaagtaa ggcattgtca1621 tcaatgaagt aattaaaact gggacctgat ctatgatacg cttttttctt tcattacacc1681 ctagctgaag gacatccagt tccccagctg tagttatgta tctgccttca agtctctgac1741 aaatgtgctg tgttagtaga gtttgatttg tatcatatga taatcttgca cttgactgag1801 ttgggacaag gcttcacata aaaaattatt tcttcacttt taacacaagt tagaaattat1861 atcccattta gttaaatgcg tgatttatat tcagaacaac ctactatgta gcgtttattt1921 tactgaatgt ggagatttaa acactgaggt ttctgttcaa actgtgagtt ctgttctttg1981 tgagaaattt tacatatatt ggaagtgaaa atatgttctg agtaaacaaa tattgctatg2041 ggagttatct ttttagattt agaataactg ttccaatgat aattattact tttatatttc2101 aaagtacact aagatcgttg aagagcaata gaacctttaa gacagtatta aaggtgtgaa2161 acaatggcaa aaaaaaaaaa aaaaaaaaaa ahTHAP1 mRNA-mutation 2 (SEQ ID NO: 3)    1gaggttgaag ctgcctccgc catcttggag atgggagacg ggcgatggct gtggtccttc   61tgctaatgca aacaacaaaa cgggcacact agtcaccccc gagggaggcc accatcactg  121taactgttgg ccaaagctac aaaagaagcg agggaatcca accgagcgca gcgacactga  181gaacagcttc ccctgccttc tgcggcggca gaagtgaagt gcctgaggac cggaaggatg  241gtgcagtcct gctccgccta cggctgcaag aaccgctacg acaaggacaa gcccgtttct  301ttccacaagt ttcctcttac tcgacccagt ctttgtaaag aatgggaggc agctgtcaga  361agaaaaaact ttaaacccac caagtatagc agtatttgtt cagagcactt tactccagac  421tgctttaaga gagagtgcaa caacaagtta ctgaaagaga atgctgtgcc cacaatactt  481ctttgtactg agccacatga caagaaagaa gatcttctgg agccacagga acagcttccc  541ccacctcctt taccgcctcc tgtttcccag gttgatgctg ctattggatt actaatgccg  601cctcttcaga cccctgttaa tctctcagtt ttctgtgacc acaactatac tgtggaggat  661acaatgcacc agcggaaaag gattcatcag ctagaacagc aagttgaaaa actcagaaag  721aagctcaaga ccgcacagca gcgatgcaga aggcaagaac ggcagcttga aaaattaaag  781gaggttgttc acttccagaa agagaaagac gacgtatcag aaagaggtta tgtgattcta  841ccaaatgact actttgaaat agttgaagta ccagcataaa aaaatgaaat gtgtattgat  901ttctaatggg gcaataccac atatcctcct ctagcctgta aaggagtttc atttaaaaaa  961ataacatttg attacttata taaaaacagt tcagaatatt tttttaaaaa aaattctata 1021tatactgtaa aattataaat ttttttgttt gtaatttcag gttttttaca ttttaacaaa 1081atattttaaa agttataaac taacctcaga cctctaatgt aagttggttt caagattggg 1141gattttgggg ttttttttta gtatttatag aaataatgta aaaataaaaa gtaaagagaa 1201tgagaacagt gtggtaaaag ggtgatttca gtttaaaact taaaattagt actgttttat 1261tgagagaatt tagttatatt ttaaatcaga agtatgggtc agatcatggg acataacttc 1321ttagaatata tatatacata tgtacatatt ctcatatgta aagtcacaag gttcatttat 1381ctttctgaat cagttatcaa agataaattg gcaagtcagt acttaagaaa aaagatttga 1441ttatcatcac agcagaaaaa agtcattgca tatctgatca ataacttcag attctaagag 1501tggatttttt ttttttacat gggctcctat tttttcccct actgtcttgc attataaaat 1561tagaagtgta ttttcagtgg aagaaacatt tttcaataaa taaagtaagg cattgtcatc 1621aatgaagtaa ttaaaactgg gacctgatct atgatacgct tttttctttc attacaccct 1681agctgaagga catccagttc cccagctgta gttatgtatc tgccttcaag tctctgacaa 1741atgtgctgtg ttagtagagt ttgatttgta tcatatgata atcttgcact tgactgagtt 1801gggacaaggc ttcacataaa aaattatttc ttcactttta acacaagtta gaaattatat 1861cccatttagt taaatgcgtg atttatattc agaacaacct actatgtagc gtttatttta 1921ctgaatgtgg agatttaaac actgaggttt ctgttcaaac tgtgagttct gttctttgtg 1981agaaatttta catatattgg aagtgaaaat atgttctgag taaacaaata ttgctatggg 2041agttatcttt ttagatttag aataactgtt ccaatgataa ttattacttt tatatttcaa 2101agtacactaa gatcgttgaa gagcaataga acctttaaga cagtattaaa ggtgtgaaac 2161aatggcaaaa aaadaaaaaa aaaaaaaaahTHAP1 mRNA-WT (SEQ ID NO: 4) (coding sequence only)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 mRNA-mutation 1 (SEQ ID NO: 5) (coding sequence only)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa acttgggttt accaccaagt atagcagtat ttgttcagag cactttactc 181cagactgctt taagagagag tgcaacaaca agttactgaa agagaatgct gtgcccacaa 241tacttctttg tactgagcca catgacaaga aagaagatct tctggagcca caggaacagc 301ttcccccacc tcctttaccg cctcctgttt cccaggttga tgctgctatt ggattactaa 361tgccgcctct tcagacccct gttaatctct cagttttctg tgaccacaac tatactgtgg 421aggatacaat gcaccagcgg aaaaggattc atcagctaga acagcaagtt gaaaaactca 481gaaagaagct caagaccgca cagcagcgat gcagaaggca agaacggcag cttgaaaaat 541taaaggaggt tgttcacttc cagaaagaga aagacgacgt atcagaaaga ggttatgtga 601ttctaccaaa tgactacttt gaaatagttg aagtaccagc ataahTHAP1 mRNA-mutation 2 (SEQ ID NO: 6) (coding sequence only)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241cttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 DNA-WT, for mutation 1 (SEQ ID NO: 7) 1 tttaaaachTHAP1 DNA-WT, for mutation 2 (SEQ ID NO: 8) 1 atatttctthTHAP1 DNA-mutation 1 (SEQ ID NO: 9) 1 ttgggtttachTHAP1 DNA-mutation 2 (SEQ ID NO: 10) 1 atacttctthTHAP1 protein (NP_060575)-WT (SEQ ID NO: 11)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-mutation 1 (full) (SEQ ID NO: 12)  1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknlglpps iavfvqstll 61qtalresatt sy hTHAP1 protein-mutation 2 (full) (SEQ ID NO: 13)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti llctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrqerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-WT (mutation 2 section) (SEQ ID NO: 14) 1 ptiflctehTHAP1 protein-mutation 1 section (SEQ ID NO: 15) 1lglppsiavf vqstllqtal resattsyhTHAP1 protein-mutation 2 section (SEQ ID NO: 16) 1 ptillcteTHAP-domain-binding sequence (THABS) probe (SEQ ID NO: 17)AGCAAGTAAGGGCAACTACTTCAT Forward primer for mutagenesis (SEQ ID NO: 18)AGAATGCTGTGCCCACAATACTTCTTTGTACTGAGCCReverse primer for mutagenesis (SEQ ID NO: 19)GGCTCAGTACAAAGAAGTATTGTGGGCACAGCATTCTForward exon 1 primer (SEQ ID NO: 20) TGTTCCAGGAGCGCGAGAAAReverse exon 1 primer (SEQ ID NO: 21) AAACACCTGGCCTCAGCCAATAForward exon 2 primer (SEQ ID NO: 22) TCCTAAGCTGGAAAGTTTGGGTGCReverse exon 2 primer (SEQ ID NO: 23) CACTGTTAACTACAAGGTTCCAGGCAForward exon 3 primer (SEQ ID NO: 24) GCCTGGTCAGTCCACAGATTCTTReverse exon 3 primer (SEQ ID NO: 25) ACTCCTTTACAGGCTAGAGGAGGATAForward exon 3A primer (SEQ ID NO: 26) AGGCAAGAACGGCAGCTTGAAAReverse exon 3A primer (SEQ ID NO: 27) AACTGGATGTCCTTCAGCTAGGGTForward exon 3B primer (SEQ ID NO: 28) AGTATGGGTCAGATCATGGGACAReverse exon 3B primer (SEQ ID NO: 29) AGCCTTGTCCCAACTCAGTCAAForward exon 3C primer (SEQ ID NO: 30) ACTGGGACCTGATCTATGATACGCTReverse exon 3C primer (SEQ ID NO: 31) TGAATCACAGTGCTATCCACTGGCC54Y Forward Primer (SEQ ID NO: 32)CCACCAAGTATAGCAGTATTTaTTCAGAGCACTTTACTCCC54Y Reverse Primer (SEQ ID NO: 33)GGAGTAAAGTGCTCTGAAtAAATACTGCTATACTTGGTGGH23Y Forward Primer (SEQ ID NO: 34)GACAAGCCCGTTTCTTTCtACAAGTTTCCTCTTACTCH23Y Reverse Primer (SEQ ID NO: 35)GAGTAAGAGGAAACTTGTaGAAAGAAACGGGCTTGTCK89R Forward Primer (SEQ ID NO: 36)GTACTGAGCCACATGACAgGAAAGAAGATCTTCTGGAK89R Reverse Primer (SEQ ID NO: 37)TCCAGAAGATCTTCTTTCcTGTCATGTGGCTCAGTACN12K Forward Primer (SEQ ID NO: 38) GCCTACGGCTGCAAGAAaCGCTACGACAAGGN12K Reverse Primer (SEQ ID NO: 39) CCTTGTCGTAGCGtTTCTTGCAGCCGTAGGCF45fs73 Forward Primer (SEQ ID NO: 40)AGCTGTCAGAAGAAAAAACTTGGGTTTACCACCAAGTATAGCAGF45fs73 Reverse Primer (SEQ ID NO: 41)AAGTTTTTTCTTCTGACAGCTGCCTCCCATTCTTTACAAAGACR29P Forward Primer (SEQ ID NO: 42)CACAAGTTTCCTCTTACTCcACCCAGTCTTTGTAAAGAAR29P Reverse Primer (SEQ ID NO: 43)TTCTTTACAAAGACTGGGTgGAGTAAGAGGAAACTTGTGS21T Forward Primer (SEQ ID NO: 44) CAAGGACAAGCCCGTTaCTTTCCACAAGTTTCCTS21T Reverse Primer (SEQ ID NO: 45) AGGAAACTTGTGGAAAGtAACGGGCTTGTCCTTG154fsX180 Forward Primer (SEQ ID NO: 46)GGAAAAGGATTCATCAGCTAGAAAGCAAGTTGAAAAACTCAG154fsX180 Reverse Primer (SEQ ID NO: 47)CTGAGTTTTTCAACTTGCTTTCTAGCTGATGAATCCTTTTCCBinding Assay Reverse Complement Oligo (SEQ ID NO: 48)ATGAAGTAGTTGCCCTTACTTGCT SEQ ID NO: 49 AGGGTT hTHAP1 mRNA-c.85C >T (SEQ ID NO: 50)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tacttgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.86G >C (SEQ ID NO: 51)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactccaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.266A >G (SEQ ID NO: 52)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaggaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.115G >A (SEQ ID NO: 53)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcaactgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 mRNA-c.460delC (SEQ ID NO: 54)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaaa gcaagttgaa aaactcagaa 481agaagctcaa gaccgcacag cagcgatgca gaaggcaaga acggcagctt gaaaaattaa 541aggaggttgt tcacttccag aaagagaaag acgacgtatc agaaagaggt tatgtgattc 601taccaaatga ctactttgaa atagttgaag taccagcata a hTHAP1 mRNA-c.161G >A (SEQ ID NO: 55)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt attcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.1A >G (SEQ ID NO: 56)   1gtggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.61T >A (SEQ ID NO: 57)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61actttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.67C >T (SEQ ID NO: 58)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttctaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.36C >A (SEQ ID NO: 59)   1atggtgcagt cctgctccgc ctacggctgc aagaaacgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 mRNA-c.2delT (SEQ ID NO: 60)   1aggtgcagtc ctgctccgcc tacggctgca agaaccgcta cgacaaggac aagcccgttt  61ctttccacaa gtttcctctt actcgaccca gtctttgtaa agaatgggag gcagctgtca 121gaagaaaaaa ctttaaaccc accaagtata gcagtatttg ttcagagcac tttactccag 181actgctttaa gagagagtgc aacaacaagt tactgaaaga gaatgctgtg cccacaatat 241ttctttgtac tgagccacat gacaagaaag aagatcttct ggagccacag gaacagcttc 301ccccacctcc tttaccgcct cctgtttccc aggttgatgc tgctattgga ttactaatgc 361cgcctcttca gacccctgtt aatctctcag ttttctgtga ccacaactat actgtggagg 421atacaatgca ccagcggaaa aggattcatc agctagaaca gcaagttgaa aaactcagaa 481agaagctcaa gaccgcacag cagcgatgca gaaggcaaga acggcagctt gaaaaattaa 541aggaggttgt tcacttccag aaagagaaag acgacgtatc agaaagaggt tatgtgattc 601taccaaatga ctactttgaa atagttgaag taccagcata a hTHAP1 mRNA-c.65T >C (SEQ ID NO: 61)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tcttcccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.140C >T (SEQ ID NO: 62)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaact caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 mRNA-c.392-394delTTT (SEQ ID NO: 63)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gtctgtgacc acaactatac tgtggaggat 421acaatgcacc agcggaaaag gattcatcag ctagaacagc aagttgaaaa actcagaaag 481aagctcaaga ccgcacagca gcgatgcaga aggcaagaac ggcagcttga aaaattaaag 541gaggttgttc acttccagaa agagaaagac gacgtatcag aaagaggtta tgtgattcta 601ccaaatgact actttgaaat agttgaagta ccagcataa hTHAP1 mRNA-c.11C >T (SEQ ID NO: 64)   1atggtgcagt tctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.580T >C (SEQ ID NO: 65)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtac cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aa hTHAP1 mRNA-c.424A >G (SEQ ID NO: 66)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatgcaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagcgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 mRNA-c.250-251delAC (SEQ ID NO: 67)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgtt gagccacatg acaagaaaga agatcttctg gagccacagg aacagcttcc 301cccacctcct ttaccgcctc ctgtttccca ggttgatgct gctattggat tactaatgcc 361gcctcttcag acccctgtta atctctcagt tttctgtgac cacaactata ctgtggagga 421tacaatgcac cagcggaaaa ggattcatca gctagaacag caagttgaaa aactcagaaa 481gaagctcaag accgcacagc agcgatgcag aaggcaagaa cggcagcttg aaaaattaaa 541ggaggttgtt cacttccaga aagagaaaga cgacgtatca gaaagaggtt atgtgattct 601accaaatgac tactttgaaa tagttgaagt accagcataa hTHAP1 mRNA-c.505C >T (SEQ ID NO: 68)   1atggtgcagt cctgctccgc ctacggctgc aagaaccgct acgacaagga caagcccgtt  61tctttccaca agtttcctct tactcgaccc agtctttgta aagaatggga ggcagctgtc 121agaagaaaaa actttaaacc caccaagtat agcagtattt gttcagagca ctttactcca 181gactgcttta agagagagtg caacaacaag ttactgaaag agaatgctgt gcccacaata 241tttctttgta ctgagccaca tgacaagaaa gaagatcttc tggagccaca ggaacagctt 301cccccacctc ctttaccgcc tcctgtttcc caggttgatg ctgctattgg attactaatg 361ccgcctcttc agacccctgt taatctctca gttttctgtg accacaacta tactgtggag 421gatacaatgc accagcggaa aaggattcat cagctagaac agcaagttga aaaactcaga 481aagaagctca agaccgcaca gcagtgatgc agaaggcaag aacggcagct tgaaaaatta 541aaggaggttg ttcacttcca gaaagagaaa gacgacgtat cagaaagagg ttatgtgatt 601ctaccaaatg actactttga aatagttgaa gtaccagcat aahTHAP1 protein-p.R29X (SEQ ID NO: 69) 1 mvqscsaygc knrydkdkpv sfhkfplthTHAP1 protein-p.R29P-(SEQ ID NO: 70)   1mvqscsaygc knrydkdkpv sfhkfpltpp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.K89R (SEQ ID NO: 71)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdrk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.A39T (SEQ ID NO: 72)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweatv rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.Q154fs18(SEQ ID NO: 73)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleskiknse rssrphssda egkngslknhTHAP1 protein-p.C54Y (SEQ ID NO: 74)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssiysehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.S21T (SEQ ID NO: 75)   1mvqscsaygc knrydkdkpv tfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.H23Y (SEQ ID NO: 76)   1mvqscsaygc knrydkdkpv sfykfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.N12K (SEQ ID NO: 77)   1mvqscsaygc kkrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.F22S (SEQ ID NO: 78)   1mvqscsaygc knrydkdkpv sshkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.P47L (SEQ ID NO: 79)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkltky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.AF132 (SEQ ID NO: 80)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vcdhnytved tmhqrkrihq leqqveklrk klktaqqrcr rqerqleklk 181evvhfqkekd dvsergyvil pndyfeivev pa hTHAP1 protein-p.S4F (SEQ ID NO: 81)  1 mvqfcsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp 61 dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm121 pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrgerqlekl181 kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.S194P (SEQ ID NO: 82)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqqrc rrqerqlekl 181kevvhfqkek ddvpergyvi lpndyfeive vpahTHAP1 protein-p.T142A (SEQ ID NO: 83)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve damhqrkrih qleqqveklr kklktaqqrc rrqerqlekl 181kevvhfqkek ddvsergyvi lpndyfeive vpahTHAP1 protein-p.T84X (SEQ ID NO: 84)  1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp 61dcfkrecnnk llkenavpti flc hTHAP1 protein-p.R169X (SEQ ID NO: 85)   1mvqscsaygc knrydkdkpv sfhkfpltrp slckeweaav rrknfkptky ssicsehftp  61dcfkrecnnk llkenavpti flctephdkk edllepqeql pppplpppvs qvdaaigllm 121pplqtpvnls vfcdhnytve dtmhqrkrih qleqqveklr kklktaqq

What is claimed:
 1. An isolated nucleic acid comprising the sequence ofSEQ ID NO: 3 or SEQ ID NO: 6, or the complementary sequence of SEQ IDNO: 3 or SEQ ID NO: 6; wherein the nucleic acid is labeled with a moietyselected from the group consisting of radioisotopes, fluorescentcompounds, enzymes, and enzyme co-factors.
 2. A kit for detecting thepresence of a THAP1 mutation in a biological sample, comprising thenucleic acid of claim 1 and instructions.
 3. The kit of claim 2, whereinthe kit further comprises a primer pair selected from the groupconsisting of: SEQ ID NO: 20 and SEQ ID NO: 21; SEQ ID NO: 22 and SEQ IDNO: 23; SEQ ID NO: 24 and SEQ ID NO: 25; SEQ ID NO: 26 and SEQ ID NO:27; SEQ ID NO: 28 and SEQ ID NO: 29; and SEQ ID NO: 30 and SEQ ID NO:31.